


Covid-19 Literature Update



A CURATED SELECTION AND OVERVIEW OF COVID-19 PUBLICATIONS

Update July 27 - August 02, 2020,

Dr. Peter J. Lansberg MD, PhD

Weekly COVID-19 Literature Update

will keep you up-to-date with all recent PubMed publications
categorized by relevant topics

COVID-19 publications - Week 31 2020

759 Publications

PubMed based Covid-19 weekly literature update

For those interested in receiving weekly updates
click [here](#)

For questions and requests for topics to add send an e-mail
lansberg@gmail.com

Reliable on-line resources for Covid 19

[WHO](#)

[Daily dashboard](#)

[Country Guidance](#)

[Travel restriction](#)

[Covid Counter](#)

[Covid forecasts](#)

[CDC](#)

[AHA](#)

[ESC](#)

[EMEA](#)

[Evidence EPPI](#)

[Wikipedia](#)

[Cardionerds - COVID-19](#)

[Genomic epidemiology](#)

[Oxygenation Ventilation toolkit](#)

[Cochrane](#)

[BMJ](#)

[The Lancet](#)

[New England Journal of Medicine](#)

[JAMA](#)

[Cell](#)

[Science](#)

[Oxford University Press](#)

[Cambridge University Press](#)

[Springer Nature](#)

[Elsevier](#)

[Wiley](#)

[PLOS](#)

[LitCovid NIH-NLM](#)

[SSRN \(Pre-prints\)](#)

[German \(ICU\) bed capacity](#)

[COVID reference \(Steinhauser Verlag\)](#)

[COVID-19 Projections tracker](#)

[AAN - Neurology resources](#)

[COVID-19 resources \(Harvard\)](#)

[COVID-19 resources \(McMasters\)](#)

[COVID-19 resources \(NHLBI\)](#)

[COVID-19 resources \(MEDSCAPE\)](#)

[COVID-19 Diabetes \(JDRF\)](#)

[COVID-19 TELEMEDICINE \(BMJ\)](#)

[Global Causes of death \(Johns Hopkins\)](#)

[COVID-19 calculators \(Medscape\)](#)

Guidelines

[NICE Guidelines Covid-19](#)

[Korean CDC Covid-19 guidelines](#)

[Flattening the curve - Korea](#)

[IDSA COVID-19 Guidelines](#)

[Airway Management Clinical Practice Guidelines \(SIAARTI/EAMS, 2020\)](#)

[ESICM Ventilation Guidelines](#)

[Performing Procedures on Patients With Known or Suspected COVID-19 \(ASA, 2020\)](#)

[OSHA Guidance on Preparing the Workplace for COVID-19 \(2020\)](#)

[Policy for Sterilizers, Disinfectant Devices, and Air Purifiers \(FDA, 2020\)](#)

[Breast Cancer Patient Triage Guidelines \(CPBCC, 2020\)](#)

[clinical guidance for adult Belgian patients with suspected or confirmed COVID-19](#)

[National Covid-19 Testing Action Plan \(Rockefeller Foundation\)](#)

[ASE issues Echo-cardiography guidance](#)

Trials & Registries

[CAPACITY European registry COVID 19 patients](#)

[WHO launches global megatrial](#)

[FDA launches Convalescent plasma trial](#)

[Lets Beat Covid-19 Survey to help plan hospital services](#)

[COVID IBD registry](#)

[Google mobility reports per country COVID 19](#)

[World's largest trial of potential coronavirus treatments rolled out across the UK](#)

[Pregnancy Registry \(US\)](#)

[ICNARC report on COVID-19 in critical care - NHS April 24](#)

[COVID-19 Human Genetics - Biobanks](#)

[COVID19 settings of transmission database](#)

Mainstream Media

[New York Times - Corona update](#)

Coronavirus Vaccine Tracker

A Hospital Forgot to Bill Her Coronavirus Test. It Cost Her \$1,980.

Scientists Uncover Biological Signatures of the Worst Covid-19 Case

There Is No Silver Bullet,' W.H.O. Chief Says

The Mask Slackers of 1918

Is Telemedicine Here to Stay?

Russia Sets Mass Vaccination for October After Shortened Trial

Washington Post - Corona update

These airports are leading coronavirus testing for international travelers

No national testing strategy for coronavirus. These states banded to make one.

Fauci amplifies Birx's warning about 'new phase' of coronavirus spread in U.S.

Congress flails as coronavirus ravages the nation and the economy stalls

Nonprofits in trouble: One-third of may not survive pandemic, recession

A coronavirus vaccine won't change the world right away.

Guardian - Corona update

Does coronavirus spread in the air and how do we stay safe?

Why has a major incident been declared in Greater Manchester?

Stage 4 lockdown in Melbourne ablow to Covid-weakened Australian economy.

How the world is coping with coronavirus, six months on

Coronavirus live news: global death toll passes 700,000

UK biobank seroprevalences study in UK

Key Articles

- 1. Characteristics of Clinical Trials relating to COVID-19 registered at ClinicalTrials.gov.** *J. Clin. Pharm. Ther.* 2020; Wang Y, Zhou Q, Xu M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32734670>
- 2. Statins as early therapy to mitigate COVID-19 (SARS-CoV-2)-associated ARDS and cytokine storm syndrome – time is of the essence.** *Journal of Clinical and Translational Research* 2020; Teoh N, Farrell G.
- 3. Prospective study comparing deep-throat saliva with other respiratory tract specimens in the diagnosis of novel coronavirus disease (COVID-19).** *J Infect Dis* 2020; Lai CKC, Chen Z, Lui G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32738137>
- 4. Predictors of Adverse Prognosis in Covid-19: A Systematic Review and Meta-analysis.** *Eur. J. Clin. Invest.* 2020:e13362Figliozzi S, Masci PG, Ahmadi N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32726868>
- 5. Comorbidities and the risk of severe or fatal outcomes associated with coronavirus disease 2019: A systematic review and meta-analysis.** *Int J Infect Dis* 2020; Zhou Y, Yang Q, Chi J *et al.*

<http://www.ncbi.nlm.nih.gov/pubmed/?term=32721533>

6. **ACE gene polymorphism and severe lung injury in patients with COVID-19.** Am. J. Pathol. 2020; Zheng H, Cao JJ.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=32735889>
7. **Characteristics and transmission dynamics of COVID-19 in healthcare workers at a London teaching hospital.** J Hosp Infect 2020; Zheng C, Hafezi-Bakhtiari N, Cooper V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32730771>
8. **Cardiovascular disease and COVID-19: Australian and New Zealand consensus statement.** Med. J. Aust. 2020; Zaman S, Maclsaac AI, Jennings GL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32734645>
9. **In-flight transmission cluster of COVID-19: a retrospective case series.** Infect Dis (Lond) 2020:1-11 Yang N, Shen Y, Shi C *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=32735163>
10. **Concerns for management of STEMI patients in the COVID-19 era: a paradox phenomenon.** J. Thromb. Thrombolysis 2020; Vlachakis PK, Tentolouris A, Kanakakis I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32734526>
11. **Postmortem Kidney Pathology Findings in Patients with COVID-19.** J Am Soc Nephrol 2020; Santoriello D, Khairallah P, Bomback AS *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=32727719>
12. **Epidemiology, Clinical Characteristics of the First Cases of COVID-19.** Eur. J. Clin. Invest. 2020:e13364 Liu J, Liu S, Wei H, Yang X.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=32725884>
13. **Consensus on Criteria for Good Practices in Video Consultation: A Delphi Study.** Int J Environ Res Public Health 2020; 17 Jiménez-Rodríguez D, Ruiz-Salvador D, Rodríguez Salvador MDM *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=32727042>
14. **Particle sizes of infectious aerosols: implications for infection control.** The Lancet Respiratory Medicine 2020; Fennelly KP.
15. **COVID-19 in pregnant women: A systematic review and meta-analysis.** Eur. J. Obstet. Gynecol. Reprod. Biol. 2020; Capobianco G, Saderi L, Aliberti S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32713730>

Basic Science (32 articles)

1. **JAK/STAT Pathway Inhibition May Be a Promising Therapy for COVID-19-Related Hyperinflammation in Hematologic Patients.** Acta Haematol. 2020:1-5 Rojas P, Sarmiento M.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=32726783>

2. **Molecular Insights into Small Molecule Drug Discovery for SARS-CoV-2.** *Angew. Chem. Int. Ed. Engl.* 2020; Su H, Su H, Zhou F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32729180>
3. **Flavonoids Activation of the Transcription Factor Nrf2 as a Hypothesis Approach for the Prevention and Modulation of SARS-CoV-2 Infection Severity.** *Antioxidants (Basel)* 2020; 9Mendonca P, Soliman KFA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32722164>
4. **Mechanistic insights of host cell fusion of SARS-CoV-1 and SARS-CoV-2 from atomic resolution structure and membrane dynamics.** *Biophys. Chem.* 2020; 265:106438Chakraborty H, Bhattacharjya S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32721790>
5. **The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity.** *Cell* 2020; Li Q, Wu J, Nie J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32730807>
6. **A Replication-Competent Vesicular Stomatitis Virus for Studies of SARS-CoV-2 Spike-Mediated Cell Entry and Its Inhibition.** *Cell Host Microbe* 2020; Dieterle ME, Haslwanter D, Bortz RH, 3rd *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32738193>
7. **A Message from the Human Placenta: Structural and Immunomodulatory Defense against SARS-CoV-2.** *Cells* 2020; 9Kreis NN, Ritter A, Louwen F, Yuan J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32722449>
8. **Relationship Between serum SARS-CoV-2 nucleic acid(RNAemia) and Organ Damage in COVID-19 Patients: A Cohort Study.** *Clin Infect Dis* 2020; Xu D, Zhou F, Sun W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32720678>
9. **In silico ADMET and molecular docking study on searching potential inhibitors from limonoids and triterpenoids for COVID-19.** *Comput. Biol. Med.* 2020; 124:103936Vardhan S, Sahoo SK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32738628>
10. **Differential Tropism of SARS-CoV and SARS-CoV-2 in Bat Cells.** *Emerg Infect Dis* 2020; 26Lau SKP, Wong ACP, Luk HKH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32730733>
11. **Structure-based drug repositioning over the human TMPRSS2 protease domain: search for chemical probes able to repress SARS-CoV-2 Spike protein cleavages.** *Eur. J. Pharm. Sci.* 2020:105495Singh N, Decroly E, Khatib AM, Villoutreix BO. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32730844>
12. **The ACE2-deficient mouse: A model for a cytokine storm-driven inflammation.** *Faseb j* 2020; Wang J, Kaplan N, Wysocki J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32725927>
13. **Severe Acute Respiratory Syndrome Coronavirus 2: From Gene Structure to Pathogenic Mechanisms and Potential Therapy.** *Front. Microbiol.* 2020; 11:1576Wu J, Yuan X, Wang B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32719672>
14. **Analysis of ACE2 Gene-Encoded Proteins Across Mammalian Species.** *Front Vet Sci* 2020; 7:457Cao Y, Sun Y, Tian X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32719819>
15. **Decoding the proteome of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) for cell-penetrating peptides involved in pathogenesis or applicable as drug delivery vectors.** *Infect Genet Evol* 2020:104474Hemmati S, Behzadipour Y, Haddad M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32712315>
16. **In silico Study of Azithromycin, Chloroquine and Hydroxychloroquine and their Potential Mechanisms of Action against SARS-CoV-2 Infection.** *Int J Antimicrob Agents* 2020:106119Braz HLB, de Moraes Silveira JA, Marinho AD *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32738306>
17. **Isolation and phylogenetic analysis of SARS-CoV-2 variants collected in Russia during COVID-19 outbreak.** *Int J Infect Dis* 2020; Kozlovskaya L, Pinaeva A, Ignatyev G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32721529>
18. **Pt-, Rh-, Ru-, and Cu-Single-Wall Carbon Nanotubes Are Exceptional Candidates for Design of Anti-Viral Surfaces: A Theoretical Study.** *Int J Mol Sci* 2020; 21Aasi A, Aghaei SM, Moore MD, Panchapakesan B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32717853>
19. **Computational Studies of SARS-CoV-2 3CLpro: Insights from MD Simulations.** *Int J Mol Sci* 2020; 21Grottesi A, Bešker N, Emerson A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32731361>
20. **The Lord of the NanoRings: cyclodextrins and the battle against SARS-CoV-2.** *Int. J. Pharm.* 2020:119689Garrido PF, Calvelo M, Blanco-González A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32717282>
21. **Tackling COVID-19: identification of potential main protease inhibitors via structural analysis, virtual screening, molecular docking and MM-PBSA calculations.** *J Biomol Struct Dyn* 2020:1-16Al-Shar'i NA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32734828>
22. **Identification of some novel oxazine substituted 9-anilinoacridines as SARS-CoV-2 inhibitors for COVID-19 by molecular docking, free energy calculation and molecular dynamics studies.** *J Biomol Struct Dyn* 2020:1-12Rajagopal K, Varakumar P, Aparna B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32720578>
23. **In silico study to evaluate the antiviral activity of novel structures against 3C-like protease of Novel Coronavirus (COVID-19) and SARS-CoV.** *Med. Chem.* 2020; Chunduru K, Sankhe R, Begum F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32720605>
24. **Identification of potential Mpro inhibitors for the treatment of COVID-19 by using systematic virtual screening approach.** *Mol. Divers.* 2020; Kanhed AM, Patel DV, Teli DM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32737681>
25. **A Computational Approach to Identify Potential Novel Inhibitors against the Coronavirus SARS-CoV-2.** *Mol Inform* 2020; Battisti V, Wieder O, Garon A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32721082>
26. **In silico Drug Repurposing for COVID-19: Targeting SARS-CoV-2 Proteins through Docking and Consensus Ranking.** *Mol Inform* 2020; Cavasotto C, Di Filippo J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32722864>
27. **Evolutionary origins of the SARS-CoV-2 sarbecovirus lineage responsible for the COVID-19 pandemic.** *Nat Microbiol* 2020; Boni MF, Lemey P, Jiang X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32724171>
28. **Mouse Model of SARS-CoV-2 Reveals Inflammatory Role of Type I Interferon Signaling.** *Ssrn* 2020:3628297Goldman-Israelow B, Song E, Mao T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32714125>
29. **Candidate Targets for Immune Responses to 2019-Novels Coronavirus (nCoV): Sequence Homology- and Bioinformatic-Based Predictions.** *Ssrn* 2020:3541361Grifoni A, Sidney J, Zhang Y *et al.*

- <http://www.ncbi.nlm.nih.gov/pubmed/?term=32714104>
30. **Integrative Network Biology Framework Elucidates Molecular Mechanisms of SARS-CoV-2 Pathogenesis.** *Ssrn* 2020:3581857 Kumar N, Mishra B, Mehmood A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=32714115>
 31. **Bats and humans during the SARS-CoV-2 outbreak: the case of bat-coronavirus from Mexico.** *Transbound Emerg Dis* 2020; Pablo CS, Giovani HC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32725795>
 32. **In Silico Insights into the SARS CoV-2 Main Protease Suggest NADH Endogenous Defences in the Control of the Pandemic Coronavirus Infection.** *Viruses* 2020; 12 Martorana A, Gentile C, Lauria A.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=32722574>

Biomarkers - Genetics (71 articles)

1. **High neutrophil-to-lymphocyte ratio associated with progression to critical illness in older patients with COVID-19: a multicenter retrospective study.** *Aging (Albany NY)* 2020; 12 Lian J, Jin C, Hao S *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=32730223>
2. **Clinical characteristics, laboratory outcome characteristics, comorbidities, and complications of related COVID-19 deceased: a systematic review and meta-analysis.** *Aging Clin. Exp. Res.* 2020; Qiu P, Zhou Y, Wang F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32734576>
3. **Antibodies in serum of convalescent patients following mild COVID-19 do not always prevent virus receptor binding.** *Allergy* 2020; Gattinger P, Borochova K, Dorofeeva Y *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=32734595>
4. **SARS-CoV-2 receptor ACE2 protein expression in serum is significantly associated with age.** *Allergy* 2020; Pavel AB, Wu J, Renert-Yuval Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32726474>
5. **Lactate dehydrogenase levels predict coronavirus disease 2019 (COVID-19) severity and mortality: A pooled analysis.** *Am J Emerg Med* 2020; 38:1722-1726 Henry BM, Aggarwal G, Wong J *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=32738466>
6. **ACE gene polymorphism and severe lung injury in patients with COVID-19.** *Am. J. Pathol.* 2020; Zheng H, Cao JJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32735889>
7. **SARS-CoV-2 infection among healthcare workers of a gastroenterological service in a tertiary care facility.** *Arab J Gastroenterol* 2020; Kassem AM, Talaat H, Shawky S *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=32732168>
8. **Could breath analysis by MS could be a solution to rapid, non-invasive testing for COVID-19?** *Bioanalysis* 2020; Walker HJ, Burrell MM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32734782>
9. **Virtual laboratories during coronavirus (COVID-19) pandemic.** *Biochem Mol Biol Educ* 2020; Vasiliadou R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32722891>
10. **Blood routine test in mild and common 2019 coronavirus (COVID-19) patients.** *Biosci. Rep.* 2020; Djakpo DK, Wang Z, Zhang R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32725148>
11. **Clinically practiced and commercially viable nanobio engineered analytical methods for COVID-19 diagnosis.** *Biosens. Bioelectron.* 2020; 165:112361 Mahapatra S, Chandra P.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=32729494>
12. **Real-time diagnosis of reactive oxygen species (ROS) in fresh sputum by electrochemical tracing; correlation between COVID-19 and viral-induced ROS in lung/respiratory epithelium during this pandemic.** *Biosens. Bioelectron.* 2020; 165:112435 Miripour ZS, Sarrami-Forooshani R, Sanati H *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=32729548>
13. **Diagnostics for SARS-CoV-2 detection: A comprehensive review of the FDA-EUA COVID-19 testing landscape.** *Biosens. Bioelectron.* 2020; 165:112454 Ravi N, Cortade DL, Ng E, Wang SX.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=32729549>
14. **SARS-CoV-2 specific serological pattern in healthcare workers of an Italian COVID-19 forefront hospital.** *BMC Pulm. Med.* 2020; 20:203 Sotgiu G, Barassi A, Miozzo M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=32727446>
15. **Computationally Optimized SARS-CoV-2 MHC Class I and II Vaccine Formulations Predicted to Target Human Haplotype Distributions.** *Cell Syst* 2020; Liu G, Carter B, Bricken T *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=32721383>
16. **Relationship Between serum SARS-CoV-2 nucleic acid (RNAemia) and Organ Damage in COVID-19 Patients: A Cohort Study.** *Clin Infect Dis* 2020; Xu D, Zhou F, Sun W *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=32720678>
17. **Evaluating the newly developed BioFire® COVID-19 test for SARS-Cov-2 molecular detection.** *Clin Microbiol Infect* 2020; Liotti FM, Menchinelli G, Marchetti S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32735938>
18. **Loop-Mediated Isothermal Amplification Screening for COVID-19 in Asymptomatic Preoperative Orthopedic Patients in a General Hospital in Kanagawa, Japan.** *Cureus* 2020; 12:e9331 Uchida K, Sekiguchi H, Higashiyama R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32714714>
19. **Blood type O as protective factor?: Gene variants have influence on the progression of COVID-19.** *Deutsche Apotheker Zeitung* 2020; 160.
20. **Corona provisional appraisal in North Rhine: Courier services during the peak phase of the pandemic increasingly in demand.** *Deutsche Apotheker Zeitung* 2020; 160.
21. **Hyperglycemia is a strong predictor of poor prognosis in COVID-19.** *Diabetes Res Clin Pract* 2020:108338 Liu SP, Zhang Q, Wang W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32712122>
22. **SARS-CoV-2 detection in different respiratory sites: A systematic review and meta-analysis.** *EBioMedicine* 2020:102903 Mohammadi A, Esmailzadeh E, Li Y *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=32718896>
23. **Seroprevalence of SARS-CoV-2 and Infection Fatality Ratio, Orleans and Jefferson Parishes, Louisiana, USA, May 2020.** *Emerg Infect Dis* 2020; 26 Feehan AK, Fort D, Garcia-Diaz J *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=32731911>
24. **Detection of SARS-CoV-2 in Hemodialysis Effluent of Patient with COVID-19 Pneumonia, Japan.** *Emerg Infect Dis* 2020; 26 Okuhama A, Ishikane M, Katagiri D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32730734>
25. **Seroprevalence of SARS-CoV-2-Specific Antibodies, Faroe Islands.** *Emerg Infect Dis* 2020; 26 Petersen MS, Strøm M, Christiansen DH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32726200>

26. **Nationwide External Quality Assessment of SARS-CoV-2 Molecular Testing, South Korea.** *Emerg Infect Dis* 2020; 26:Sung H, Han MG, Yoo CK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32723432>
27. **Contribution of acute-phase reaction proteins to the diagnosis and treatment of 2019 novel coronavirus disease (COVID-19).** *Epidemiol Infect* 2020; 148:e164Li L, Chen C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32713370>
28. **Authors' response: COVID-19: how accurate are seroprevalence studies?** *Euro Surveill* 2020; 25:Cassaniti I, Percivalle E, Sarasini A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32734854>
29. **Letter to the editor: COVID-19: how accurate are seroprevalence studies?** *Euro Surveill* 2020; 25:Kadkhoda K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32734860>
30. **Duration of SARS-CoV-2 RNA detection in COVID-19 patients in home isolation, Rhineland-Palatinate, Germany, 2020 - an interval-censored survival analysis.** *Euro Surveill* 2020; 25:Omar S, Bartz C, Becker S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32734855>
31. **Network perturbation analysis in human bronchial epithelial cells following SARS-CoV2 infection.** *Exp. Cell Res.* 2020;112204Nunnari G, Sanfilippo C, Castrogiovanni P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32735892>
32. **Tumor markers as an entry for SARS-CoV-2 infection?** *Febs j.*2020; Xia P, Dubrovskaya A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32738184>
33. **False Positive COVID-19 Antibody Test in a Case of Granulomatosis With Polyangiitis.** *Front Med (Lausanne)* 2020; 7:399Tzouveleki A, Karamitsakos T, Krompa A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32733908>
34. **Immune Phenotyping Based on the Neutrophil-to-Lymphocyte Ratio and IgG Level Predicts Disease Severity and Outcome for Patients With COVID-19.** *Front Mol Biosci* 2020; 7:157Zhang B, Zhou X, Zhu C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32719810>
35. **Seroprevalence of COVID-19 antibodies in the cleaning and oncological staff of a municipal clinic.** *GMS Hyg Infect Control* 2020; 15:Doc18Epstude J, Harsch IA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32733782>
36. **The African-American population with a low allele frequency of SNP rs1990760 (T allele) in IFIH1 predicts less IFN-beta expression and potential vulnerability to COVID-19 infection.** *Immunogenetics* 2020; Maiti AK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32737579>
37. **A Narrative Systematic Review of the Clinical Utility of Cycle Threshold Values in the Context of COVID-19.** *Infect Dis Ther* 2020; Rao SN, Manissero D, Steele VR, Pareja J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32725536>
38. **Prognostic value of serum amyloid A in patients with COVID-19.** *Infection* 2020; Cheng L, Yang JZ, Bai WH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32734556>
39. **Diagnostic performance of initial blood urea nitrogen combined with D-Dimer levels for predicting in-hospital mortality in COVID-19 patients.** *Int J Antimicrob Agents* 2020;106110Cheng A, Hu L, Wang Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32712332>
40. **Willingness and Readiness to test for COVID-19; A qualitative exploration of community pharmacists.** *Int J Clin Pract* 2020:e13620Mukattash TL, Jarab AS, Abu-Farha RK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32734628>
41. **Acute Onset Olfactory/Taste Disorders are Associated with a High Viral Burden in Mild or Asymptomatic SARS-CoV-2 Infections.** *Int J Infect Dis* 2020; Nakagawara K, Masaki K, Uwamino Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32726723>
42. **Peripheral blood morphologic findings in patients with COVID-19.** *Int. J. Lab. Hematol.* 2020; Sadigh S, Massoth LR, Christensen BB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32730694>
43. **HLA-B*44 and C*01 Prevalence Correlates with Covid19 Spreading across Italy.** *Int J Mol Sci* 2020; 21:Correale P, Mutti L, Pentimalli F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32717807>
44. **High Prevalence of Asymptomatic COVID-19 Infection in Hemodialysis Patients Detected Using Serologic Screening.** *J Am Soc Nephrol* 2020; Clarke C, Predecki M, Dhutia A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32732391>
45. **Head-to-Head Comparison of Two SARS-CoV-2 Serology Assays.** *J Appl Lab Med* 2020; Merrill AE, Jackson JB, Ehlers A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32717056>
46. **Virtual screening, ADMET prediction and dynamics simulation of potential compounds targeting the main protease of SARS-CoV-2.** *J Biomol Struct Dyn* 2020;1-16Yadav R, Imran M, Dhamija P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32715956>
47. **Head-to-Head Accuracy Comparison of Three Commercial COVID-19 IgM/IgG Serology Rapid Tests.** *J Clin Med* 2020; 9:Andrey DO, Cohen P, Meyer B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32722191>
48. **The characteristics and outcomes of 681 severe cases with COVID-19 in China.** *J Crit Care* 2020; 60:32-37Chen FF, Zhong M, Liu Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32736197>
49. **Repeated negative serological testing in otherwise healthy patients with COVID-19.** *J Infect Dis* 2020; Chatzidimitriou M, Chatzopoulou F, Gavriilaki E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32726440>
50. **Prospective study comparing deep-throat saliva with other respiratory tract specimens in the diagnosis of novel coronavirus disease (COVID-19).** *J Infect Dis* 2020; Lai CKC, Chen Z, Lui G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32738137>
51. **Immunoserologic detection and diagnostic relevance of cross-reactive auto-antibodies in COVID-19 patients.** *J Infect Dis* 2020; Schiaffino MT, Di Natale M, Garcia-Martínez E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32738141>
52. **IgG Seroprevalence of COVID-19 among Individuals without a History of the Coronavirus Disease Infection in Daegu, Korea.** *J Korean Med Sci* 2020; 35:e269Song SK, Lee DH, Nam JH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32715672>
53. **Clinical validation of an immunochromatographic SARS-Cov-2 IgM/IgG antibody assay with Japanese cohort.** *J Med Virol* 2020; Kaneko S, Nukui Y, Arashiro T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32720704>
54. **The Association of Interleukin-6 value, Interleukin inhibitors and Outcomes of Patients with COVID-19 in New York City.** *J Med Virol* 2020; Maeda T, Obata R, Rizk DD, Kuno T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32720702>
55. **Risk factors for the COVID-19 severity and its correlation with viral shedding: a retrospective cohort study.** *J Med Virol* 2020; Zheng X, Chen J, Deng L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32725915>

56. **A modular framework for the development of targeted Covid-19 blood transcript profiling panels.** *J Transl Med* 2020; 18:291 Rinchai D, Syed Ahamed Kabeer B, Toufiq M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32736569>
57. **Utility of D-dimer for diagnosis of deep vein thrombosis in COVID-19 infection.** *J Vasc Surg Venous Lymphat Disord* 2020; Cho ES, McClelland PH, Cheng O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32738407>
58. **Optimum naso-oropharyngeal swab procedure for COVID-19: step by step preparation and technical hints.** *Laryngoscope* 2020; Coden E, Russo F, Arosio AD *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32716074>
59. **The role of cytokine profile and lymphocyte subsets in the severity of coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis.** *Life Sci* 2020:118167 Akbari H, Tabrizi R, Lankarani KB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32735885>
60. **Molecular profiling of immune cell-enriched Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) interacting protein USP13.** *Life Sci* 2020:118170 Süt BB. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32735883>
61. **'The Double-Edged Sword' - A hypothesis for Covid-19-induced salivary biomarkers.** *Med. Hypotheses* 2020; 143:110124 Adeoye J, Thomson P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32721813>
62. **SARS-CoV-2: A Piece of Bad News.** *Medeni Med J* 2020; 35:151-160 Abdullah SF, Sharquie IK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32733765>
63. **SARS-CoV-2 RNA Persistence in Naso-Pharyngeal Swabs.** *Microorganisms* 2020; 8:Danzetta ML, Amato L, Cito F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32722621>
64. **Low Albumin Levels Are Associated with Poorer Outcomes in a Case Series of COVID-19 Patients in Spain: A Retrospective Cohort Study.** *Microorganisms* 2020; 8:de la Rica R, Borges M, Aranda M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32722020>
65. **Implementation of Antibody Rapid Diagnostic Testing versus Real-Time Reverse Transcription-PCR Sample Pooling in the Screening of COVID-19: a Case of Different Testing Strategies in Africa.** *mSphere* 2020; 5:Nyazika TK, Kaela R, Mugoni M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32727861>
66. **Monitoring bronchoalveolar lavage with electrical impedance tomography: first experience in a patient with COVID-19.** *Physiol. Meas.* 2020; Fu Y, Zou R, Wang S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32736369>
67. **Haplotype networks of SARS-CoV-2 infections in the Diamond Princess cruise ship outbreak.** *Proc Natl Acad Sci U S A* 2020; Sekizuka T, Itokawa K, Kageyama T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32723824>
68. **Nox2 activation in Covid-19.** *Redox Biol* 2020; 36:101655 Violi F, Oliva A, Cangemi R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32738789>
69. **Early Recognition of Coronavirus 2019 Disease (COVID-19) Infection in Surgical Inpatients: The Importance of a Risk-Stratified Approach for Early Testing and Isolation.** *Surg Infect (Larchmt)* 2020; Wee LE, Sim XYJ, Conceicao EP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32716758>
70. **The effect of COVID-19 on absolute neutrophil counts in patients taking clozapine.** *Ther Adv Psychopharmacol* 2020; 10:2045125320940935 Gee S, Taylor D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32728419>
71. **Development of a fully automated high throughput PCR for the detection of SARS-CoV-2: The need for speed.** *Virulence* 2020; 11:964-967 Mayer FJ, Ratzinger F, Schmidt RLJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32726172>

Children (15 articles)

1. **Ruptured cerebral pseudoaneurysm in an adolescent as an early onset of COVID-19 infection: case report.** *Acta Neurochir. (Wien.)* 2020; Savić D, Alsheikh TM, Alhaj AK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32720013>
2. **Bone in the Time of Corona: Suggestions for Managing Pediatric Orthopaedics Conditions in a Resource-limited Environment during the COVID-19 Pandemic.** *Arch Bone Jt Surg* 2020; 8:231-234 Baghdadi S, Nabian MH, Baghdadi T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32733979>
3. **COVID-19 in Children with Nephrotic Syndrome on Anti-CD20 Chronic Immunosuppression.** *Clin J Am Soc Nephrol* 2020; Angeletti A, Drovandi S, Sanguineri F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32718953>
4. **PIMS is not the same as Kawasaki: New findings on COVID-19-associated inflammatory syndrome in children.** *Deutsche Apotheker Zeitung* 2020; 160 Bruhn C.
5. **PANDEMIE SPEZIAL: Kinder seltener mit SARS-CoV-2 infiziert?** *Deutsche Apotheker Zeitung* 2020; 160 Bruhn C.
6. **Children and adolescents with eating disorders during COVID-19 confinement: Difficulties and future challenges.** *Eur Eat Disord Rev* 2020; Graell M, Morón-Nozaleda MG, Camarero R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32729139>
7. **Case Report: Systemic Inflammatory Response and Fast Recovery in a Pediatric Patient With COVID-19.** *Front. Immunol.* 2020; 11:1665 Klocperk A, Parackova Z, Dissou J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32719688>
8. **Kidney Replacement Therapy in COVID-19 Induced Kidney Failure and Septic Shock: A Pediatric Continuous Renal Replacement Therapy [PCRRT] Position on Emergency Preparedness With Resource Allocation.** *Front Pediatr* 2020; 8:413 Raina R, Chakraborty R, Sethi SK, Bunchman T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32719758>
9. **Impact of the Covid-19 Pandemic in Children with Allergic Asthma.** *J Allergy Clin Immunol Pract* 2020; Ruano FJ, Somoza Álvarez ML, Haroun-Díaz E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32730834>
10. **How is COVID-19 Affecting the Mental Health of Children with Special Educational Needs and Disabilities and Their Families?** *J. Autism Dev. Disord.* 2020; Asbury K, Fox L, Deniz E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32737668>
11. **Multisystem inflammatory syndrome in children and COVID-19 are distinct presentations of SARS-CoV-2.** *J. Clin. Invest.* 2020; Diorio C, Henrickson SE, Vella LA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/>

term=32730233

12. **COVID-19 Infection in Children with Pre-existing Heart Disease.** *J. Pediatr.* 2020; Simpson M, Collins C, Nash DB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32730815>
13. **Clinical characteristics of COVID-19 in children: a systematic review.** *Pediatr Pulmonol* 2020; Yasuhara J, Kuno T, Takagi H, Sumitomo N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32725955>
14. **COVID-19 in pediatric patients: a case series from the Bronx, NY.** *Pediatr Radiol* 2020; Blumfield E, Levin TL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32728901>
15. **[Covid-19 and child health: confinement and its impact according to child professionals.]** *Rev. Esp. Salud Publica* 2020; 94Valero Alzaga E, Martín Roncero U, Domínguez-Rodríguez A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32713937>

Clinical Features (35 articles)

- **Clinical characteristics of COVID-19 and its comparison with influenza pneumonia.** *Acta Clin. Belg.* 2020;1-9Qu J, Chang LK, Tang X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32723027>
- **Coronavirus Disease 2019 (COVID-19): A Haematologist's Perspective.** *Acta Haematol.* 2020;1-14Cheung CKM, Law MF, Lui GCY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32721958>
- **COVID-19 induced liver function abnormality associates with age.** *Aging (Albany NY)* 2020; 12Li S, Li J, Zhang Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32721928>
- **Clinical characteristics, laboratory outcome characteristics, comorbidities, and complications of related COVID-19 deceased: a systematic review and meta-analysis.** *Aging Clin. Exp. Res.* 2020; Qiu P, Zhou Y, Wang F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32734576>
- **Dermatologic manifestations and complications of COVID-19.** *Am J Emerg Med* 2020; 38:1715-1721Gottlieb M, Long B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32731141>
- **Clinical outcomes of COVID-19 in Wuhan, China: a large cohort study.** *Ann Intensive Care* 2020; 10:99Liu J, Zhang S, Wu Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32737627>
- **Clinical characteristics of 276 hospitalized patients with coronavirus disease 2019 in Zengdu District, Hubei Province: a single-center descriptive study.** *BMC Infect. Dis.* 2020; 20:549Wei Y, Zeng W, Huang X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32727456>
- **Organ-specific manifestations of COVID-19 infection.** *Clin. Exp. Med.* 2020; Gavriatopoulou M, Korompoki E, Fotiou D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32720223>
- **Gastrointestinal Manifestations in COVID-19 Infection and Its Practical Applications.** *Cureus* 2020; 12:e8750Mandal A, Konala VM, Adapa S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32714688>
- **Nonspecific COVID-19 symptoms: Every tenth complains only about gastrointestinal problems.** *Deutsche Apotheker Zeitung* 2020; 160Buchheit M.
- **Epidemiology, Clinical Characteristics of the First Cases of COVID-19.** *Eur. J. Clin. Invest.* 2020:e13364Liu J, Liu S, Wei H, Yang X. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32725884>
- **COVID-19 pneumonia: relationship between inflammation assessed by whole-body FDG PET/CT and short-term clinical outcome.** *Eur J Nucl Med Mol Imaging* 2020; Dietz M, Chironi G, Claessens YE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32712702>
- **Clinical Characteristics of Adult Febrile COVID-19 Patients and Predictors for Developing Severe Events.** *Front Med (Lausanne)* 2020; 7:324Wang G, Zhang Q, Wu C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32719804>
- **The clinical characteristics and course of COVID-19 in hemodialysis patients.** *Hemodial Int* 2020; Aydin Bahat K, Parmaksiz E, Sert S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32730678>
- **Androgenetic alopecia in COVID-19: compared to age-matched epidemiologic studies and hospital outcomes with or without the Gabrin sign.** *J Am Acad Dermatol* 2020; Wambier CG, Vaño-Galván S, McCoy J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32735970>
- **The characteristics and outcomes of 681 severe cases with COVID-19 in China.** *J Crit Care* 2020; 60:32-37Chen FF, Zhong M, Liu Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32736197>
- **Clinical characteristics and outcomes of COVID-19 patients presenting with initial gastrointestinal symptoms in Wuhan, China: a retrospective cohort study.** *J Gastroenterol Hepatol* 2020; Luo S, Deng Z, Zhang X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32721038>
- **Epidemiological and clinical characteristics of 1663 hospitalized patients infected with COVID-19 in Wuhan, China: a single-center experience.** *J Infect Public Health* 2020; Yu C, Lei Q, Li W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32718894>
- **COVID-19 retinal microangiopathy as an in vivo biomarker of systemic vascular disease?** *J Intern Med* 2020; Landecho MF, Yuste JR, Gándara E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32729633>
- **Characteristics of COVID-19 Patients Who Progress to Pneumonia on Follow-Up Chest Radiograph: 236 Patients from a Single Isolated Cohort in Daegu, South Korea.** *Korean J Radiol* 2020; Jung HK, Kim JY, Lee MS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32729278>
- **Opportunistic Fungal Infections in the Epidemic Area of COVID-19: A Clinical and Diagnostic Perspective from Iran.** *Mycopathologia* 2020; Salehi M, Ahmadikia K, Badali H, Khodavaisy S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32737746>
- **Fungal Co-infections Associated with Global COVID-19 Pandemic: A Clinical and Diagnostic Perspective from China.** *Mycopathologia* 2020; Song G, Liang G, Liu W. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32737747>
- **Acute Parotitis as a Presentation of COVID-19?** *Oral Dis* 2020; Riad A, Kassem I, Badrah M, Klugar M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32713097>
- **Oral mucositis in a Sars-CoV-2 infected patient: secondary or truly associated condition?** *Oral Dis* 2020; Tomo S, Miyahara GI, Simonato LE. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32726467>
- **Clinical characteristics of COVID-19 in children: a systematic review.** *Pediatr Pulmonol* 2020; Yasuhara J, Kuno T, Takagi H, Sumitomo N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32725955>
- **COVID-19 in pediatric patients: a case series from the Bronx, NY.** *Pediatr Radiol* 2020; Blumfield E, Levin TL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32728901>
- **Chest CT for early detection and management of coronavirus disease (COVID-19): a report of 314 patients admitted to Emergency Department with suspected pneumonia.** *Radiol Med* 2020; Gaia C, Maria Chiara C, Silvia L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32729028>

- **Clinical characteristics of 31 hemodialysis patients with 2019 novel coronavirus: a retrospective study.** *Ren. Fail.* 2020; 42:726-732 Zhang J, Cao F, Wu SK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32722980>
- **The pathophysiology of 'happy' hypoxemia in COVID-19.** *Respir Res* 2020; 21:198 Dhont S, Derom E, Van Braeckel E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32723327>
- **The first 100 cases of COVID-19 in a Hospital in Madrid with a 2-month follow-up.** *Rev. Esp. Quimioter.* 2020; Muñoz P, Galar A, Catalán P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32729288>
- **Going viral: A brief history of Chilblain-like skin lesions ("COVID toes") amidst the COVID-19 pandemic.** *Semin. Oncol.* 2020; Massey PR, Jones KM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32736881>
- **Characteristics of asymptomatic COVID-19 infection and progression: a multicenter, retrospective study.** *Virulence* 2020; Yu C, Zhou M, Liu Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32722990>
- **[Clinical characteristics and death risk factors of severe COVID-19].** *Zhonghua Jie He He Hu Xi Za Zhi* 2020; 43:648-653 Qin W, Hu BZ, Zhang Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32727175>
- **[Analysis of clinical characteristics of 49 cases of COVID-19].** *Zhonghua Jie He He Hu Xi Za Zhi* 2020; 43:654-658 Zeng YL, Zhang C, Gao F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32727176>
- **[Clinical characteristics and outcome of 64 patients with severe COVID-19].** *Zhonghua Jie He He Hu Xi Za Zhi* 2020; 43:659-664 Zhu Q, Zhang W, Wang Q *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32727177>

CNS (22 articles)

1. **Smell loss is a prognostic factor for lower severity of COVID-19.** *Ann. Allergy. Asthma. Immunol.* 2020; Foster KJ, Jauregui E, Tajudeen B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32717301>
2. **COVID-19: New findings. Manifestation in the nervous system.** *Arzneimitteltherapie* 2020; 38:225-226 Diener HC.
3. **SARS-CoV-2 and Guillain-Barré syndrome: molecular mimicry with human heat shock proteins as potential pathogenic mechanism.** *Cell Stress Chaperones* 2020; Lucchese G, Flöel A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32729001>
4. **A First Case of Acute Cerebellitis Associated with Coronavirus Disease (COVID-19): a Case Report and Literature Review.** *Cerebellum* 2020; Fadakar N, Ghaemmaghami S, Masoompour SM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32737799>
5. **Neurological Complications in COVID-19 Patients and its Implications for Associated Mortality.** *Curr. Neurovasc. Res.* 2020; AboTaleb HA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32718292>
6. **What the physicians should know about mast cells, dendritic cells, urticaria and omalizumab during COVID-19 or asymptomatic infections due to SARS-CoV-2?** *Dermatol Ther* 2020; Criado PR, Pagliari C, Criado RFJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32713127>
7. **Neuropathogenesis of SARS-CoV-2 infection.** *Elife* 2020; 9 Khan S, Gomes J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32729463>
8. **The effect of COVID-19 pandemic on seizure control and self-reported stress on patient with epilepsy.** *Epilepsy Behav.* 2020; 112:107323 Alkhotani A, Siddiqui MI, Almontashri F, Baothman R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32712565>
9. **Olfactory and taste disorders in healthcare workers with COVID-19 infection.** *Eur Arch Otorhinolaryngol* 2020; Villarreal IM, Morato M, Martínez-RuizCoello M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32725271>
10. **Epilepsy Care in the Time of COVID-19 Pandemic in Italy: Risk Factors for Seizure Worsening.** *Front. Neurol.* 2020; 11:737 Assenza G, Lanzone J, Brigo F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32719655>
11. **Acute Onset Olfactory/Taste Disorders are Associated with a High Viral Burden in Mild or Asymptomatic SARS-CoV-2 Infections.** *Int J Infect Dis* 2020; Nakagawara K, Masaki K, Uwamino Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32726723>
12. **Neurologic and Immunologic Complications of COVID-19: Potential Long-Term Risk Factors for Alzheimer's Disease.** *J Alzheimers Dis Rep* 2020; 4:217-221 Lennon JC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32715280>
13. **COVID-19 retinal microangiopathy as an in vivo biomarker of systemic vascular disease?** *J Intern Med* 2020; Landecho MF, Yuste JR, Gándara E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32729633>
14. **Description of 3 patients with myasthenia gravis and COVID-19.** *J Neurol Sci* 2020; 417:117053 Rein N, Haham N, Orenbuch-Harroch E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32731059>
15. **A Rare Case of Acute Hemorrhagic Leukoencephalitis in a COVID-19 Patient.** *J Neurol Sci* 2020; 416:117035 Yong MH, Chan YFZ, Liu J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32738478>
16. **Moving Forward in Times of Crisis.** *J. Parkinsons Dis.* 2020; Bloem BR, Brundin P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32716323>
17. **Does COVID-19 cause permanent damage to olfactory and gustatory function?** *Med. Hypotheses* 2020; 143:110086 Paolo G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32721795>
18. **Effortful speech with distortion of prosody following SARS-CoV-2 infection.** *Neurol Sci* 2020; Cotelli MS, Cotelli M, Manelli F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32719902>
19. **Dyspnea perception and neurological symptoms in non-severe COVID-19 patients.** *Neurol Sci* 2020; Ora J, Liguori C, Puxeddu E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32734396>
20. **Neuroinvasion, neurotropic, and neuroinflammatory events of SARS-CoV-2: understanding the neurological manifestations in COVID-19 patients.** *Neurol Sci* 2020; Yachou Y, El Idrissi A, Belapasov V, Ait Benali S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32725449>
21. **COVID-19: A Perspective from Clinical Neurology and Neuroscience.** *Neuroscientist* 2020;1073858420946749 Pero A, Ng S, Cai D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32713251>
22. **A Pharmacological Interactome between COVID-19 Patient Samples and Human Sensory Neurons Reveals Potential Drivers of Neurogenic Pulmonary Dysfunction.** *Ssrn* 2020;3581446 Ray P, Wangzhou A, Ghneim N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32714114>

Complications (75 articles)

1. **Semiquantitative lung ultrasound scores in the evaluation and follow-up of critically ill patients with COVID-19: a single-center study.** *Acad Radiol* 2020; Deng Q, Zhang Y, Wang H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32713715>
2. **Phosphate metabolism and Respiratory Alkalosis: a forgotten lesson in COVID-19.** *Age Ageing* 2020; Seers T, Davenport R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32725143>
3. **COVID-19 Among People Living with HIV: A Systematic Review.** *AIDS Behav.* 2020; Mirzaei H, McFarland W, Karamouzian M, Sharifi H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32734438>
4. **Bilateral spontaneous pneumothorax in SARS-CoV-2 infection: A very rare, life-threatening complication.** *Am J Emerg Med* 2020; González-Pacheco H, Gopar-Nieto R, Jiménez-Rodríguez GM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32712235>
5. **Dermatologic manifestations and complications of COVID-19.** *Am J Emerg Med* 2020; 38:1715-1721 Gottlieb M, Long B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32731141>
6. **Left Ventricular Thrombus in a Patient Infecting by Covid-19.** *Ann Thorac Surg* 2020; Gozgec E, Ogul H, Alay H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32735791>
7. **Clinical efficacy of glucocorticoid on the treatment of patients with COVID-19 pneumonia: A single-center experience.** *Biomed. Pharmacother.* 2020; 130:110529Hu Y, Wang T, Hu Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32736237>
8. **Severe Acute Respiratory Syndrome Coronavirus 2 and Coronavirus Disease 2019: A Clinical Overview and Primer.** *Biopreserv. Biobank.* 2020; Knight TE. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32726140>
9. **Identification of Complex Pneumonia during the Outbreak of COVID-19: Bacterial Pneumonia Combined with Acute Eosinophilic Pneumonia in Patients with Maintenance Hemodialysis.** *Blood Purif.* 2020;1-5Hu QD, Mao N, Huang XC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32721968>
10. **Regulating inspiratory pressure to individualise tidal volumes in a simulated two-patient, one-ventilator system.** *Br J Anaesth* 2020; Chen GH, Hellman S, Irie T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32718725>
11. **SARS-CoV-2 and cancer: Are they really partners in crime?** *Cancer Treat. Rev.* 2020; 89:102068van Dam PA, Huizing M, Mestach G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32731090>
12. **SARS-CoV-2 and Guillain-Barré syndrome: molecular mimicry with human heat shock proteins as potential pathogenic mechanism.** *Cell Stress Chaperones* 2020; Lucchese G, Flöel A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32729001>
13. **Successful treatment of two Japanese ESRD cases with severe COVID-19 pneumonia.** *CEN Case Rep* 2020; Abe T, Izumo T, Ueda A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32715376>
14. **A First Case of Acute Cerebellitis Associated with Coronavirus Disease (COVID-19): a Case Report and Literature Review.** *Cerebellum* 2020; Fadakar N, Ghaemmaghami S, Masoompour SM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32737799>
15. **Israeli Position Paper: Triage Decisions for Severely Ill Patients During the COVID-19 Pandemic.** *Chest* 2020; Steinberg A, Levy-Lahad E, Karni T, Sprung CL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32730765>
16. **Characteristics of Acute Pulmonary Embolism in Patients With COVID-19 Associated Pneumonia From the City of Wuhan.** *Clin. Appl. Thromb. Hemost.* 2020; 26:1076029620936772Chen J, Wang X, Zhang S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32726134>
17. **COVID-19-Associated Coagulopathy: An Exacerbated Immunothrombosis Response.** *Clin. Appl. Thromb. Hemost.* 2020; 26:1076029620943293Jayarangaiah A, Kariyanna PT, Chen X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32735131>
18. **Epidemiology of invasive pulmonary aspergillosis among COVID-19 intubated patients: a prospective study.** *Clin Infect Dis* 2020; Bartoletti M, Pascale R, Cricca M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32719848>
19. **Relationship Between serum SARS-CoV-2 nucleic acid(RNAemia) and Organ Damage in COVID-19 Patients: A Cohort Study.** *Clin Infect Dis* 2020; Xu D, Zhou F, Sun W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32720678>
20. **Attenuated Novel SARS Coronavirus 2 Infection in an Allogeneic Hematopoietic Stem Cell Transplant Patient on Ruxolitinib.** *Clin. Lymphoma Myeloma Leuk.* 2020; Foss FM, Rubinowitz A, Landry ML *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32727701>
21. **Predictive model of increased mortality and bed occupancy if thrombolysis becomes the initial treatment strategy for STEMI during the SARS-CoV-2 pandemic.** *Clin Med (Lond)* 2020; Dancy L, O'Gallagher K, Ryan M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32719037>
22. **Nosocomial spread of COVID-19: lessons learned from an audit on a stroke/neurology ward in a UK district general hospital.** *Clin Med (Lond)* 2020; Jewkes SV, Zhang Y, Nicholl DJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32719035>
23. **Hemorrhagic presentations of COVID-19: Risk factors for mortality.** *Clin. Neurol. Neurosurg.* 2020; 198:106112Altschul DJ, Unda SR, de La Garza Ramos R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32738585>
24. **Successful recovery of recurrence of positive SARS-CoV-2 RNA in COVID-19 patient with systemic lupus erythematosus: a case report and review.** *Clin Rheumatol* 2020; He F, Luo Q, Lei M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32725351>
25. **Concomitant new diagnosis of systemic lupus erythematosus and COVID-19 with possible antiphospholipid syndrome. Just a coincidence? A case report and review of intertwining pathophysiology.** *Clin Rheumatol* 2020; Mantovani Cardoso E, Hundal J, Feterman D, Magaldi J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32720260>
26. **Determinants of COVID-19 disease severity in patients with underlying rheumatic disease.** *Clin Rheumatol* 2020; Santos CS, Morales CM, Álvarez ED *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32720259>
27. **Auricle perniois as a manifestation of Covid-19 infection.** *Dermatol Ther* 2020:e14089Proietti I, Tolino E, Bernardini N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32720420>
28. **DAZ AKTUELL: Jour fixe: Wirkstoffe für die Intensivmedizin im Fokus.** *Deutsche Apotheker Zeitung* 2020; 160.

29. **Successes with dexamethasone: Glucocorticoid can improve prognosis in the case of severe COVID-19 disease.** *Deutsche Apotheker Zeitung* 2020; 160Jungmayr P.
30. **Prone Positioning in Non-intubated Patients with COVID-19 Outside the Intensive Care Unit: More Evidence Needed.** *Disaster Med Public Health Prep* 2020;1-6Ripoll-Gallardo A, Grillenzoni L, Bollon J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32713387>
31. **Nursing care for hospitalized patients in COVID-19 units.** *Enferm. Clin.* 2020; de Andrés-Gimeno B, Solís-Muñoz M, Revuelta-Zamorano M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32732015>
32. **ESMO management and treatment adapted recommendations in the COVID-19 era: gynaecological malignancies.** *ESMO Open* 2020; 5Colombo I, Zaccarelli E, Del Grande M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32718919>
33. **High Inflammatory Burden: A Potential Cause of Myocardial Injury in Critically Ill Patients With COVID-19.** *Front Cardiovasc Med* 2020; 7:128Song Y, Gao P, Ran T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32733921>
34. **Role of Immune Dysregulation in Increased Mortality Among a Specific Subset of COVID-19 Patients and Immune-Enhancement Strategies for Combatting Through Nutritional Supplements.** *Front Immunol.* 2020; 11:1548Rao KS, Suryaprakash V, Senthilkumar R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32733487>
35. **Clinical Characteristics of Adult Febrile COVID-19 Patients and Predictors for Developing Severe Events.** *Front Med (Lausanne)* 2020; 7:324Wang G, Zhang Q, Wu C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32719804>
36. **Severe Acute Respiratory Syndrome Coronavirus 2: From Gene Structure to Pathogenic Mechanisms and Potential Therapy.** *Front Microbiol.* 2020; 11:1576Wu J, Yuan X, Wang B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32719672>
37. **Clinical Outcomes of Acute Pancreatitis in Patients with COVID-19.** *Gastroenterology* 2020; Dirweesh A, Li Y, Trikudanathan G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32721439>
38. **Clinical characteristics and outcome of multiple myeloma patients with concomitant COVID-19 at Comprehensive Cancer Centers in Germany.** *Haematologica* 2020; Engelhardt M, Shoumariyeh K, Rösner A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32732357>
39. **Impact of COVID-19 Infection on 24 Patients with Sickle Cell Disease. One Center Urban Experience, Detroit, MI, USA.** *Hemoglobin* 2020;1-6Balanchivadze N, Kudirka AA, Askar S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32722950>
40. **Prevalence of chronic liver disease in patients with COVID-19 and their clinical outcomes: a systematic review and meta-analysis.** *Hepato Int* 2020; Kovalic AJ, Satapathy SK, Thuluvath PJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32725453>
41. **SARS-CoV-2 infection associated acute kidney injury in patients with pre-existing chronic renal disease: A report of two cases.** *Immun Inflamm Dis* 2020; Wang Y, Lv Y, Liu Q. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32725744>
42. **Guidelines for Surgical Tracheostomy and Tracheostomy Tube Change During the COVID-19 Pandemic: A Review Article.** *Indian J Otolaryngol Head Neck Surg* 2020; 72:398-401Radhakrishnan S, Perumbally HA, Surya S, Ponneth MS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32719738>
43. **Co-infection of SARS-CoV-2 with Chlamydia or Mycoplasma pneumoniae: a case series and review of the literature.** *Infection* 2020; Oliva A, Siccardi G, Migliarini A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32725598>
44. **Association between COVID-19 and cardiovascular disease.** *Int J Cardiol Heart Vasc* 2020; 29:100583Srivastava K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32715080>
45. **Treatment of severe COVID-19 courses in intensive care medicine.** *Internist* 2020; Wiesner O, Busch M, David S.
46. **Neurologic and Immunologic Complications of COVID-19: Potential Long-Term Risk Factors for Alzheimer's Disease.** *J Alzheimers Dis Rep* 2020; 4:217-221Lennon JC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32715280>
47. **Effect of an aerosol box on tracheal intubation difficulty.** *J Anesth.* 2020; Wakabayashi R, Ishida T, Yamada T, Kawamata M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32728963>
48. **Role of extracorporeal membrane oxygenation in COVID-19: A systematic review.** *J. Card. Surg.* 2020; Haiduc AA, Alom S, Melamed N, Harky A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32717771>
49. **Bilateral adrenal hemorrhage in Coronavirus disease 2019 patient: A case report.** *J. Clin. Endocrinol. Metab.* 2020; Frankel M, Feldman I, Levine M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32738040>
50. **The characteristics and outcomes of 681 severe cases with COVID-19 in China.** *J Crit Care* 2020; 60:32-37Chen FF, Zhong M, Liu Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32736197>
51. **Extracorporeal membrane oxygenation for refractory COVID-19 acute respiratory distress syndrome.** *J Crit Care* 2020; 60:10-12Le Breton C, Besset S, Freita-Ramos S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32731100>
52. **The Impact of SARS-Cov-2 Virus Infection on the Endocrine System.** *J Endocr Soc* 2020; 4:bvaa082Somasundaram NP, Ranathunga I, Ratnasamy V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32728654>
53. **Drug reaction with eosinophilia and systemic symptoms syndrome in a patient with COVID-19.** *J Eur Acad Dermatol Venereol* 2020; Herman A, Matthews M, Mairlot M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32735713>
54. **Clinical characteristics and outcomes of COVID-19 patients presenting with initial gastrointestinal symptoms in Wuhan, China: a retrospective cohort study.** *J Gastroenterol Hepatol* 2020; Luo S, Deng Z, Zhang X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32721038>
55. **Differences in antibody kinetics and functionality between severe and mild SARS-CoV-2 infections.** *J Infect Dis* 2020; Rijkers G, Murk JL, Wintermans B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32726417>
56. **Eosinophil-Derived Neurotoxin and Respiratory Tract Infection and Inflammation: Implications for COVID 19 Management.** *J. Interferon Cytokine Res.* 2020; Dosanjh A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32721252>
57. **In the shadow of COVID-19: HIV-infected individuals need more attention.** *J Med Virol* 2020; Zhao T, Xuan K, Uy JP, Sun C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32735365>
58. **Description of 3 patients with myasthenia gravis and COVID-19.** *J Neurol Sci* 2020; 417:117053Rein N, Haham N, Orenbuch-Harroch E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32731059>

59. **A Rare Case of Acute Hemorrhagic Leukoencephalitis in a COVID-19 Patient.** *J Neurol Sci* 2020; 416:117035Yong MH, Chan YFZ, Liu J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32738478>
60. **Rehabilitative of COVID-19 patients with acute lower extremity Ischemia and amputation.** *J Rehabil Med* 2020; Brugliera L, Spina A, Castellazzi P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32720698>
61. **Acute abdomen in patients with SARS-CoV-2 infection or co-infection.** *Langenbecks Arch. Surg.* 2020; Seeliger B, Philouze G, Cherkaoui Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32720012>
62. **Does COVID-19 cause permanent damage to olfactory and gustatory function?** *Med. Hypotheses* 2020; 143:110086Paolo G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32721795>
63. **Opportunistic Fungal Infections in the Epidemic Area of COVID-19: A Clinical and Diagnostic Perspective from Iran.** *Mycopathologia* 2020; Salehi M, Ahmadikia K, Badali H, Khodavaisy S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32737746>
64. **Fungal Co-infections Associated with Global COVID-19 Pandemic: A Clinical and Diagnostic Perspective from China.** *Mycopathologia* 2020; Song G, Liang G, Liu W. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32737747>
65. **Effortful speech with distortion of prosody following SARS-CoV-2 infection.** *Neurol Sci* 2020; Cotelli MS, Cotelli M, Manelli F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32719902>
66. **PEEP/ FIO2 ARDSNet Scale Grouping of a Single Ventilator for Two Patients: Modeling Tidal Volume Response.** *Respir. Care* 2020; 65:1094-1103Kheyfets VO, Lammers SR, Wagner J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32712582>
67. **Gastrointestinal perforation in a critically ill patient with COVID-19 pneumonia.** *SAGE Open Med Case Rep* 2020; 8:2050313x20940570Kangas-Dick A, Prien C, Rojas K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32728444>
68. **Intermittent occupancy combined with ventilation: An efficient strategy for the reduction of airborne transmission indoors.** *Sci Total Environ* 2020; 744:140908Melikov AK, Ai ZT, Markov DG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32721678>
69. **COVID-19: Urgent Reconsideration of Lung Edema as a Preventable Outcome: Inhibition of TRPV4 As a Promising and Feasible Approach.** *Ssrn* 2020:3558887Kuebler W, Jordt SE, Liedtke W. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32714108>
70. **Clinical Features of COVID-19 and Factors Associated with Severe Clinical Course: A Systematic Review and Meta-Analysis.** *Ssrn* 2020:3566166Kumar A, Arora A, Sharma P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32714109>
71. **A Pharmacological Interactome between COVID-19 Patient Samples and Human Sensory Neurons Reveals Potential Drivers of Neurogenic Pulmonary Dysfunction.** *Ssrn* 2020:3581446Ray P, Wangzhou A, Ghneim N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32714114>
72. **RECOVERY- Respiratory Support: Respiratory Strategies for patients with suspected or proven COVID-19 respiratory failure; Continuous Positive Airway Pressure, High-flow Nasal Oxygen, and standard care: A structured summary of a study protocol for a randomised controlled trial.** *Trials* 2020; 21:687Perkins GD, Couper K, Connolly B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32727624>
73. **[Clinical characteristics and death risk factors of severe COVID-19].** *Zhonghua Jie He He Hu Xi Za Zhi* 2020; 43:648-653Qin W, Hu BZ, Zhang Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32727175>
74. **[Analysis of clinical characteristics of 49 cases of COVID-19].** *Zhonghua Jie He He Hu Xi Za Zhi* 2020; 43:654-658Zeng YL, Zhang C, Gao F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32727176>
75. **[Clinical characteristics and outcome of 64 patients with severe COVID-19].** *Zhonghua Jie He He Hu Xi Za Zhi* 2020; 43:659-664Zhu Q, Zhang W, Wang Q *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32727177>

Cured – Recovered (10 articles)

1. **COVID-19 Among People Living with HIV: A Systematic Review.** *AIDS Behav.* 2020; Mirzaei H, McFarland W, Karamouzian M, Sharifi H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32734438>
2. **Post-COVID-19 chronic symptoms: a post-infectious entity?** *Clin Microbiol Infect* 2020; Davido B, Seang S, Tubiana R, de Truchis P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32712242>
3. **Successful recovery of recurrence of positive SARS-CoV-2 RNA in COVID-19 patient with systemic lupus erythematosus: a case report and review.** *Clin Rheumatol* 2020; He F, Luo Q, Lei M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32725351>
4. **(18)F-FDG brain PET hypometabolism in post-SARS-CoV-2 infection: substrate for persistent/delayed disorders?** *Eur J Nucl Med Mol Imaging* 2020; Guedj E, Million M, Dudouet P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32728799>
5. **Pulmonary function in patients surviving to COVID-19 pneumonia.** *Infection* 2020; Fumagalli A, Misuraca C, Bianchi A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32725597>
6. **Absent immune response to SARS-CoV-2 in a 3-month recurrence of coronavirus disease 2019 (COVID-19) case.** *Infection* 2020; Gao G, Zhu Z, Fan L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32725596>
7. **HIIT: A potential rehabilitation treatment in COVID-19 pneumonia with heart disease.** *Int J Cardiol* 2020; Li Y, Liu D, Wu H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32721412>
8. **Rehabilitative of COVID-19 patients with acute lower extremity Ischemia and amputation.** *J Rehabil Med* 2020; Brugliera L, Spina A, Castellazzi P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32720698>
9. **Rehabilitative of COVID-19 patients with acute lower extremity Ischemia and amputation.** *J Rehabil Med* 2020; Brugliera L, Spina A, Castellazzi P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32720698>
10. **Systematic Review of Changes and Recovery in Physical Function and Fitness After Severe Acute Respiratory Syndrome-Related Coronavirus Infection: Implications for COVID-19 Rehabilitation.** *Phys Ther* 2020; Rooney S, Webster A, Paul L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32737507>

Cardiovascular disease (47 articles)

1. **Impact of COVID-19-related public containment measures on the ST elevation myocardial infarction epidemic in Belgium: a nationwide, serial, cross-sectional study.** *Acta Cardiol.* 2020;1-7Claeys MJ, Argacha JF, Collart P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32727305>
2. **Ruptured cerebral pseudoaneurysm in an adolescent as an early onset of COVID-19 infection: case report.** *Acta Neurochir. (Wien.)* 2020; Savić D, Alsheikh TM, Alhaj AK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32720013>
3. **Left Ventricular Thrombus in a Patient Infecting by Covid-19.** *Ann Thorac Surg* 2020; Gozgec E, Ogul H, Alay H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32735791>
4. **COVID-19: A Concern for Cardiovascular Disease Patients.** *Cardiovasc. Toxicol.* 2020; Sharma S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32729064>
5. **Impact of public health emergency response to COVID-19 on management and outcome for NSTEMI patients in Beijing: A single-center historic control.** *Catheter. Cardiovasc. Interv.* 2020; Liu S, Song C, Yin D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32725858>
6. **Characteristics of Acute Pulmonary Embolism in Patients With COVID-19 Associated Pneumonia From the City of Wuhan.** *Clin. Appl. Thromb. Hemost.* 2020; 26:1076029620936772Chen J, Wang X, Zhang S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32726134>
7. **Pathogenesis and Treatment Strategies of COVID-19-Related Hypercoagulant and Thrombotic Complications.** *Clin. Appl. Thromb. Hemost.* 2020; 26:1076029620944497Haime MA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32722927>
8. **COVID-19-Associated Coagulopathy: An Exacerbated Immunothrombosis Response.** *Clin. Appl. Thromb. Hemost.* 2020; 26:1076029620943293Jayarangaiah A, Kariyanna PT, Chen X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32735131>
9. **Statins in COVID-19: is there any foundation?** *Clin. Investig. Arterioscler* 2020; Lima Martínez MM, Contreras MA, Marín W, D'Marco L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32718669>
10. **Predictive model of increased mortality and bed occupancy if thrombolysis becomes the initial treatment strategy for STEMI during the SARS-CoV-2 pandemic.** *Clin. Med (Lond)* 2020; Dancy L, O'Gallagher K, Ryan M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32719037>
11. **Nosocomial spread of COVID-19: lessons learned from an audit on a stroke/neurology ward in a UK district general hospital.** *Clin. Med (Lond)* 2020; Jewkes SV, Zhang Y, Nicholl DJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32719035>
12. **The global impact of COVID-19 on acute stroke care.** *CNS Neurosci. Ther.* 2020; Liu R, Zhao J, Fisher M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32725844>
13. **Cardiac injury associated with severe disease or ICU admission and death in hospitalized patients with COVID-19: a meta-analysis and systematic review.** *Crit. Care* 2020; 24:468Li X, Pan X, Li Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32723362>
14. **Incidence and mortality of pulmonary embolism in COVID-19: a systematic review and meta-analysis.** *Crit. Care* 2020; 24:464Liao SC, Shao SC, Chen YT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32718343>
15. **ACEI/ARB therapy in COVID-19: the double-edged sword of ACE2 and SARS-CoV-2 viral docking.** *Crit. Care* 2020; 24:475Onweni CL, Zhang YS, Caulfield T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32736573>
16. **COVID-19 Fears May Be Worse Than the Virus: A Case of Cardiogenic Shock Secondary to Post-Myocardial Infarction Ventricular Septum Rupture.** *Cureus* 2020; 12:e8809Gaballa S, AlJaf A, Patel K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32724754>
17. **PIMS is not the same as Kawasaki: New findings on COVID-19-associated inflammatory syndrome in children.** *Deutsche Apotheker Zeitung* 2020; 160Bruhn C.
18. **Easy game for SARS-CoV-2?: Influence of ACE inhibitors and sartans on the risk of COVID-19 is examined carefully.** *Deutsche Apotheker Zeitung* 2020; 160Hein L, Lothar A, Wirth L.
19. **The four horsemen of a viral Apocalypse: The pathogenesis of SARS-CoV-2 infection (COVID-19).** *EBioMedicine* 2020; 58:102887Domingo P, Mur I, Pomar V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32736307>
20. **COVID-19 and Hypercoagulability: Potential Impact on Management with Oral Contraceptives, Estrogen Therapy and Pregnancy.** *Endocrinology* 2020; Spratt DI, Buchsbaum RJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32725207>
21. **High Inflammatory Burden: A Potential Cause of Myocardial Injury in Critically Ill Patients With COVID-19.** *Front. Cardiovasc. Med.* 2020; 7:128Song Y, Gao P, Ran T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32733921>
22. **Heart failure and COVID-19.** *Heart Fail. Rev.* 2020; Bader F, Manla Y, Atallah B, Starling RC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32720082>
23. **Recommendations for Cardiovascular Prevention During the Sars-Cov-2 Pandemic: An Executive Document by the Board of the Italian Society of Cardiovascular Prevention.** *High Blood Press Cardiovasc. Prev.* 2020; Volpe M, Battistoni A, Bellotti P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32734561>
24. **Cardiac manifestations of COVID-19 in Shenzhen, China.** *Infection* 2020; Zeng JH, Wu WB, Qu JX *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32725595>
25. **HIIT: A potential rehabilitation treatment in COVID-19 pneumonia with heart disease.** *Int. J. Cardiol.* 2020; Li Y, Liu D, Wu H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32721412>
26. **Systematic review of the role of renin-angiotensin system inhibitors in late studies on Covid-19: A new challenge overcome?** *Int. J. Cardiol.* 2020; Volpe M, Battistoni A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32738257>
27. **COVID-19 cardiovascular epidemiology, cellular pathogenesis, clinical manifestations and management.** *Int. J. Cardiol. Heart Vasc.* 2020; 29:100589Sattar Y, Ullah W, Rauf H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32724831>
28. **Association between COVID-19 and cardiovascular disease.** *Int. J. Cardiol. Heart Vasc.* 2020; 29:100583Srivastava K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32715080>
29. **Myocardial Injury in COVID-19 Patients: The Beginning or the End?** *J. Am. Coll. Cardiol.* 2020; 76:547-549Uriel N, Sayer G, Clerkin KJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32731932>
30. **Transcatheter aortic valve implantation during the COVID-19 pandemic: Clinical expert opinion and consensus statement for Asia.** *J. Card. Surg.* 2020; Tay EL, Hayashida K, Chen M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32720374>

31. **COVID-19 and cardiovascular diseases.** *J. Cardiol.* 2020; Mai F, Del Pinto R, Ferri C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32736906>
32. **The potential effects of DPP-4 inhibitors on cardiovascular system in COVID-19 patients.** *J Cell Mol Med* 2020; Du H, Wang DW, Chen C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32713161>
33. **Evaluation of electrocardiographic ventricular repolarization variables in patients with newly diagnosed COVID-19.** *J. Electrocardiol.* 2020; 62:5-9 Yenercağ M, Arslan U, Doğduş M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32731139>
34. **Novel coronavirus infection and Kawasaki disease.** *J Matern Fetal Neonatal Med* 2020:1-5 Bitsadze VO, Grigoreva K, Khizroeva JK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32731783>
35. **A Rare Case of Acute Hemorrhagic Leukoencephalitis in a COVID-19 Patient.** *J Neurol Sci* 2020; 416:117035 Yong MH, Chan YFZ, Liu J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32738478>
36. **COVID-19 Infection in Children with Pre-existing Heart Disease.** *J. Pediatr.* 2020; Simpson M, Collins C, Nash DB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32730815>
37. **Rehabilitative of COVID-19 patients with acute lower extremity Ischemia and amputation.** *J Rehabil Med* 2020; Brugliera L, Spina A, Castellazzi P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32720698>
38. **Concerns for management of STEMI patients in the COVID-19 era: a paradox phenomenon.** *J. Thromb. Thrombolysis* 2020; Vlachakis PK, Tentolouris A, Kanakakis I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32734526>
39. **Utility of D-dimer for diagnosis of deep vein thrombosis in COVID-19 infection.** *J Vasc Surg Venous Lymphat Disord* 2020; Cho ES, McClelland PH, Cheng O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32738407>
40. **Statins as early therapy to mitigate COVID-19 (SARS-CoV-2)-associated ARDS and cytokine storm syndrome – time is of the essence.** *Journal of Clinical and Translational Research* 2020; Teoh N, Farrell G.
41. **What we know about SARS-CoV-2 and the renin angiotensin system.** *Kardiovaskulare Medizin* 2020; 23 Armelle T, Urs E, Nazmi K.
42. **The interaction of RAAS inhibitors with COVID-19: Current progress, perspective and future.** *Life Sci* 2020:118142 Zhang J, Wang M, Ding W, Wan J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32712300>
43. **Cardiovascular disease and COVID-19: Australian and New Zealand consensus statement.** *Med. J. Aust.* 2020; Zaman S, MacIsaac AJ, Jennings GL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32734645>
44. **Oral cancer and ACE2 receptor of SARS-CoV-2.** *Oral Oncol* 2020:104920 Martelli-Júnior H, Machado RA, Martelli DRB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32713810>
45. **[Lipid treatment in the period COVID-19].** *Semergen* 2020; Frías Vargas M, Díaz Rodríguez A, Díaz Fernández B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32718781>
46. **Acute Stroke Management During the COVID-19 Pandemic: Does Confinement Impact Eligibility for Endovascular Therapy?** *Stroke* 2020; 51:2593-2596 Hajdu SD, Pittet V, Puccinelli F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32716828>
47. **Pandemic Guidance for Stroke Centers Aiding COVID-19 Treatment Teams.** *Stroke* 2020; 51:2587-2592 Wira CR, Goyal M, Southerland AM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32716826>

Diagnosis (1 articles)

1. **Clinically practiced and commercially viable nanobio engineered analytical methods for COVID-19 diagnosis.** *Biosens. Bioelectron.* 2020; 165:112361 Mahapatra S, Chandra P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32729494>

DM-MS-Obesity (9 articles)

1. **SARS-CoV-2 and diabetes.** *Arzneimitteltherapie* 2020; 38:175 Fischer S.
2. **The Deadly Quartet (Covid-19, old age, lung disease, and heart failure) explain why coronavirus-related mortality in northern Italy was so high.** *Curr. Cardiol. Rev.* 2020; Calcaterra G, Bassareo PP, Barilla F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32735524>
3. **Fat mass as risk factor: Why overweight and obesity are adverse to the COVID-19 progression.** *Deutsche Apotheker Zeitung* 2020; 160 Stefan N.
4. **Hyperglycemia is a strong predictor of poor prognosis in COVID-19.** *Diabetes Res Clin Pract* 2020:108338 Liu SP, Zhang Q, Wang W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32712122>
5. **Commentary: Coronavirus and Obesity: Could Insulin Resistance Mediate the Severity of Covid-19 Infection?** *Front Public Health* 2020; 8:351 Frisardi V. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32733840>
6. **The potential effects of DPP-4 inhibitors on cardiovascular system in COVID-19 patients.** *J Cell Mol Med* 2020; Du H, Wang DW, Chen C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32713161>
7. **Inflammation: A bridge between diabetes and COVID-19, and possible management with sitagliptin.** *Med. Hypotheses* 2020; 143:110111 Mozafari N, Azadi S, Mehdi-Alamdarlou S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32721805>
8. **Visceral fat shows the strongest association with the need of intensive Care in Patients with COVID-19.** *Metabolism* 2020:154319 Watanabe M, Caruso D, Tuccinardi D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32712222>
9. **Impact of obesity on hospitalizations and mortality, due to COVID-19: A systematic review.** *Obes. Res. Clin. Pract.* 2020; de Siqueira JVV, Almeida LG, Zica BO *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32736969>

Education and training and science (21 articles)

1. **Latinx Health Disparities Research During COVID-19: Challenges and Innovations.** *Ann. Behav. Med.* 2020; Harkness A, Gattamorta KA, Estrada Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32716033>

2. **Trial under fire: one New York City anaesthesiology residency programme's redesign for the COVID-19 surge.** *Br J Anaesth* 2020; Jotwani R, Cheung CA, Hoyler MM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32711846>
3. **Virus-CKB: an integrated bioinformatics platform and analysis resource for COVID-19 research.** *Brief. Bioinform* 2020; Feng Z, Chen M, Liang T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32715315>
4. **Celebrating Eid-ul-Adha in the era of COVID-19 pandemic in Pakistan: potential threats and precautionary measures.** *Clin Microbiol Infect* 2020; Mallhi TH, Khan YH, Alotaibi NH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32712243>
5. **Engaging Third-Year Medical Students on Their Internal Medicine Clerkship in Telehealth During COVID-19.** *Cureus* 2020; 12:e8791Abraham HN, Opara IN, Dwaihy RL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32724740>
6. **DAV Summit becomes digital: Series of events go on in spite of the corona crisis.** *Deutsche Apotheker Zeitung* 2020; 160.
7. **Learning and teaching during corona: "Departure into the unknown" - How did pharmaceutical chemistry start into the summer semester of 2020?** *Deutsche Apotheker Zeitung* 2020; 160Bendas G.
8. **Stranger months: how SARS-CoV-2, fear of contagion, and lockdown measures impacted attendance and clinical activity during February and March 2020 at an urban Emergency Department in Milan.** *Disaster Med Public Health Prep* 2020;1-23Franchini S, Spessot M, Landoni G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32713377>
9. **Letter to the editor: COVID-19: how accurate are seroprevalence studies?** *Euro Surveill* 2020; 25Kadkhoda K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32734860>
10. **The North American Layman's Understanding of COVID-19: Are We Doing Enough?** *Front Public Health* 2020; 8:358Salimi A, ElHawary H, Diab N, Smith L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32719768>
11. **Health Care Team Training and Simulation-Based Education in Obstetrics During the COVID-19 Pandemic.** *J Obstet. Gynaecol. Can.* 2020; 42:1017-1020Kiely DJ, Posner GD, Sansregret A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32736852>
12. **Global Palliative Care Education in the Time of COVID-19.** *J Pain Symptom Manage* 2020; Glass M, Rana S, Coghlan R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32717367>
13. **The impact of COVID-19 on research.** *J. Pediatr. Urol.* 2020; Harper L, Kalfa N, Beckers GMA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32713792>
14. **Sleep of preschoolers during the coronavirus disease 2019 (COVID-19) outbreak.** *J. Sleep Res.* 2020:e13142Liu Z, Tang H, Jin Q *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32716566>
15. **Medical student views on returning to clinical placement after months of online learning as a result of the COVID-19 pandemic.** *Med. Educ. Online* 2020; 25:1800981Hickland MM, Gosney ER, Hare KL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32723165>
16. **Collaboration during a crisis - the Lighthouse Lab volunteers.** *Microbiology* 2020; Ulhuq FR, Berry SK, Kelly L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32720889>
17. **The push to modernize nursing regulations during the pandemic.** *Nurs. Outlook* 2020; Bachtel MK, Hayes R, Nelson MA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32711938>
18. **Medical Education and Path to Residency in Ophthalmology in the COVID-19 Era: A Perspective from Medical Student Educators.** *Ophthalmology* 2020; Duong AT, Van Tassel SH, Alzaga Fernandez AG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32712074>
19. **University students' changes in mental health status and determinants of behavior during the COVID-19 lockdown in Greece.** *Psychiatry Res* 2020; 292:113298Patsali ME, Mousa DV, Papadopoulou EVK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32717710>
20. **Shall Universities at the UAE Continue Distance Learning after the COVID-19 Pandemic? Revealing Students' Perspective.** *Ssrn* 2020:3620824Almuraqab NAS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32714122>
21. **SARS-CoV-2: characteristics and current advances in research.** *Virology* 2020; 17:117Yang Y, Xiao Z, Ye K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32727485>

Elderly (21 articles)

1. **COVID-19 outbreak: organisation of a geriatric assessment and coordination unit. A French example.** *Age Ageing* 2020; 49:516-522Koeberle S, Tannou T, Bouiller K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32725209>
2. **Rationing care by frailty during the COVID-19 pandemic.** *Age Ageing* 2020; Lewis EG, Breckons M, Lee RP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32725156>
3. **COVID-19 induced liver function abnormality associates with age.** *Aging (Albany NY)* 2020; 12Li S, Li J, Zhang Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32721928>
4. **High neutrophil-to-lymphocyte ratio associated with progression to critical illness in older patients with COVID-19: a multicenter retrospective study.** *Aging (Albany NY)* 2020; 12Lian J, Jin C, Hao S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32730223>
5. **Mental Health in Elderly Spanish People in Times of COVID-19 Outbreak.** *Am J Geriatr Psychiatry* 2020; García-Fernández L, Romero-Ferreiro V, López-Roldán PD *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32718855>
6. **Experiences and Needs of Caregivers of Persons With Dementia in India During the COVID-19 Pandemic-A Qualitative Study.** *Am J Geriatr Psychiatry* 2020; Vaitheswaran S, Lakshminarayanan M, Ramanujam V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32736918>
7. **The Deadly Quartet (Covid-19, old age, lung disease, and heart failure) explain why coronavirus-related mortality in northern Italy was so high.** *Curr. Cardiol. Rev.* 2020; Calcaterra G, Bassareo PP, Barilla F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32735524>
8. **Presenting features of COVID-19 in older people: relationships with frailty, inflammation and mortality.** *Eur. Geriatr. Med.* 2020; Knopp P, Miles A, Webb TE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32734464>
9. **Physical Exercise Potentials Against Viral Diseases Like COVID-19 in the Elderly.** *Front Med (Lausanne)* 2020; 7:379Amatriain-Fernández S, Gronwald T, Murillo-Rodríguez E *et al.*

- <http://www.ncbi.nlm.nih.gov/pubmed/?term=32714938>
10. **Compliance to Recommendations and Mental Health Consequences among Elderly in Sweden during the Initial Phase of the COVID-19 Pandemic-A Cross Sectional Online Survey.** *Int J Environ Res Public Health* 2020; 17Gustavsson J, Beckman L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32722624>
 11. **COVID-19 and Telehealth in Older Adult Psychiatry- opportunities for now and the Future.** *Int J Geriatr Psychiatry* 2020; Sorinmade OA, Kossoff L, Peisah C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32729632>
 12. **Expanding frontiers of risk management: care safety in nursing home during COVID-19 pandemic.** *Int J Qual Health Care* 2020; Scopetti M, Santurro A, Tartaglia R *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32720688>
 13. **COVID-19 in Nursing Homes: Calming the Perfect Storm.** *J Am Geriatr Soc* 2020; Ouslander JG, Grabowski DC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32735036>
 14. **Effects of age-targeted sequestration for COVID-19.** *J Biol Dyn* 2020; 14:621-632Jamieson-Lane A, Cytrynbaum E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32715932>
 15. **Effectiveness of a On-Site Medicalization Program for Nursing Homes with COVID-19 Outbreaks.** *J Gerontol A Biol Sci Med Sci* 2020; Bernabeu-Wittel M, Ternero-Vega JE, Nieto-Martín MD *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32738140>
 16. **From "Coffin Dodger" to "Boomer Remover:" Outbreaks of Ageism in Three Countries with Divergent Approaches to Coronavirus Control.** *J Gerontol. B Psychol. Sci. Soc. Sci.* 2020; Lichtenstein B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32719851>
 17. **It Is Not Just Mortality: A Call From Chile for Comprehensive COVID-19 Policy Responses Among Older People.** *J Gerontol. B Psychol. Sci. Soc. Sci.* 2020; Villalobos Dintrans P, Browne J, Madero-Cabib I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32735013>
 18. **INCREASED RISK OF SARS-CoV-2 INFECTION IN STAFF WORKING ACROSS DIFFERENT CARE HOMES ENHANCED CoVID-19 OUTBREAK INVESTIGATIONS IN LONDON CARE HOMES.** *J Infect* 2020; Ladhani SN, Chow JY, Janarthanan R *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32735893>
 19. **BCG vaccination early in life does not improve COVID-19 outcome of elderly populations, based on nationally reported data.** *Lett. Appl. Microbiol.* 2020; Wassenaar TM, Buzard GS, Newman DJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32734625>
 20. **[Older people representation on the media during COVID-19 pandemic: A reinforcement of ageism?].** *Rev Esp Geriatr Gerontol* 2020; Bravo-Segal S, Villar F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32718581>
 21. **[Variables associated with mortality in a selected sample of patients older than 80 years and with some degree of functional dependence hospitalized for COVID-19 in a Geriatrics Service].** *Rev Esp Geriatr Gerontol* 2020; Gutiérrez Rodríguez J, Montero Muñoz J, Jiménez Muela F *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32736821>

Epidemiology 71 articles)

1. **A spatial analysis of COVID-19 period prevalence in US counties through June 28, 2020: Where geography matters?** *Ann. Epidemiol.* 2020; Sun F, Matthews SA, Yang TC, Hu MH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32736059>
2. **SARS-CoV-2 infection among healthcare workers of a gastroenterological service in a tertiary care facility.** *Arab J Gastroenterol* 2020; Kassem AM, Talaat H, Shawky S *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32732168>
3. **COVID-19: a wreak havoc across the globe.** *Arch. Physiol. Biochem.* 2020;1-13Rehman H, Ahmad MI. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32730095>
4. **Real-world issues and potential solutions in HCT during the COVID-19 pandemic: Perspectives from the WBMT and the CIBMTR's Health Services and International Studies Committee.** *Biol Blood Marrow Transplant* 2020; Algwaiz G, Aljurf M, Koh M *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32717432>
5. **Impact of lockdown on COVID-19 epidemic in Île-de-France and possible exit strategies.** *BMC Med* 2020; 18:240Di Domenico L, Pullano G, Sabbatini CE *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32727547>
6. **Willingness and beliefs associated with reporting travel history to high-risk coronavirus disease 2019 epidemic regions among the Chinese public: a cross-sectional study.** *BMC Public Health* 2020; 20:1164Wei L, Sha Z, Wang Y *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32711503>
7. **SARS-CoV-2 in rural Latin America. A population-based study in coastal Ecuador.** *Clin Infect Dis* 2020; Del Brutto OH, Costa AF, Mera RM *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32717052>
8. **The risk of COVID-19 transmission in train passengers: an epidemiological and modelling study.** *Clin Infect Dis* 2020; Hu M, Lin H, Wang J *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32726405>
9. **The first 100 days of SARS-CoV-2 control in Vietnam.** *Clin Infect Dis* 2020; Pham QT, Rabaa MA, Duong HL *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32738143>
10. **A prospective cohort study in non-hospitalized household contacts with SARS-CoV-2 infection: symptom profiles and symptom change over time.** *Clin Infect Dis* 2020; Yousaf AR, Duca LM, Chu V *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32719874>
11. **Celebrating Eid-ul-Adha in the era of COVID-19 pandemic in Pakistan: potential threats and precautionary measures.** *Clin Microbiol Infect* 2020; Mallhi TH, Khan YH, Alotaibi NH *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32712243>
12. **Data on social and health vulnerability in rural India: A case of covid-19.** *Data Brief* 2020; 31:106020Singh S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32715046>
13. **COVID-19 and Mass Fatality Management: A Public Health Challenge.** *Disaster Med Public Health Prep* 2020;1-4Kumar A, Nayar KR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32713413>
14. **COVID-19 as a Natural Disaster: Focusing on Exposure and Vulnerability for Response.** *Disaster Med Public Health Prep* 2020;1-4Seddighi H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32713408>
15. **Effects of COVID-19 Prevention Measures on Other Common Infections, Taiwan.** *Emerg Infect Dis* 2020; 26Lee HH, Lin SH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32730735>

16. **Influence of airborne transmission of SARS-CoV-2 on COVID-19 pandemic. A review.** *Environ. Res.* 2020; 188:109861 Domingo JL, Marquès M, Rovira J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32718835>
17. **Prevention and control mechanism for coronavirus disease 2019 epidemic at the primary level: perspective from China.** *Epidemiol Infect* 2020; 148:e161 Zhang X, Wang Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32713366>
18. **Epidemiology, Clinical Characteristics of the First Cases of COVID-19.** *Eur. J. Clin. Invest.* 2020:e13364 Liu J, Liu S, Wei H, Yang X. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32725884>
19. **Letter to the editor: Generation interval for COVID-19 based on symptom onset data.** *Euro Surveill* 2020; 25Bacallado S, Zhao Q, Ju N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32720635>
20. **Authors' response: Estimating the generation interval for COVID-19 based on symptom onset data.** *Euro Surveill* 2020; 25Kremer C, Ganyani T, Chen D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32720639>
21. **A large COVID-19 outbreak in a high school 10 days after schools' reopening, Israel, May 2020.** *Euro Surveill* 2020; 25Stein-Zamir C, Abramson N, Shoob H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32720636>
22. **Kerala, India's Front Runner in Novel Coronavirus Disease (COVID-19).** *Front Med (Lausanne)* 2020; 7:355 Udhaya Kumar S, Thirumal Kumar D, Siva R, George Priya Doss C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32714937>
23. **COVID-19 Transmission Within a Family Cluster in Yancheng, China.** *Front Med (Lausanne)* 2020; 7:387 Zhang H, Chen R, Chen J, Chen B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32719808>
24. **Community Drivers Affecting Adherence to WHO Guidelines Against COVID-19 Amongst Rural Ugandan Market Vendors.** *Front Public Health* 2020; 8:340 Usman IM, Ssempijja F, Ssebuufu R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32733839>
25. **Survival-Convolution Models for Predicting COVID-19 Cases and Assessing Effects of Mitigation Strategies.** *Front Public Health* 2020; 8:325 Wang Q, Xie S, Wang Y, Zeng D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32719764>
26. **Younger ages at risk of Covid-19 mortality in communities of color.** *Gates Open Res* 2020; 4:69 Klugman KP, Zewdu S, Mahon BE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32715283>
27. **An evidence-based theory of change for reducing SARS-CoV-2 transmission in reopened schools.** *Health Place* 2020; 64:102398 Bonell C, Melendez-Torres GJ, Viner RM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32736311>
28. **Spatiotemporal transmission dynamics of the COVID-19 pandemic and its impact on critical healthcare capacity.** *Health Place* 2020; 64:102404 Cuadros DF, Xiao Y, Mukandavire Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32736312>
29. **Lessons from South Korea Regarding the Early Stage of the COVID-19 Outbreak.** *Healthcare (Basel)* 2020; 8 Chang MC, Baek JH, Park D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32722174>
30. **Current understanding, knowledge gaps and a perspective on the future of COVID-19 Infections: A systematic review.** *Indian J. Med. Microbiol.* 2020; 38:1-8 Chakravarti A, Upadhyay S, Bharara T, Broor S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32719202>
31. **In-flight transmission cluster of COVID-19: a retrospective case series.** *Infect Dis (Lond)* 2020; 1-11 Yang N, Shen Y, Shi C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32735163>
32. **Willingness and Readiness to test for COVID-19; A qualitative exploration of community pharmacists.** *Int J Clin Pract* 2020:e13620 Mukattash TL, Jarab AS, Abu-Farha RK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32734628>
33. **Review of Big Data Analytics, Artificial Intelligence and Nature-Inspired Computing Models towards Accurate Detection of COVID-19 Pandemic Cases and Contact Tracing.** *Int J Environ Res Public Health* 2020; 17 Agbehadji IE, Awuzie BO, Ngowi AB, Millham RC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32722154>
34. **On the True Number of COVID-19 Infections: Effect of Sensitivity, Specificity and Number of Tests on Prevalence Ratio Estimation.** *Int J Environ Res Public Health* 2020; 17 Altman E, Mounir I, Najid FZ, Perlaza SM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32722110>
35. **One Month into the Reinforcement of Social Distancing due to the COVID-19 Outbreak: Subjective Health, Health Behaviors, and Loneliness among People with Chronic Medical Conditions.** *Int J Environ Res Public Health* 2020; 17 Elran-Barak R, Mozeikov M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32727103>
36. **A Systems Approach to Assess Transport and Diffusion of Hazardous Airborne Particles in a Large Surgical Suite: Potential Impacts on Viral Airborne Transmission.** *Int J Environ Res Public Health* 2020; 17 Garbey M, Joerger G, Furr S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32727142>
37. **Coronavirus: COVID-19 Transmission in Pacific Small Island Developing States.** *Int J Environ Res Public Health* 2020; 17 Leal Filho W, Lütz JM, Sattler DN, Nunn PD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32731327>
38. **High Boredom Proneness and Low Trait Self-Control Impair Adherence to Social Distancing Guidelines during the COVID-19 Pandemic.** *Int J Environ Res Public Health* 2020; 17 Wolff W, Martarelli CS, Schüler J, Bieleke M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32731369>
39. **Advances and challenges in the prevention and treatment of COVID-19.** *Int. J. Med. Sci.* 2020; 17:1803-1810 Han YJ, Ren ZG, Li XX *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32714083>
40. **Coronavirus disease- COVID-19: New perceptives towards epidemic to pandemic.** *J. Drug Target.* 2020; 1-19 S BS, A MST, M SM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32729367>
41. **Epidemiology of the first 100 cases of COVID-19 in Taiwan and its implications on outbreak control.** *J Formos Med Assoc* 2020; Tsou TP, Chen WC, Huang AS, Chang SC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32718892>
42. **From "Coffin Dodger" to "Boomer Remover:" Outbreaks of Ageism in Three Countries with Divergent Approaches to Coronavirus Control.** *J. Gerontol. B Psychol. Sci. Soc. Sci.* 2020; Lichtenstein B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32719851>
43. **Epidemiology of SARS-CoV-2 Emergence Amidst Community-Acquired Respiratory Viruses.** *J Infect Dis* 2020; Leuzinger K, Roloff T, Gosert R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32726441>
44. **COVID-19 epidemic doubling time in the United States before and during stay-at-home restrictions.** *J Infect Dis* 2020; Lurie MN, Silva J, Yorlets RR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32738142>
45. **COVID-19 Pandemic: Disparate Health Impact on the Hispanic/Latinx Population in the United States.** *J Infect Dis* 2020; Macias Gil R, Marcelin JR, Zuniga-Blanco B *et al.*

- <http://www.ncbi.nlm.nih.gov/pubmed/?term=32729903>
46. **Epidemiological and clinical characteristics of 1663 hospitalized patients infected with COVID-19 in Wuhan, China: a single-center experience.** *J Infect Public Health* 2020; Yu C, Lei Q, Li W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32718894>
 47. **Why we (probably) must deliberately infect.** *J Law Biosci* 2020; 7:lsaa024Kolber AJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32728467>
 48. **COVID-19 pandemic and derogation to human rights.** *J Law Biosci* 2020; 7:lsaa015Lebret A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32728461>
 49. **Mass surveillance in the age of COVID-19.** *J Law Biosci* 2020; 7:lsaa023Ram N, Gray D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32728466>
 50. **Epidemiology of paediatric Middle East respiratory syndrome coronavirus and implications for the control of coronavirus virus disease 2019.** *J. Paediatr. Child Health* 2020; MacIntyre CR, Chen X, Adam DC, Chughtai AA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32729192>
 51. **The actual and potential impact of the novel 2019 coronavirus on pediatric rehabilitation: A commentary and review of its effects and potential disparate influence on Black, Latinx and Native American marginalized populations in the United States.** *J. Pediatr. Rehabil. Med.* 2020; Sholas MG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32716335>
 52. **Factors determining different death rates because of the COVID-19 outbreak among countries.** *J Public Health (Oxf)* 2020; Fountoulakis KN, Fountoulakis NK, Koupidis SA, Prezerakos PE. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32728758>
 53. **Particle sizes of infectious aerosols: implications for infection control.** *The Lancet Respiratory Medicine* 2020; Fennelly KP.
 54. **Properties of a scale of concern for COVID-19: Exploratory analysis in a Peruvian sample.** *Med Clin (Barc)* 2020; Ruiz Mamani PG, Morales-García WC, White M, Marquez-Ruiz MS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32718717>
 55. **SARS-CoV-2: A Piece of Bad News.** *Medeni Med J* 2020; 35:151-160Abdullah SF, Sharquie IK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32733765>
 56. **Timing social distancing to avert unmanageable COVID-19 hospital surges.** *Proc Natl Acad Sci U S A* 2020; Duque D, Morton DP, Singh B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32727898>
 57. **Haplotype networks of SARS-CoV-2 infections in the Diamond Princess cruise ship outbreak.** *Proc Natl Acad Sci U S A* 2020; Sekizuka T, Itokawa K, Kageyama T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32723824>
 58. **Social distancing responses to COVID-19 emergency declarations strongly differentiated by income.** *Proc Natl Acad Sci U S A* 2020; Weill JA, Stigler M, Deschenes O, Springborn MR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32727905>
 59. **Secondary Attack Rate of COVID-19 in household contacts: Systematic review.** *QJM* 2020; Shah K, Saxena D, Mavalankar D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32726452>
 60. **[Older people representation on the media during COVID-19 pandemic: A reinforcement of ageism?].** *Rev Esp Geriatr Gerontol* 2020; Bravo-Segal S, Villar F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32718581>
 61. **A chemical cocktail during the COVID-19 outbreak in Beijing, China: Insights from six-year aerosol particle composition measurements during the Chinese New Year holiday.** *Sci Total Environ* 2020; 742:140739Sun Y, Lei L, Zhou W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32721760>
 62. **Democracy and Mobility: A Preliminary Analysis of Global Adherence to Non-Pharmaceutical Interventions for COVID-19.** *Ssrn* 2020:3570206C MH, T KB, E YL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32714111>
 63. **COVID-19 Susceptibility Among Latin People in El Paso, TX.** *Ssrn* 2020:3608396Cione C, Castaneda E, Ferdinando A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32714118>
 64. **COVID-19 Severity in Europe and the USA: Could the Seasonal Influenza Vaccination Play a Role?** *Ssrn* 2020:3621446Consortium E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32714123>
 65. **Exploring the Mediation Effect of Awareness and Quarantine in Affecting Rate: A Study on COVID-19.** *Ssrn* 2020:3624017Kalam A, Alamgir Hossain M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32714124>
 66. **Summoning a New Artificial Intelligence Patent Model: In the Age of Pandemic.** *Ssrn* 2020:3619069Yanisky-Ravid S, Jin R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32714121>
 67. **COVID-19 Outbreak Following a Single Patient Exposure at an Entertainment Site: An Epidemiological Study.** *Transbound Emerg Dis* 2020; Bao C, Pan E, Ai J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32725765>
 68. **National Institutes of Health social and behavioral research in response to the SARS-CoV2 Pandemic.** *Transl. Behav. Med.* 2020; Riley WT, Borja SE, Hooper MW *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32716038>
 69. **Lockdown exit strategy: How the United Kingdom would like to emerge from the corona crisis.** *Z. Allgemeinmed.* 2020; 96:257-260Kochen MM, Blankenfeld H, Pömsl J, Kaduszkiewicz H.
 70. **[Epidemiological study design of asymptomatic infection of the 2019 novel coronavirus].** *Zhonghua Liu Xing Bing Xue Za Zhi* 2020; 41:E078He N, Lu YH, Li LM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32736419>
 71. **[Inference of start time of resurgent COVID-19 epidemic in Beijing with SEIR dynamics model and evaluation of control measure effect].** *Zhonghua Liu Xing Bing Xue Za Zhi* 2020; 41:E077Wei YY, Guan JX, Zhao Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32736418>

Management (57 articles)

1. **COVID-19 outbreak: organisation of a geriatric assessment and coordination unit. A French example.** *Age Ageing* 2020; 49:516-522Koeberle S, Tannou T, Bouiller K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32725209>
2. **Phosphate metabolism and Respiratory Alkalosis: a forgotten lesson in COVID-19.** *Age Ageing* 2020; Seers T, Davenport R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32725143>
3. **Medication utilization in patients in New York hospitals during the COVID-19 pandemic.** *Am. J. Health Syst. Pharm.* 2020; Dabestani A, DeAngelo D, Chhay SR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32712675>

4. **National drug shortages worsen during COVID-19 crisis: Proposal for a comprehensive model to monitor and address critical drug shortages.** *Am. J. Health Syst. Pharm.* 2020; Piatek OI, Ning JC, Touchette DR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32716030>
5. **COVID-19 Pandemic Response: Development of Outpatient Palliative Care Toolkit Based on Narrative Communication.** *Am. J. Hosp. Palliat. Care* 2020:1049909120944868Roberts B, Wright SM, Christmas C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32720520>
6. **Real-world issues and potential solutions in HCT during the COVID-19 pandemic: Perspectives from the WBMT and the CIBMTR's Health Services and International Studies Committee.** *Biol Blood Marrow Transplant* 2020; Algwaiz G, Aljurf M, Koh M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32717432>
7. **Clinical efficacy of glucocorticoid on the treatment of patients with COVID-19 pneumonia: A single-center experience.** *Biomed. Pharmacother.* 2020; 130:110529Hu Y, Wang T, Hu Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32736237>
8. **Regulating inspiratory pressure to individualise tidal volumes in a simulated two-patient, one-ventilator system.** *Br J Anaesth* 2020; Chen GH, Hellman S, Irie T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32718725>
9. **Successful treatment of two Japanese ESRD cases with severe COVID-19 pneumonia.** *CEN Case Rep* 2020; Abe T, Izumo T, Ueda A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32715376>
10. **Israeli Position Paper: Triage Decisions for Severely Ill Patients During the COVID-19 Pandemic.** *Chest* 2020; Steinberg A, Levy-Lahad E, Karni T, Sprung CL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32730765>
11. **Pathogenesis and Treatment Strategies of COVID-19-Related Hypercoagulant and Thrombotic Complications.** *Clin. Appl. Thromb. Hemost.* 2020; 26:1076029620944497Haimei MA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32722927>
12. **Physical exercise as a tool to help the immune system against COVID-19: an integrative review of the current literature.** *Clin. Exp. Med.* 2020; da Silveira MP, da Silva Fagundes KK, Bizuti MR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32728975>
13. **Could Targeting HMGB1 be useful for the Clinical Management of COVID-19 Infection?** *Comb. Chem. High Throughput Screen.* 2020; Çelebier M, Haznedaroğlu İ C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32723229>
14. **DAZ AKTUELL: Jour fixe: Wirkstoffe für die Intensivmedizin im Fokus.** *Deutsche Apotheker Zeitung* 2020; 160.
15. **Corona provisional appraisal in North Rhine: Courier services during the peak phase of the pandemic increasingly in demand.** *Deutsche Apotheker Zeitung* 2020; 160.
16. **Dreaded cytokine storm: How excessive immune responses in COVID-19 should be prevented.** *Deutsche Apotheker Zeitung* 2020; 160Blasius H.
17. **Successes with dexamethasone: Glucocorticoid can improve prognosis in the case of severe COVID-19 disease.** *Deutsche Apotheker Zeitung* 2020; 160Jungmayr P.
18. **No general antibiotic prophylaxis: The superinfection risk in COVID-19 seems to be small during the early phase.** *Deutsche Apotheker Zeitung* 2020; 160Jungmayr P.
19. **No better weapon.** *Deutsche Apotheker Zeitung* 2020; 160Uhl D.
20. **Airway Management Considerations for Upper Gastrointestinal Endoscopic Procedures in COVID-19 Era.** *Dig. Dis. Sci.* 2020; Thiruvankatarajan V, Lorenzetti M, Chung A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32712781>
21. **Prone Positioning in Non-intubated Patients with COVID-19 Outside the Intensive Care Unit: More Evidence Needed.** *Disaster Med Public Health Prep* 2020:1-6Ripoll-Gallardo A, Grillenzoni L, Bollon J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32713387>
22. **COVID-19 as a Natural Disaster: Focusing on Exposure and Vulnerability for Response.** *Disaster Med Public Health Prep* 2020:1-4Seddighi H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32713408>
23. **Pathogenesis and treatment of idiopathic and rheumatoid arthritis-related interstitial pneumonia. The possible lesson from COVID-19 pneumonia.** *Expert Rev. Clin. Immunol.* 2020; Manfredi A, Luppi F, Cassone G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32722946>
24. **Role of Immune Dysregulation in Increased Mortality Among a Specific Subset of COVID-19 Patients and Immune-Enhancement Strategies for Combatting Through Nutritional Supplements.** *Front. Immunol.* 2020; 11:1548Rao KS, Suryaprakash V, Senthilkumar R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32733487>
25. **Physical Exercise Potentials Against Viral Diseases Like COVID-19 in the Elderly.** *Front Med (Lausanne)* 2020; 7:379Amatriain-Fernández S, Gronwald T, Murillo-Rodríguez E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32714938>
26. **Challenges in the Management of SARS-CoV2 Infection: The Role of Oral Bacteriotherapy as Complementary Therapeutic Strategy to Avoid the Progression of COVID-19.** *Front Med (Lausanne)* 2020; 7:389d'Ettorre G, Ceccarelli G, Marazzato M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32733907>
27. **Non-pharmaceutical Interventions for Pandemic COVID-19: A Cross-Sectional Investigation of US General Public Beliefs, Attitudes, and Actions.** *Front Med (Lausanne)* 2020; 7:384Kantor BN, Kantor J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32719807>
28. **Medium Term Follow-Up of 337 Patients With Coronavirus Disease 2019 (COVID-19) in a Fangcang Shelter Hospital in Wuhan, China.** *Front Med (Lausanne)* 2020; 7:373Yan N, Wang W, Gao Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32719806>
29. **While We Wait for a Vaccine Against SARS-CoV-2, Why Not Think About Available Drugs?** *Front. Physiol.* 2020; 11:820Barrantes FJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32719619>
30. **Clinical Use of Short-Course and Low-Dose Corticosteroids in Patients With Non-severe COVID-19 During Pneumonia Progression.** *Front Public Health* 2020; 8:355Hu Z, Lv Y, Xu C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32719766>
31. **Advances and challenges in the prevention and treatment of COVID-19.** *Int. J. Med. Sci.* 2020; 17:1803-1810Han YJ, Ren ZG, Li XX *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32714083>
32. **Treatment of severe COVID-19 courses in intensive care medicine.** *Internist* 2020; Wiesner O, Busch M, David S.
33. **COVID-19 in Nursing Homes: Calming the Perfect Storm.** *J Am Geriatr Soc* 2020; Ouslander JG, Grabowski DC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32735036>

34. **Role of extracorporeal membrane oxygenation in COVID-19: A systematic review.** *J. Card. Surg.* 2020; Haiduc AA, Alom S, Melamed N, Harky A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32717771>
35. **The potential effects of DPP-4 inhibitors on cardiovascular system in COVID-19 patients.** *J Cell Mol Med* 2020; Du H, Wang DW, Chen C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32713161>
36. **Extracorporeal membrane oxygenation for refractory COVID-19 acute respiratory distress syndrome.** *J Crit Care* 2020; 60:10-12 Le Brevet C, Besset S, Freita-Ramos S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32731100>
37. **Effectiveness of a On-Site Medicalization Program for Nursing Homes with COVID-19 Outbreaks.** *J Gerontol A Biol Sci Med Sci* 2020; Bernabeu-Wittel M, Ternero-Vega JE, Nieto-Martín MD *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32738140>
38. **Procalcitonin as an antibiotic stewardship tool in COVID-19 patients in the intensive care.** *J Glob Antimicrob Resist* 2020; Heesom L, Rehnberg L, Nasim-Mohi M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32717489>
39. **In the shadow of COVID-19: HIV-infected individuals need more attention.** *J Med Virol* 2020; Zhao T, Xuan K, Uy JP, Sun C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32735365>
40. **Dying from Covid-19: Loneliness, end-of-life discussions and support for patients and their families in nursing homes and hospitals. A national register study.** *J Pain Symptom Manage* 2020; Peter S, Jonas B, Lisa M, Staffan L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32721500>
41. **Addressing the COVID-19 Nutrition Crisis in Vulnerable Communities: Applying a Primary Care Perspective.** *J. Prim. Care Community Health* 2020; 11:2150132720946951 Ong MM, Ong RM, Reyes GK, Sumpaico-Tanchanco LB. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32715893>
42. **Statins as early therapy to mitigate COVID-19 (SARS-CoV-2)-associated ARDS and cytokine storm syndrome – time is of the essence.** *Journal of Clinical and Translational Research* 2020; Teoh N, Farrell G.
43. **SARS-CoV-2: A Piece of Bad News.** *Medeni Med J* 2020; 35:151-160 Abdullah SF, Sharquie IK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32733765>
44. **Commentary. Eliminating Vitamin D Deficiency During the COVID-19 Pandemic: A Call to Action.** *Metabolism* 2020:154322 Manson JE, Bassuk SS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32712223>
45. **Parenteral fish oil: An adjuvant pharmacotherapy for coronavirus disease 2019?** *Nutrition* 2020; 81:110900 Torrinas RS, Calder PC, Lemos GO, Waitzberg DL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32738510>
46. **An audit of end-of-life symptom control in patients with corona virus disease 2019 (COVID-19) dying in a hospital in the United Kingdom.** *Palliat. Med.* 2020:269216320947312 Alderman B, Webber K, Davies A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32736493>
47. **The need for early referral to palliative care especially for Black, Asian and minority ethnic groups in a COVID-19 pandemic: Findings from a service evaluation.** *Palliat. Med.* 2020:269216320946688 Chidiac C, Feuer D, Flatley M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32736485>
48. **Treatment with Dexamethasone in Patients with COVID-19 - A Position Paper of the German Respiratory Society (DGP).** *Pneumologie (Stuttgart, Germany)* 2020; Kolditz M, Dellweg D, Geerdes-Fenge H *et al.*
49. **PEEP/ FIO2 ARDSNet Scale Grouping of a Single Ventilator for Two Patients: Modeling Tidal Volume Response.** *Respir. Care* 2020; 65:1094-1103 Kheyfets VO, Lammers SR, Wagner J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32712582>
50. **Intermittent occupancy combined with ventilation: An efficient strategy for the reduction of airborne transmission indoors.** *Sci Total Environ* 2020; 744:140908 Melikov AK, Ai ZT, Markov DG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32721678>
51. **Democracy and Mobility: A Preliminary Analysis of Global Adherence to Non-Pharmaceutical Interventions for COVID-19.** *Ssrn* 2020:3570206C MH, T KB, E YL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32714111>
52. **COVID-19: Urgent Reconsideration of Lung Edema as a Preventable Outcome: Inhibition of TRPV4 As a Promising and Feasible Approach.** *Ssrn* 2020:3558887 Kuebler W, Jordt SE, Liedtke W. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32714108>
53. **Countries with High Registered Nurse (RN) Concentrations Observe Reduced Mortality Rates of Coronavirus Disease 2019 (COVID-19).** *Ssrn* 2020:3566190 Padula WV, Davidson P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32714110>
54. **COVID-19 management in a cancer center: the ICU storm.** *Support. Care Cancer* 2020; Boilève A, Stoclin A, Barlesi F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32734394>
55. **RECOVERY- Respiratory Support: Respiratory Strategies for patients with suspected or proven COVID-19 respiratory failure; Continuous Positive Airway Pressure, High-flow Nasal Oxygen, and standard care: A structured summary of a study protocol for a randomised controlled trial.** *Trials* 2020; 21:687 Perkins GD, Couper K, Connolly B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32727624>
56. **Outcome of Non-Critical COVID-19 Patients with Early Hospitalization and Early Antiviral Treatment Outside the ICU.** *Turk J Med Sci* 2020; Çalik BaŞaran N, UyaroĖlu OA, Tellil Dızman G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32718127>
57. **Retrolective therapy monitoring within the framework of COVID-19 pandemic.** *Zeitschrift fur Phytotherapie* 2020; 41:111-112 Adler M.

Mental – public health (64 articles)

1. **Anxiety and depression in the Republic of Ireland during the COVID-19 pandemic.** *Acta Psychiatr. Scand.* 2020; Hyland P, Shevlin M, McBride O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32716520>
2. **Impact of COVID-19 Pandemic on Sexual Minority Populations in Brazil: An Analysis of Social/Racial Disparities in Maintaining Social Distancing and a Description of Sexual Behavior.** *AIDS Behav.* 2020; Torres TS, Hoagland B, Bezerra DRB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32737817>
3. **Is Alcohol an "Essential Good" During COVID-19? Yes, but Only as a Disinfectant!** *Alcohol. Clin. Exp. Res.* 2020; Neufeld M, Lachenmeier DW, Ferreira-Borges C, Rehm J.

- <http://www.ncbi.nlm.nih.gov/pubmed/?term=32735694>
4. **The Mental Health Benefits of Physical Activity in Older Adults Survive the COVID-19 Pandemic.** *Am J Geriatr Psychiatry* 2020; Callow DD, Arnold-Nedimala NA, Jordan LS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32713754>
 5. **Mental Health in Elderly Spanish People in Times of COVID-19 Outbreak.** *Am J Geriatr Psychiatry* 2020; García-Fernández L, Romero-Ferreiro V, López-Roldán PD *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32718855>
 6. **Experiences and Needs of Caregivers of Persons With Dementia in India During the COVID-19 Pandemic-A Qualitative Study.** *Am J Geriatr Psychiatry* 2020; Vaitheswaran S, Lakshminarayanan M, Ramanujam V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32736918>
 7. **A Holistic View of Health Infrastructure Resilience before and after COVID-19.** *Arch Bone Jt Surg* 2020; 8:262-269 Barabadi A, Ghiasi MH, Nouri Qarahasanlou A, Mottahedi A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32733981>
 8. **Supporting the vulnerable: developing a strategic community mental health response to the COVID-19 pandemic.** *Australas Psychiatry* 2020:1039856220944701 Thomson S, Doan T, Liu D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32729320>
 9. **"The post-COVID era": challenges in the treatment of substance use disorder (SUD) after the pandemic.** *BMC Med* 2020; 18:241 López-Pelayo H, Aubin HJ, Drummond C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32731868>
 10. **Anxiety and depression in COVID-19 survivors: role of inflammatory and clinical predictors.** *Brain Behav Immun* 2020; Gennaro Mazza M, De Lorenzo R, Conte C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32738287>
 11. **Resilience in the Time of Pandemic.** *Can. J. Psychiatry* 2020:706743720946170 Adams GC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32720516>
 12. **Impact of public health emergency response to COVID-19 on management and outcome for NSTEMI patients in Beijing: A single-center historic control.** *Catheter Cardiovasc. Interv.* 2020; Liu S, Song C, Yin D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32725858>
 13. **Initial changes in neuropsychologists clinical practice during the COVID-19 pandemic: a survey study.** *Clin. Neuropsychol.* 2020:1-16 Marra DE, Hoelzle JB, Davis JJ, Schwartz ES. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32723158>
 14. **Data on social and health vulnerability in rural India: A case of covid-19.** *Data Brief* 2020; 31:106020 Singh S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32715046>
 15. **Gossip, rumors and the COVID-19 crisis.** *Disaster Med Public Health Prep* 2020:1-4 Abdoli A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32713376>
 16. **Non-pharmaceutical Interventions for Pandemic COVID-19: A Cross-Sectional Investigation of US General Public Beliefs, Attitudes, and Actions.** *Front Med (Lausanne)* 2020; 7:384 Kantor BN, Kantor J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32719807>
 17. **Parents' Stress and Children's Psychological Problems in Families Facing the COVID-19 Outbreak in Italy.** *Front. Psychol.* 2020; 11:1713 Spinelli M, Lionetti F, Pastore M, Fasolo M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32719646>
 18. **Healthcare Capacity, Health Expenditure, and Civil Society as Predictors of COVID-19 Case Fatalities: A Global Analysis.** *Front Public Health* 2020; 8:347 Khan JR, Awan N, Islam MM, Muurlink O. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32719765>
 19. **Precise Decision-Making and Adaptive Response Strategies Based on the Situations of Stress During the Coronavirus Disease 2019 (COVID-19) Pandemic.** *Front Public Health* 2020; 8:364 Shen W. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32733841>
 20. **Community Drivers Affecting Adherence to WHO Guidelines Against COVID-19 Amongst Rural Ugandan Market Vendors.** *Front Public Health* 2020; 8:340 Usman IM, Ssempijja F, Ssebuufu R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32733839>
 21. **Pseudoscientific beliefs and psychopathological risks increase after COVID-19 social quarantine.** *Global Health* 2020; 16:72 Escolà-Gascón A, Marín FX, Rusiñol J, Gallifa J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32731864>
 22. **Prevalence of depression and its correlative factors among female adolescents in China during the coronavirus disease 2019 outbreak.** *Global Health* 2020; 16:69 Zhou J, Yuan X, Qi H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32723373>
 23. **Spatiotemporal transmission dynamics of the COVID-19 pandemic and its impact on critical healthcare capacity.** *Health Place* 2020; 64:102404 Cuadros DF, Xiao Y, Mukandavire Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32736312>
 24. **Development of a Remote Psychological First Aid Protocol for Healthcare Workers Following the COVID-19 Pandemic in a University Teaching Hospital, Malaysia.** *Healthcare (Basel)* 2020; 8:Sulaiman AH, Ahmad Sabki Z, Jaafa MJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32722042>
 25. **Is Anxiety a Rising Concern during COVID-19 Pandemic among Healthcare Workers?** *Indian J. Crit. Care Med.* 2020; 24:369-370 Murthy PR, Venkatesha Gupta KV, Ajith Kumar AK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32728334>
 26. **Response to "Italian IBD Patients Coping With COVID-19 Emergency: The Mitigating Role of Psychological Readiness to Engage in Self-Care".** *Inflamm. Bowel Dis.* 2020; Occhipinti V, Sociale OR, Pastorelli L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32720980>
 27. **Assessment of Individuals' Attitude, Knowledge and Anxiety Toward Covid 19 At The First Period of the Outbreak in Turkey: A Web Based Cross-Sectional Survey.** *Int J Clin Pract* 2020:e13622 Ayhan Başer D, Çevik M, Gümüştakım Ş, Başara E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32726515>
 28. **Addressing co-occurring public health emergencies: The importance of naloxone distribution in the era of COVID-19.** *Int. J. Drug Policy* 2020:102872 Collins AB, Ndoye CD, Arene-Morley D, Marshall BDL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32713765>
 29. **Perceived Job Insecurity and Depressive Symptoms among Italian Dentists: The Moderating Role of Fear of COVID-19.** *Int J Environ Res Public Health* 2020; 17:Gasparro R, Scandurra C, Maldonato NM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32722202>
 30. **Compliance to Recommendations and Mental Health Consequences among Elderly in Sweden during the Initial Phase of the COVID-19 Pandemic-A Cross Sectional Online Survey.** *Int J Environ Res Public Health* 2020; 17:Gustavsson J, Beckman L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32722624>

31. **Tobacco Quit Intentions and Behaviors among Cigar Smokers in the United States in Response to COVID-19.** *Int J Environ Res Public Health* 2020; 17:Kowitz SD, Cornacchione Ross J, Jarman KL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32722469>
32. **A model of disparities: risk factors associated with COVID-19 infection.** *Int J Equity Health* 2020; 19:126Rozenfeld Y, Beam J, Maier H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32727486>
33. **COVID-19 and Telehealth in Older Adult Psychiatry- opportunities for now and the Future.** *Int. J. Geriatr. Psychiatry* 2020; Sorinmade OA, Kossoff L, Peisah C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32729632>
34. **Psychological impact of the COVID-19 pandemic among pregnant women in Sri Lanka.** *Int J Gynaecol Obstet* 2020; Patabendige M, Gamage MM, Weerasinghe M, Jayawardane A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32731307>
35. **Preferential Tax Policies: An Invisible Hand behind Preparedness for Public Health Emergencies.** *Int J Health Policy Manag* 2020; Fan Y, Yang S, Jia P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32729287>
36. **Unexpected public health consequences of the COVID-19 pandemic: a national survey examining anti-Asian attitudes in the USA.** *Int J Public Health* 2020; Dhanani LY, Franz B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32728852>
37. **Mental health in biological disasters: From SARS to COVID-19.** *Int J Soc Psychiatry* 2020;20764020944200Hsieh KY, Kao WT, Li DJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32722974>
38. **Psychological stress among health care professionals during the 2019 novel coronavirus disease outbreak: Cases from online consulting customers.** *Intensive Crit Care Nurs* 2020;102905Ma Y, Rosenheck R, He H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32712069>
39. **Maternal psychological distress & mental health service use during the COVID-19 pandemic.** *J. Affect. Disord.* 2020; 276:765-774Cameron EE, Joyce KM, Delaquis CP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32736186>
40. **Prevalence of anxiety and depression symptom, and the demands for psychological knowledge and interventions in college students during COVID-19 epidemic: A large cross-sectional study.** *J. Affect. Disord.* 2020; 275:188-193Wang ZH, Yang HL, Yang YQ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32734907>
41. **Ethics and Informatics in the Age of COVID-19: Challenges and Recommendations for Public Health Organization and Public Policy.** *J Am Med Inform Assoc* 2020; Subbian V, Solomonides A, Clarkson M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32722749>
42. **How is COVID-19 Affecting the Mental Health of Children with Special Educational Needs and Disabilities and Their Families?** *J. Autism Dev. Disord.* 2020; Asbury K, Fox L, Deniz E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32737668>
43. **It Is Not Just Mortality: A Call From Chile for Comprehensive COVID-19 Policy Responses Among Older People.** *J. Gerontol. B Psychol. Sci. Soc. Sci.* 2020; Villalobos Dintrans P, Browne J, Madero-Cabib I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32735013>
44. **Public health law and science in the community mitigation strategy for Covid-19.** *J Law Biosci* 2020; 7:1saa019Wiley LF. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32728464>
45. **Psychological consequences of COVID-19 pandemic in Italian MS patients: signs of resilience?** *J. Neurol.* 2020; Capuano R, Altieri M, Bisecco A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32725312>
46. **Dying from Covid-19: Loneliness, end-of-life discussions and support for patients and their families in nursing homes and hospitals. A national register study.** *J Pain Symptom Manage* 2020; Peter S, Jonas B, Lisa M, Staffan L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32721500>
47. **Identification of the awareness level by the public of Arab countries toward COVID-19: cross-sectional study following an outbreak.** *J Pharm Policy Pract* 2020; 13:43Bonyan R, Al-Karasneh AF, El-Dahiyat F, Jairoun AA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32724659>
48. **Addressing the COVID-19 Nutrition Crisis in Vulnerable Communities: Applying a Primary Care Perspective.** *J. Prim. Care Community Health* 2020; 11:2150132720946951Ong MM, Ong RM, Reyes GK, Sumpaico-Tanchanco LB. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32715893>
49. **We Can Do Better: Why Pastoral Care Visitation to Hospitals is Essential, Especially in Times of Crisis.** *J Relig Health* 2020; Hall DE. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32734516>
50. **An Offering of Hope During COVID-19: A Personal Reflection.** *J Relig Health* 2020; Simmerling M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32734517>
51. **A Community Responds to the COVID-19 Pandemic: a Case Study in Protecting the Health and Human Rights of People Who Use Drugs.** *J. Urban Health* 2020; Heimer R, McNeil R, Vlahov D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32720298>
52. **Unemployment, suicide and COVID-19: using the evidence to plan for prevention.** *Med. J. Aust.* 2020; Deady M, Tan L, Kugenthiran N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32729145>
53. **Dignity and rights of the dead and their families: A compromise in the time of coronavirus disease 2019.** *Med. Sci. Law* 2020;25802420945937Shrestha R, Krishan K, Kanchan T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32727307>
54. **Rapid and Impressive Response to a Combined Treatment with Single-Dose Tocilizumab and NIV in a Patient with COVID-19 Pneumonia/ARDS.** *Medicina (Kaunas)* 2020; 56:Cascella M, Mauro I, De Blasio E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32727107>
55. **The COVID-19 pandemic has not changed the number but the type of psychiatric emergencies: A comparison of care data between 2019 and 2020.** *Nervenarzt* 2020; Aly L, Sondergeld R, Hölzle P *et al.*
56. **Interdependence and the cost of uncoordinated responses to COVID-19.** *Proc Natl Acad Sci U S A* 2020; Holtz D, Zhao M, Benzell SG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32732433>
57. **Social distancing responses to COVID-19 emergency declarations strongly differentiated by income.** *Proc Natl Acad Sci U S A* 2020; Weill JA, Stigler M, Deschenes O, Springborn MR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32727905>
58. **Mental health services for mood disorder outpatients in Milan during COVID-19 outbreak: The experience of the health care providers at San Raffaele hospital.** *Psychiatry Res* 2020; 292:113317Franchini L, Ragone N, Seghi F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32721785>
59. **The COVID-19 anxiety syndrome scale: Development and psychometric properties.** *Psychiatry Res* 2020; 292:113322Nikčević AV, Spada MM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32736267>

60. **University students' changes in mental health status and determinants of behavior during the COVID-19 lockdown in Greece.** *Psychiatry Res* 2020; 292:113298Patsali ME, Mousa DV, Papadopoulou EVK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32717710>
61. **Adjustment Disorder, Depression, Stress Symptoms, Corona Related Anxieties and Coping Strategies during the Corona Pandemic (COVID-19) in Swiss Medical Staff.** *Psychother. Psychosom. Med. Psychol.* 2020; 70:272-282Krammer S, Augstburger R, Haeck M, Maercker A.
62. **Exploring the Mediation Effect of Awareness and Quarantine in Affecting Rate: A Study on COVID-19.** *Ssrn* 2020:3624017Kalam A, Alamgir Hossain M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32714124>
63. **The double-edged relationship between COVID-19 stress and smoking: Implications for smoking cessation.** *Tob Induc Dis* 2020; 18:63Bommele J, Hopman P, Walters BH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32733178>
64. **National Institutes of Health social and behavioral research in response to the SARS-CoV2 Pandemic.** *Transl. Behav. Med.* 2020; Riley WT, Borja SE, Hooper MW *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32716038>

Meta-analyses - systematic reviews (12 articles)

1. **Clinical characteristics, laboratory outcome characteristics, comorbidities, and complications of related COVID-19 deceased: a systematic review and meta-analysis.** *Aging Clin. Exp. Res.* 2020; Qiu P, Zhou Y, Wang F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32734576>
2. **Prevalence of Comorbidities in COVID-19 Patients: A Systematic Review and Meta-Analysis.** *Arch Bone Jt Surg* 2020; 8:247-255Baradaran A, Ebrahimzadeh MH, Baradaran A, Kachooei AR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32733980>
3. **Cardiac injury associated with severe disease or ICU admission and death in hospitalized patients with COVID-19: a meta-analysis and systematic review.** *Crit Care* 2020; 24:468Li X, Pan X, Li Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32723362>
4. **Incidence and mortality of pulmonary embolism in COVID-19: a systematic review and meta-analysis.** *Crit Care* 2020; 24:464Liao SC, Shao SC, Chen YT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32718343>
5. **SARS-CoV-2 detection in different respiratory sites: A systematic review and meta-analysis.** *EBioMedicine* 2020:102903Mohammadi A, Esmaeilzadeh E, Li Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32718896>
6. **Predictors of Adverse Prognosis in Covid-19: A Systematic Review and Meta-analysis.** *Eur. J. Clin. Invest.* 2020:e13362Figliozzi S, Masci PG, Ahmadi N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32726868>
7. **COVID-19 in pregnant women: A systematic review and meta-analysis.** *Eur. J. Obstet. Gynecol. Reprod. Biol.* 2020; Capobianco G, Saderi L, Aliberti S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32713730>
8. **Prevalence of chronic liver disease in patients with COVID-19 and their clinical outcomes: a systematic review and meta-analysis.** *Hepatol Int* 2020; Kovalic AJ, Satapathy SK, Thuluvath PJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32725453>
9. **Tocilizumab for severe COVID-19: a systematic review and meta-analysis.** *Int J Antimicrob Agents* 2020:106103Lan SH, Lai CC, Huang HT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32712333>
10. **Comorbidities and the risk of severe or fatal outcomes associated with coronavirus disease 2019: A systematic review and meta-analysis.** *Int J Infect Dis* 2020; Zhou Y, Yang Q, Chi J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32721533>
11. **Efficacy of Corticosteroids in Patients with SARS, MERS and COVID-19: A Systematic Review and Meta-Analysis.** *J Clin Med* 2020; 9Lee KH, Yoon S, Jeong GH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32726951>
12. **Clinical Features of COVID-19 and Factors Associated with Severe Clinical Course: A Systematic Review and Meta-Analysis.** *Ssrn* 2020:3566166Kumar A, Arora A, Sharma P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32714109>

Mortality (26 articles)

1. **Lactate dehydrogenase levels predict coronavirus disease 2019 (COVID-19) severity and mortality: A pooled analysis.** *Am J Emerg Med* 2020; 38:1722-1726Henry BM, Aggarwal G, Wong J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32738466>
2. **High Viral Load and Poor Ventilation: Cause of High Mortality From COVID-19.** *Asia Pac. J. Public Health* 2020:1010539520944725Aggarwal S, Aggarwal S, Aggarwal A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32715729>
3. **CT lung lesions as predictors of early death or ICU admission in COVID-19 patients.** *Clin Microbiol Infect* 2020; Ruch Y, Kaeuffer C, Ohana M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32717417>
4. **Hemorrhagic presentations of COVID-19: Risk factors for mortality.** *Clin. Neurol. Neurosurg.* 2020; 198:106112Altschul DJ, Unda SR, de La Garza Ramos R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32738585>
5. **Cardiac injury associated with severe disease or ICU admission and death in hospitalized patients with COVID-19: a meta-analysis and systematic review.** *Crit Care* 2020; 24:468Li X, Pan X, Li Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32723362>
6. **Incidence and mortality of pulmonary embolism in COVID-19: a systematic review and meta-analysis.** *Crit Care* 2020; 24:464Liao SC, Shao SC, Chen YT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32718343>
7. **Neurological Complications in COVID-19 Patients and its Implications for Associated Mortality.** *Curr. Neurovasc. Res.* 2020; AboTaleb HA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32718292>
8. **COVID-19 and Mass Fatality Management: A Public Health Challenge.** *Disaster Med Public Health Prep* 2020:1-4Kumar A, Nayar KR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32713413>

9. **Seroprevalence of SARS-CoV-2 and Infection Fatality Ratio, Orleans and Jefferson Parishes, Louisiana, USA, May 2020.** *Emerg Infect Dis* 2020; 26:Feehan AK, Fort D, Garcia-Diaz J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32731911>
10. **Presenting features of COVID-19 in older people: relationships with frailty, inflammation and mortality.** *Eur. Geriatr. Med.* 2020; Knopp P, Miles A, Webb TE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32734464>
11. **Call for proper documentation of COVID-19 deaths in poor resource setting: a necessity for management of future occurrences.** *Expert Rev. Anti Infect. Ther.* 2020; Mbanuzuru AV, Okoro CC, Mbanuzuru CM, Ibeh CC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32729754>
12. **Healthcare Capacity, Health Expenditure, and Civil Society as Predictors of COVID-19 Case Fatalities: A Global Analysis.** *Front Public Health* 2020; 8:347Khan JR, Awan N, Islam MM, Muurlink O. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32719765>
13. **Younger ages at risk of Covid-19 mortality in communities of color.** *Gates Open Res* 2020; 4:69Klugman KP, Zewdu S, Mahon BE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32715283>
14. **Diagnostic performance of initial blood urea nitrogen combined with D-Dimer levels for predicting in-hospital mortality in COVID-19 patients.** *Int J Antimicrob Agents* 2020:106110Cheng A, Hu L, Wang Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32712332>
15. **The Role of Health Preconditions on COVID-19 Deaths in Portugal: Evidence from Surveillance Data of the First 20293 Infection Cases.** *J Clin Med* 2020; 9:Nogueira PJ, de Araújo Nobre M, Costa A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32722159>
16. **Comorbidities for fatal outcome among the COVID-19 patients: a hospital-based case-control study.** *J Infect* 2020; Lu QB, Jiang WL, Zhang X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32731000>
17. **The impact of socioeconomic status on 30-day mortality in hospitalised patients with COVID-19 infection.** *J Med Virol* 2020; Khan KS, Torpiano G, McLellan M, Mahmud S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32729937>
18. **Coronaviruses: a challenge of today and a call for extended human postmortem brain analyses.** *J Neural Transm (Vienna)* 2020; Riederer P, Ter Meulen V. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32725545>
19. **Dying from Covid-19: Loneliness, end-of-life discussions and support for patients and their families in nursing homes and hospitals. A national register study.** *J Pain Symptom Manage* 2020; Peter S, Jonas B, Lisa M, Staffan L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32721500>
20. **Factors determining different death rates because of the COVID-19 outbreak among countries.** *J Public Health (Oxf)* 2020; Fountoulakis KN, Fountoulakis NK, Koupidis SA, Prezerakos PE. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32728758>
21. **A logistic model for age-specific COVID-19 case-fatality rates.** *JAMIA Open* 2020; 3:151-153Gao X, Dong Q. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32734152>
22. **Dignity and rights of the dead and their families: A compromise in the time of coronavirus disease 2019.** *Med. Sci. Law* 2020:25802420945937Shrestha R, Krishan K, Kanchan T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32727307>
23. **Impact of obesity on hospitalizations and mortality, due to COVID-19: A systematic review.** *Obes. Res. Clin. Pract.* 2020; de Siqueira JVV, Almeida LG, Zica BO *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32736969>
24. **An audit of end-of-life symptom control in patients with corona virus disease 2019 (COVID-19) dying in a hospital in the United Kingdom.** *Palliat. Med.* 2020:269216320947312Alderman B, Webber K, Davies A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32736493>
25. **The need for early referral to palliative care especially for Black, Asian and minority ethnic groups in a COVID-19 pandemic: Findings from a service evaluation.** *Palliat. Med.* 2020:269216320946688Chidiac C, Feuer D, Flatley M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32736485>
26. **[Clinical characteristics and death risk factors of severe COVID-19].** *Zhonghua Jie He He Hu Xi Za Zhi* 2020; 43:648-653Qin W, Hu BZ, Zhang Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32727175>

Online – IT – Apps (28 articles)

1. **Digital Screen Time During COVID-19 Pandemic: Risk for a Further Myopia Boom?** *Am. J. Ophthalmol.* 2020; Wai Wong C, Tsai A, Jonas JB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32738229>
2. **Telemedicine for preoperative assessment during a COVID-19 pandemic: Recommendations for clinical care.** *Best Pract. Res. Clin. Anaesthesiol.* 2020; 34:345-351Mihalj M, Carrel T, Gregoric ID *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32711839>
3. **Could breath analysis by MS could be a solution to rapid, non-invasive testing for COVID-19?** *Bioanalysis* 2020; Walker HJ, Burrell MM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32734782>
4. **Virus-CKB: an integrated bioinformatics platform and analysis resource for COVID-19 research.** *Brief. Bioinform.* 2020; Feng Z, Chen M, Liang T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32715315>
5. **The Use of Digital Applications and COVID-19.** *Community Ment. Health J.* 2020; Alexopoulos AR, Hudson JG, Otenigbagbe O. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32734311>
6. **The Virtue of 'Virtual' Patch Testing - a case report.** *Contact Dermatitis* 2020; Cunningham L, Ferguson FJ, White IR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32712999>
7. **Engaging Third-Year Medical Students on Their Internal Medicine Clerkship in Telehealth During COVID-19.** *Cureus* 2020; 12:e8791Abraham HN, Opara IN, Dwaihy RL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32724740>
8. **Telemedicine Pays: Billing and Coding Update.** *Curr. Allergy Asthma Rep.* 2020; 20:60Bajowala SS, Milosch J, Bansal C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32715353>
9. **DAV Summit becomes digital: Series of events go on in spite of the corona crisis.** *Deutsche Apotheker Zeitung* 2020; 160.
10. **Decision Making on Telemedicine for Patients With Epilepsy During the Coronavirus Disease 2019 (COVID-19) Crisis.** *Front. Neurol.* 2020; 11:722Kuroda N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32714276>

11. **COVID-19 Patient Health Prediction Using Boosted Random Forest Algorithm.** *Front Public Health* 2020; 8:3571wendi C, Bashir AK, Peshkar A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32719767>
12. **Contact-Tracing Apps in Contact Tracing of COVID-19.** *Gesundheitswesen (Bundesverband der Ärzte des Öffentlichen Gesundheitsdienstes (Germany))* 2020; Jahnel T, Kernebeck S, Böbel S *et al.*
13. **The Virtual Spine Examination: Telemedicine in the Era of COVID-19 and Beyond.** *Global Spine J* 2020:2192568220947744Satin AM, Lieberman IH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32734784>
14. **Assessment of Individuals' Attitude, Knowledge and Anxiety Toward Covid 19 At The First Period of the Outbreak in Turkey: A Web Based Cross-Sectional Survey.** *Int J Clin Pract* 2020:e13622Ayhan Başer D, Çevik M, Gümüştakım Ş, Başara E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32726515>
15. **Telehealth transition in a comprehensive care unit for eating disorders: Challenges and long-term benefits.** *Int. J. Eat. Disord.* 2020; Datta N, Derenne J, Sanders M, Lock JD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32715512>
16. **Review of Big Data Analytics, Artificial Intelligence and Nature-Inspired Computing Models towards Accurate Detection of COVID-19 Pandemic Cases and Contact Tracing.** *Int J Environ Res Public Health* 2020; 17Agbehadji IE, Awuzie BO, Ngowi AB, Millham RC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32722154>
17. **Consensus on Criteria for Good Practices in Video Consultation: A Delphi Study.** *Int J Environ Res Public Health* 2020; 17Jiménez-Rodríguez D, Ruiz-Salvador D, Rodríguez Salvador MDM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32727042>
18. **COVID-19 and Telehealth in Older Adult Psychiatry- opportunities for now and the Future.** *Int. J. Geriatr. Psychiatry* 2020; Sorinmade OA, Kossoff L, Peisah C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32729632>
19. **Assessing the Impact of a Rapidly Scaled Virtual Urgent Care in New York City During the COVID-19 Pandemic.** *J. Emerg. Med.* 2020; Koziatek CA, Rubin A, Lakdawala V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32737005>
20. **COVID-19 contact tracing apps: a stress test for privacy, the GDPR, and data protection regimes.** *J Law Biosci* 2020; 7:Isaa034Bradford L, Aboy M, Liddell K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32728470>
21. **Usage Patterns of a Web-Based Palliative Care Content Platform (PalliCOVID) during the COVID-19 Pandemic.** *J Pain Symptom Manage* 2020; Lai L, Sato R, He S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32730951>
22. **Implementation of a Deep Learning-Based Computer-Aided Detection System for the Interpretation of Chest Radiographs in Patients Suspected for COVID-19.** *Korean J Radiol* 2020; Hwang EJ, Kim H, Yoon SH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32729263>
23. **Telemedicine in Minority and Socioeconomically Disadvantaged Communities Amidst COVID-19 Pandemic.** *Otolaryngol Head Neck Surg* 2020:194599820947667Ramirez AV, Ojeaga M, Espinoza V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32720844>
24. **Telemedicine for parkinsonism: A two-step model based on the COVID-19 experience in Milan, Italy.** *Parkinsonism Relat. Disord.* 2020; Cilia R, Mancini F, Bloem BR, Eleopra R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32723588>
25. **Virtual Rheumatology During COVID-19: A Personal Perspective.** *Rheumatol Ther* 2020; Dacre J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32725408>
26. **Feasibility and effectiveness of teleconsultation in children with epilepsy amidst the ongoing COVID-19 pandemic in a resource-limited country.** *Seizure* 2020; 81:29-35Panda PK, Dawman L, Panda P, Sharawat IK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32712376>
27. **Shall Universities at the UAE Continue Distance Learning after the COVID-19 Pandemic? Revealing Students' Perspective.** *Ssrn* 2020:3620824Almuraqab NAS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32714122>
28. **Summoning a New Artificial Intelligence Patent Model: In the Age of Pandemic.** *Ssrn* 2020:3619069Yanisky-Ravid S, Jin R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32714121>

Other – Miscellaneous (38 articles)

1. **COVID-19 and food security in Africa: Building more resilient food systems.** *AAS Open Res* 2020; 3:27Shilomboleni H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32734141>
2. **Coronavirus disease 2019 pandemic and identifying insufflators with desufflation mode and surgical smoke evacuators for safe CO(2) removal.** *Asian J Endosc Surg* 2020; da Costa KM, Saxena AK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32715659>
3. **Love in the time of Corona.** *Australas Psychiatry* 2020:1039856220936142Alchin D, McLean L, Korner A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32722964>
4. **Spotlight on Avian Pathology: Can We Reduce the Pandemic Threat of H9N2 Avian Influenza to Human and Animal Health?** *Avian Pathol.* 2020:1-4Sims LD, Tripodi A, Swayne DE. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32720513>
5. **To Toci or Not to Toci for COVID-19: Is That Still the Question?** *Clin Infect Dis* 2020; Cheng GS, Hill JA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32735642>
6. **Influence of the COVID-19 pandemic on contact lens wear in Spain.** *Cont Lens Anterior Eye* 2020; García-Ayuso D, Escámez-Torrecilla M, Galindo-Romero C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32713774>
7. **Pharmacists without Borders celebrate 20th birthday: The organization fights globally against the corona pandemic in its anniversary year.** *Deutsche Apotheker Zeitung* 2020; 160.
8. **Between justified concerns and conspiracy myths: What influence the corona crisis has on our risk perception - an opinion piece.** *Deutsche Apotheker Zeitung* 2020; 160Gaissmaier W.
9. **Parental allowance: New legal regulation. No losses due to the corona situation.** *Deutsche Apotheker Zeitung* 2020; 160Joachimsthaler S.
10. **That changes in the tax law due to corona: Finance tips for employees and pensioners.** *Deutsche Apotheker Zeitung* 2020; 160Van Den Heuvel M.
11. **Work Environment Surrounding COVID-19 Outbreak in Call Center, South Korea.** *Emerg Infect Dis* 2020; 26Kim T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32723433>

12. **Explosion in hearing aid demands after Covid-19 outbreak curfew.** *Eur Arch Otorhinolaryngol* 2020; Ertugrul S, Soylemez E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32737646>
13. **Predictors of Health-Related Quality of Life and Influencing Factors for COVID-19 Patients, a Follow-Up at One Month.** *Front Psychiatry* 2020; 11:668Chen KY, Li T, Gong FH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32733299>
14. **Modified Bhramari Pranayama in Covid 19 Infection.** *Indian J Otolaryngol Head Neck Surg* 2020; 72:395-397Taneja MK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32719737>
15. **COVID-19 and neglected tropical diseases in Africa: impacts, interactions, consequences.** *Int Health* 2020; Molyneux DH, Aboe A, Isiyaku S, Bush S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32725145>
16. **Effects of Weather on Coronavirus Pandemic.** *Int J Environ Res Public Health* 2020; 17Bukhari Q, Massaro JM, D'Agostino RB, Sr., Khan S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32727067>
17. **Assessment of COVID-19 Waste Flows During the Emergency State in Romania and Related Public Health and Environmental Concerns.** *Int J Environ Res Public Health* 2020; 17Mihai FC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32731593>
18. **Influence of Absolute Humidity, Temperature and Population Density on COVID-19 Spread and Decay Durations: Multi-Prefecture Study in Japan.** *Int J Environ Res Public Health* 2020; 17Rashed EA, Kodera S, Gomez-Tames J, Hirata A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32722294>
19. **Positive and Negative Changes in Food Habits, Physical Activity Patterns, and Weight Status during COVID-19 Confinement: Associated Factors in the Chilean Population.** *Int J Environ Res Public Health* 2020; 17Reyes-Olavarría D, Latorre-Román P, Guzmán-Guzmán IP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32731509>
20. **Preferential Tax Policies: An Invisible Hand behind Preparedness for Public Health Emergencies.** *Int J Health Policy Manag* 2020; Fan Y, Yang S, Jia P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32729287>
21. **Unexpected public health consequences of the COVID-19 pandemic: a national survey examining anti-Asian attitudes in the USA.** *Int J Public Health* 2020; Dhanani LY, Franz B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32728852>
22. **Protecting and Supporting the WHO International Code During COVID-19.** *J Hum Lact* 2020; 36:387-389Dodgson JE. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32735498>
23. **Indemnifying precaution: economic insights for regulation of a highly infectious disease.** *J Law Biosci* 2020; 7:Isaa032Robertson CT, Schaefer KA, Scheitrum D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32733690>
24. **Reporting, recording, and communication of COVID-19 cases in workplace: data protection as a moving target.** *J Law Biosci* 2020; 7:Isaa008Shabani M, Goffin T, Mertens H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32728456>
25. **The impact of socioeconomic status on 30-day mortality in hospitalised patients with COVID-19 infection.** *J Med Virol* 2020; Khan KS, Torpiano G, McLellan M, Mahmud S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32729937>
26. **The impact of COVID-19 on Bangladeshi readymade garment (RMG) workers.** *J Public Health (Oxf)* 2020; Kabir H, Maple M, Usher K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32734293>
27. **A crisis of ethics in the ethics of crisis.** *J Visc Surg* 2020; Zarzavadjian Le Bian A, Tresallet C, Martinod E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32718864>
28. **The war against the SARS-CoV2 infection: Is it better to fight or mitigate it?** *Med. Hypotheses* 2020; 143:110129Dal Moro F, Vendramin I, Livi U. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32721814>
29. **'Influence of conflicts of interest on public positions in the COVID-19 era, the case of Gilead Sciences' by Roussel and Raoult (2020).** *New Microbes New Infect* 2020; 37:100730Piepho HP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32733682>
30. **Choosing Evolution over Extinction: Integrating Direct Patient Care Services and Value-Based Payment Models into the Community-Based Pharmacy Setting.** *Pharmacy (Basel)* 2020; 8Mercadante AR, Yokota M, Hwang A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32722217>
31. **Legal Issues of Resource Allocation in the COVID-19 Pandemic - Between Utilitarianism and Life Value Indifference.** *Pneumologie (Stuttgart, Germany)* 2020; 74:366-370Hübner J, Schewe DM, Katalinic A, Frielitz FS.
32. **COVID-19 lockdowns cause global air pollution declines.** *Proc Natl Acad Sci U S A* 2020; Venter ZS, Aunan K, Chowdhury S, Lelieveld J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32723816>
33. **Factors influencing health behaviours during the coronavirus disease 2019 outbreak in China: an extended information-motivation-behaviour skills model.** *Public Health* 2020; 185:298-305Luo Y, Yao L, Zhou L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32717671>
34. **Nonuniform impacts of COVID-19 lockdown on air quality over the United States.** *Sci Total Environ* 2020; 745:141105Chen LA, Chien LC, Li Y, Lin G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32731074>
35. **Non-negligible impacts of clean air regulations on the reduction of tropospheric NO(2) over East China during the COVID-19 pandemic observed by OMI and TROPOMI.** *Sci Total Environ* 2020; 745:141023Huang G, Sun K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32738690>
36. **Influence of Chinese New Year overlapping COVID-19 lockdown on HONO sources in Shijiazhuang.** *Sci Total Environ* 2020; 745:141025Liu Y, Ni S, Jiang T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32738691>
37. **Municipal solid waste management during the SARS-COV-2 outbreak and lockdown ease: Lessons from Italy.** *Sci Total Environ* 2020; 745:141159Ragazzi M, Rada EC, Schiavon M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32717596>
38. **Extension Horses, Inc. experts act fast to create online resources to assist the horse industry during COVID-19.** *Transl Anim Sci* 2020; 4:txaa085Greene EA, Hein W, Wickens CL, Smarsh DN. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32728659>

Pathology (3 articles)

1. **Postmortem Kidney Pathology Findings in Patients with COVID-19.** *J Am Soc Nephrol* 2020; Santoriello D, Khairallah P, Bomback AS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32727719>
2. **Coronaviruses: a challenge of today and a call for extended human postmortem brain analyses.** *J Neural Transm (Vienna)* 2020; Riederer P, Ter Meulen V. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32725545>

3. **Timing social distancing to avert unmanageable COVID-19 hospital surges.** *Proc Natl Acad Sci U S A* 2020; Duque D, Morton DP, Singh B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32727898>

Protection (56 articles)

1. **The impact of COVID-19 outbreak on urolithiasis emergency department admissions, hospitalizations and clinical management in central Italy: a multicentric analysis.** *Actas Urol. Esp.* 2020; Antonucci M, Recupero SM, Marzio V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32713658>
2. **The impact of the COVID-19 pandemic on emergency department visits and patient safety in the United States.** *Am J Emerg Med* 2020; 38:1732-1736 Boserup B, McKenney M, Elkbuli A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32738468>
3. **Controversies on the Stethoscope During COVID-19: A Necessary Tool or an Unnecessary Evil?** *Am. J. Med. Sci.* 2020; Patel L, Gandhi D, Beddow D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32736834>
4. **A Call to Protect the Health Care Workers Fighting COVID-19 in the United States.** *Am. J. Psychiatry* 2020; appiajp202020040535 Charney AW, Katz C, Southwick SM, Charney DS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32731814>
5. **Low-cost devices to prevent SARS-CoV-2 infection during open and laparoscopic surgery.** *Am. J. Surg.* 2020; Cabrera Vargas LF, Torregrosa L, Guevara O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32736800>
6. **COVID-19 testing processes and patient protections for resumption of elective surgery.** *Am. J. Surg.* 2020; Schlosser M, Signorelli H, Gregg W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32736801>
7. **Safety of aerosol-generating procedures in COVID-19 negative patients: binomial probability modelling of intubate COVID registry data.** *Anaesthesia* 2020; Kakodkar P, Sivia DS, Pandit JJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32712950>
8. **SARS-CoV-2 infection among healthcare workers of a gastroenterological service in a tertiary care facility.** *Arab J Gastroenterol* 2020; Kasseem AM, Talaat H, Shawky S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32732168>
9. **COVID-19: potential transmission through aerosols in surgical procedures and blood products.** *Bone Joint Res* 2020; 9:200-201 Simpson A, Dall G, Haas JG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32728423>
10. **Extent of infectious SARS-CoV-2 aerosolisation as a result of oesophagogastroduodenoscopy or colonoscopy.** *Br. J. Hosp. Med. (Lond.)* 2020; 81:1-7 Hussain A, Singhal T, El-Hasani S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32730160>
11. **Efficacy and safety of decontamination for N95 respirator reuse: a systematic literature search and narrative synthesis.** *Can J Anaesth* 2020; Steinberg BE, Aoyama K, McVey M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32720256>
12. **Celebrating Eid-ul-Adha in the era of COVID-19 pandemic in Pakistan: potential threats and precautionary measures.** *Clin Microbiol Infect* 2020; Mallhi TH, Khan YH, Alotaibi NH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32712243>
13. **Personal protective equipment protecting healthcare workers in the Chinese epicenter of COVID-19.** *Clin Microbiol Infect* 2020; Zhao Y, Liang W, Luo Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32712241>
14. **Consequences of chemical impact of disinfectants: safe preventive measures against COVID-19.** *Crit. Rev. Toxicol.* 2020; 1-8 Rai NK, Ashok A, Akondi BR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32729370>
15. **Biosafety measures at the dental office after the appearance of COVID-19: A systematic review.** *Disaster Med Public Health Prep* 2020; 1-16 Cabrera-Tasayco FDP, Rivera-Carhuavilca JM, Atoche-Socola KJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32713385>
16. **Effects of COVID-19 Prevention Measures on Other Common Infections, Taiwan.** *Emerg Infect Dis* 2020; 26:Lee HH, Lin SH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32730735>
17. **Status of Occupational Protection in the COVID-19 Fangcang Shelter Hospital in Wuhan, China.** *Emerg Microbes Infect* 2020; 1-26 Zhang M, Wang L, Yu S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32726187>
18. **Safe handling of clothing and hygiene of patients and health professionals: Scoping review.** *Enferm. Clin.* 2020; Martín-Vaquero Y, González-Sanz A, Muñoz-Martín B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32723622>
19. **Reducing the consumption of personal protective equipment by setting up a multifunctional sampling station in the emergency department to screen for COVID-19 infection in Taiwan.** *Environ. Health Prev. Med.* 2020; 25:34 Lin PT, Ni TY, Chen TY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32731860>
20. **Influence of airborne transmission of SARS-CoV-2 on COVID-19 pandemic. A review.** *Environ. Res.* 2020; 188:109861 Domingo JL, Marquès M, Rovira J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32718835>
21. **Microsurgical procedures during COVID-19 pandemic: the VITOM® 3D-HD exoscopic system as alternative to the operating microscope to properly use personal protective equipment (PPE).** *Eur Arch Otorhinolaryngol* 2020; Carobbio ALC, Filairo M, Parrinello G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32728847>
22. **Olfactory and taste disorders in healthcare workers with COVID-19 infection.** *Eur Arch Otorhinolaryngol* 2020; Villarreal IM, Morato M, Martínez-Ruiz Coello M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32725271>
23. **Novel coronavirus and trauma surgery: successful infection control from a level I trauma centre.** *Eur. J. Trauma Emerg. Surg.* 2020; Jávora P, Varga E, Fekete K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32712775>
24. **Prevention and Control of COVID-19 Infection in a Chinese Mental Health Center.** *Front Med (Lausanne)* 2020; 7:356 Yang M, Wang H, Li Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32719805>
25. **AGA Institute Rapid Review and Recommendations on the Role of Pre-Procedure SARS-CoV2 Testing and Endoscopy.** *Gastroenterology* 2020; Sultan S, Siddique SM, Altayar O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32735862>
26. **Seroprevalence of COVID-19 antibodies in the cleaning and oncological staff of a municipal clinic.** *GMS Hyg Infect Control* 2020; 15:Doc18 Epstude J, Harsch IA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32735862>

term=32733782

27. **Quadrupling the N95 Supply during the COVID-19 Crisis with an Innovative 3D-Printed Mask Adaptor.** *Healthcare (Basel)* 2020; 8:Imbrie-Moore AM, Park MH, Zhu Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32717841>
28. **Knowledge and Attitude of Dental Practitioners Related to Disinfection during the COVID-19 Pandemic.** *Healthcare (Basel)* 2020; 8:Sarfaraz S, Shabbir J, Mudasser MA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32722402>
29. **Beyond the PPE shortage: Improperly fitting personal protective equipment and COVID-19 transmission among Health Care Professionals.** *Hosp Pract (1995)* 2020; Ming X, Ray C, Bandari M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32713215>
30. **Personal Protective Equipment: A Pandora's Box.** *Indian J. Crit. Care Med.* 2020; 24:371-372:Chawla G, Abrol N, Kakkar K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32728335>
31. **Decontamination and reuse of surgical masks and N95 filtering facepiece respirators during COVID-19 pandemic: a systematic review.** *Infect Control Hosp Epidemiol* 2020:1-39:Seresirikachorn K, Phoophiboon V, Chobarporn T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32729444>
32. **In-flight transmission cluster of COVID-19: a retrospective case series.** *Infect Dis (Lond)* 2020:1-11:Yang N, Shen Y, Shi C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32735163>
33. **Ocular COVID-19: Eyes as a reservoir to conceal and spread SARS-CoV-2.** *Infect Disord Drug Targets* 2020; Baig AM, Ahmad S, Khaleeq A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32729433>
34. **Personal protective equipment (PPE) and infection among healthcare workers - what is the evidence?** *Int J Clin Pract* 2020:e13617:Tian Z, Stedman M, Whyte M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32734641>
35. **One Month into the Reinforcement of Social Distancing due to the COVID-19 Outbreak: Subjective Health, Health Behaviors, and Loneliness among People with Chronic Medical Conditions.** *Int J Environ Res Public Health* 2020; 17:Elran-Barak R, Mozeikov M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32727103>
36. **A Systems Approach to Assess Transport and Diffusion of Hazardous Airborne Particles in a Large Surgical Suite: Potential Impacts on Viral Airborne Transmission.** *Int J Environ Res Public Health* 2020; 17:Garbey M, Joerger G, Furr S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32727142>
37. **High Boredom Proneness and Low Trait Self-Control Impair Adherence to Social Distancing Guidelines during the COVID-19 Pandemic.** *Int J Environ Res Public Health* 2020; 17:Wolff W, Martarelli CS, Schüler J, Bieleke M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32731369>
38. **Air and surface contamination by SARS-CoV-2 virus in a tertiary hospital in Wuhan, China.** *Int J Infect Dis* 2020; Tan L, Ma B, Lai X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32730827>
39. **Pt-, Rh-, Ru-, and Cu-Single-Wall Carbon Nanotubes Are Exceptional Candidates for Design of Anti-Viral Surfaces: A Theoretical Study.** *Int J Mol Sci* 2020; 21:Aasi A, Aghaei SM, Moore MD, Panchapakesan B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32717853>
40. **Expanding frontiers of risk management: care safety in nursing home during COVID-19 pandemic.** *Int. J. Qual. Health Care* 2020; Scopetti M, Santurro A, Tartaglia R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32720688>
41. **Effect of an aerosol box on tracheal intubation difficulty.** *J. Anesth.* 2020; Wakabayashi R, Ishida T, Yamada T, Kawamata M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32728963>
42. **COVID-19 pandemic: Radiotherapy precautions and preparedness.** *J. Cancer Res. Ther.* 2020; 16:634-637:Mummudi N, Tibdewal A, Ghosh-Laskar S, Agarwal JP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32719280>
43. **Hand eczema due to frequent hand washing in combat with COVID-19.** *J Cosmet Dermatol* 2020; Pradhan S, Kroumpouzos G, Goldust M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32716605>
44. **A review of respiratory protection measures recommended in Europe for dental procedures during the COVID-19 pandemic.** *J Hosp Infect* 2020; Persoon IF, Stankiewicz N, Smith A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32738394>
45. **Characteristics and transmission dynamics of COVID-19 in healthcare workers at a London teaching hospital.** *J Hosp Infect* 2020; Zheng C, Hafezi-Bakhtiari N, Cooper V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32730771>
46. **INCREASED RISK OF SARS-CoV-2 INFECTION IN STAFF WORKING ACROSS DIFFERENT CARE HOMES ENHANCED COVID-19 OUTBREAK INVESTIGATIONS IN LONDON CARE HOMES.** *J Infect* 2020; Ladhani SN, Chow JY, Janarthanan R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32735893>
47. **Why the mask? The effectiveness of face masks in preventing the spread of respiratory infections such as COVID-19 - a home testing protocol.** *J. Med. Eng. Technol.* 2020:1-4:Swain ID. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32716230>
48. **Risks to the community pharmacists and pharmacy personnel during COVID-19 pandemic: perspectives from a low-income country.** *J Pharm Policy Pract* 2020; 13:42:Dzingirai B, Matyanga CMJ, Mudzviti T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32724658>
49. **Low-cost, safe, and effective smoke evacuation device for surgical procedures in the COVID-19 age.** *J. Surg. Oncol.* 2020; Andrade WP, Gonçalves GG, Medeiros LC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32734636>
50. **Particle sizes of infectious aerosols: implications for infection control.** *The Lancet Respiratory Medicine* 2020; Fennelly KP.
51. **Recommended personal protective equipment for cochlear implant and other mastoid surgery during the COVID-19 era.** *Laryngoscope* 2020; Lawrence RJ, O'Donoghue G, Kitterick P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32720316>
52. **3D Printing to Support the Shortage in Personal Protective Equipment Caused by COVID-19 Pandemic.** *Materials (Basel)* 2020; 13:Tarfaoui M, Nachtane M, Goda I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32727050>
53. **Personal protective equipment and personal cooling garments to reduce heat-related stress and injuries.** *Med. Leg. J.* 2020:25817220935882:Tumram NK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32716247>
54. **Social distancing responses to COVID-19 emergency declarations strongly differentiated by income.** *Proc Natl Acad Sci U S A* 2020; Weill JA, Stigler M, Deschenes O, Springborn MR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32727905>

55. **Early Recognition of Coronavirus 2019 Disease (COVID-19) Infection in Surgical Inpatients: The Importance of a Risk-Stratified Approach for Early Testing and Isolation.** *Surg Infect (Larchmt)* 2020; Wee LE, Sim XYJ, Conceicao EP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32716758>
56. **Neurosurgical/Head and Neck drape to Prevent Aerosolization of COVID-19 - The Lenox Hill Hospital/Northwell Health solution.** *World Neurosurg* 2020; D'Amico RS, Khatri D, Kwan K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32712405>

Pulmonary disease (16 articles)

1. **Bilateral spontaneous pneumothorax in SARS-CoV-2 infection: A very rare, life-threatening complication.** *Am J Emerg Med* 2020; González-Pacheco H, Gopar-Nieto R, Jiménez-Rodríguez GM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32712235>
2. **Real-time diagnosis of reactive oxygen species (ROS) in fresh sputum by electrochemical tracing; correlation between COVID-19 and viral-induced ROS in lung/respiratory epithelium during this pandemic.** *Biosens. Bioelectron.* 2020; 165:112435Miripour ZS, Sarrami-Forooshani R, Sanati H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32729548>
3. **The Deadly Quartet (Covid-19, old age, lung disease, and heart failure) explain why coronavirus-related mortality in northern Italy was so high.** *Curr. Cardiol. Rev.* 2020; Calcaterra G, Bassareo PP, Barilla F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32735524>
4. **SARS-CoV-2 detection in different respiratory sites: A systematic review and meta-analysis.** *EBioMedicine* 2020:102903Mohammadi A, Esmailzadeh E, Li Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32718896>
5. **Network perturbation analysis in human bronchial epithelial cells following SARS-CoV2 infection.** *Exp. Cell Res.* 2020:112204Nunnari G, Sanfilippo C, Castrogiovanni P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32735892>
6. **Role of Autophagy in Lung Inflammation.** *Front. Immunol.* 2020; 11:1337Painter JD, Galle-Treger L, Akbari O. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32733448>
7. **Secondary Bacterial Infections During Pulmonary Viral Disease: Phage Therapeutics as Alternatives to Antibiotics?** *Front. Microbiol.* 2020; 11:1434Manohar P, Loh B, Athira S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32733404>
8. **Pulmonary function in patients surviving to COVID-19 pneumonia.** *Infection* 2020; Fumagalli A, Misuraca C, Bianchi A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32725597>
9. **HIIT: A potential rehabilitation treatment in COVID-19 pneumonia with heart disease.** *Int J Cardiol* 2020; Li Y, Liu D, Wu H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32721412>
10. **Impact of the Covid-19 Pandemic in Children with Allergic Asthma.** *J Allergy Clin Immunol Pract* 2020; Ruano FJ, Somoza Álvarez ML, Haroun-Díaz E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32730834>
11. **Dyspnea perception and neurological symptoms in non-severe COVID-19 patients.** *Neurol Sci* 2020; Ora J, Liguori C, Puxeddu E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32734396>
12. **Non-Steroidal Anti-Inflammatory Drugs and the Risk of Pneumonia Complications: A Systematic Review.** *Pharmacotherapy* 2020; Sodhi M, Khosrow-Khavar F, FitzGerald JM, Etminan M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32715498>
13. **Monitoring bronchoalveolar lavage with electrical impedance tomography: first experience in a patient with COVID-19.** *Physiol. Meas.* 2020; Fu Y, Zou R, Wang S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32736369>
14. **The pathophysiology of 'happy' hypoxemia in COVID-19.** *Respir Res* 2020; 21:198Dhont S, Derom E, Van Braeckel E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32723327>
15. **Letter from Italy.** *Respirology* 2020; Sotgiu G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32720423>
16. **Immunological co-ordination between gut and lungs in SARS-CoV-2 infection.** *Virus Res.* 2020:198103Ahlawat S, Asha, Sharma KK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32717345>

Renal disease (18 articles)

1. **SARS-CoV-2 and diabetes.** *Arzneimitteltherapie* 2020; 38:175Fischer S.
2. **Identification of Complex Pneumonia during the Outbreak of COVID-19: Bacterial Pneumonia Combined with Acute Eosinophilic Pneumonia in Patients with Maintenance Hemodialysis.** *Blood Purif.* 2020:1-5Hu QD, Mao N, Huang XC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32721968>
3. **CSN COVID-19 Rapid Review Program: Management of Acute Kidney Injury.** *Can J Kidney Health Dis* 2020; 7:2054358120941679Clark EG, Hiremath S, Soroka SD *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32728473>
4. **Management of Advanced Chronic Kidney Disease During the COVID-19 Pandemic: Suggestions From the Canadian Society of Nephrology COVID-19 Rapid Response Team.** *Can J Kidney Health Dis* 2020; 7:2054358120939354White CA, Kappel JE, Levin A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32733692>
5. **COVID-19 in Children with Nephrotic Syndrome on Anti-CD20 Chronic Immunosuppression.** *Clin J Am Soc Nephrol* 2020; Angeletti A, Drovandi S, Sanguineri F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32718953>
6. **The Early Days: The Postkidney Transplant Recipients' COVID-19 Journey.** *Clin J Am Soc Nephrol* 2020; Roberts GV, Gee PO. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32727854>
7. **Detection of SARS-CoV-2 in Hemodialysis Effluent of Patient with COVID-19 Pneumonia, Japan.** *Emerg Infect Dis* 2020; 26Okuhama A, Ishikane M, Katagiri D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32730734>
8. **Recommendations for the management of the patient with chronic renal disease with SARS-CoV-2.** *Enferm. Clin.* 2020; Gómez-Beltrán PA, Domínguez Carranza E, Medero Rubio F, Pérez Márquez M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32732016>
9. **Kidney Replacement Therapy in COVID-19 Induced Kidney Failure and Septic Shock: A Pediatric Continuous Renal Replacement Therapy [PCRRT] Position on Emergency Preparedness With**

- Resource Allocation.** *Front Pediatr* 2020; 8:413Raina R, Chakraborty R, Sethi SK, Bunchman T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32719758>
10. **The clinical characteristics and course of COVID-19 in hemodialysis patients.** *Hemodial Int* 2020; Aydin Bahat K, Parmaksiz E, Sert S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32730678>
 11. **SARS-CoV-2 infection associated acute kidney injury in patients with pre-existing chronic renal disease: A report of two cases.** *Immun Inflamm Dis* 2020; Wang Y, Lv Y, Liu Q. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32725744>
 12. **High Prevalence of Asymptomatic COVID-19 Infection in Hemodialysis Patients Detected Using Serologic Screening.** *J Am Soc Nephrol* 2020; Clarke C, Prendecki M, Dhutia A *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32732391>
 13. **Postmortem Kidney Pathology Findings in Patients with COVID-19.** *J Am Soc Nephrol* 2020; Santoriello D, Khairallah P, Bomback AS *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32727719>
 14. **The Impact of COVID-19 on Maintenance Haemodialysis patients: The Indian Scenario.** *Nephrology (Carlton)* 2020; Trivedi M, Shingada A, Shah M *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32713060>
 15. **When the COVID-19 pandemic changed the follow-up landscape of chronic kidney disease: a survey of real-world nephrology practice.** *Ren. Fail.* 2020; 42:733-739Chen G, Zhou Y, Xia J *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32718215>
 16. **COVID-19: a novel menace for the practice of nephrology and how to manage it with minor devastation?** *Ren. Fail.* 2020; 42:710-725Ulu S, Gungor O, Gok Oguz E *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32713282>
 17. **Clinical characteristics of 31 hemodialysis patients with 2019 novel coronavirus: a retrospective study.** *Ren. Fail.* 2020; 42:726-732Zhang J, Cao F, Wu SK *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32722980>
 18. **Immunological co-ordination between gut and lungs in SARS-CoV-2 infection.** *Virus Res.* 2020:198103Ahlawat S, Asha, Sharma KK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32717345>

Reviews (50 articles)

1. **Review of guidelines and recommendations from 17 countries highlights the challenges that clinicians face caring for neonates born to mothers with COVID-19.** *Acta Paediatr* 2020; Yeo KT, Oei JL, De Luca D *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32716579>
2. **COVID-19 Among People Living with HIV: A Systematic Review.** *AIDS Behav.* 2020; Mirzaei H, McFarland W, Karamouzian M, Sharifi H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32734438>
3. **Alcohol consumption and alcohol-related problems during the COVID-19 pandemic: a narrative review.** *Australas Psychiatry* 2020:1039856220943024Ramalho R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32722961>
4. **Severe Acute Respiratory Syndrome Coronavirus 2 and Coronavirus Disease 2019: A Clinical Overview and Primer.** *Biopreserv. Biobank.* 2020; Knight TE. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32726140>
5. **Diagnostics for SARS-CoV-2 detection: A comprehensive review of the FDA-EUA COVID-19 testing landscape.** *Biosens. Bioelectron.* 2020; 165:112454Ravi N, Cortade DL, Ng E, Wang SX. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32729549>
6. **COVID-19: a complex multisystem disorder.** *Br J Anaesth* 2020; Roberts CM, Levi M, McKee M *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32731958>
7. **CSN COVID-19 Rapid Review Program: Management of Acute Kidney Injury.** *Can J Kidney Health Dis* 2020; 7:2054358120941679Clark EG, Hiremath S, Soroka SD *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32728473>
8. **A First Case of Acute Cerebellitis Associated with Coronavirus Disease (COVID-19): a Case Report and Literature Review.** *Cerebellum* 2020; Fadakar N, Ghaemmaghami S, Masoompour SM *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32737799>
9. **Physical exercise as a tool to help the immune system against COVID-19: an integrative review of the current literature.** *Clin. Exp. Med.* 2020; da Silveira MP, da Silva Fagundes KK, Bizuti MR *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32728975>
10. **Statins in COVID-19: is there any foundation?** *Clin Investig Arterioscler* 2020; Lima Martínez MM, Contreras MA, Marín W, D'Marco L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32718669>
11. **What the physicians should know about mast cells, dendritic cells, urticaria and omalizumab during COVID-19 or asymptomatic infections due to SARS-CoV-2?** *Dermatol Ther* 2020; Criado PR, Pagliari C, Criado RFJ *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32713127>
12. **Corona ticker: News in brief on SARS-CoV-2.** *Deutsche Apotheker Zeitung* 2020; 160.
13. **Waiting for evidence: An update on the research on COVID-19 therapeutic agents.** *Deutsche Apotheker Zeitung* 2020; 160Blasius H.
14. **PANDEMIE SPEZIAL: Kinder seltener mit SARS-CoV-2 infiziert?** *Deutsche Apotheker Zeitung* 2020; 160Bruhn C.
15. **"We know that we know nothing": Pharmacon@home informs on the current state of SARS-CoV-2 infections.** *Deutsche Apotheker Zeitung* 2020; 160Neb H.
16. **OUTBREAK of novel corona virus disease (COVID-19): Antecedence and aftermath.** *Eur. J. Pharmacol.* 2020:173381Awasthi A, Vishwas S, Corrie L *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32721449>
17. **Beyond Anti-viral Effects of Chloroquine/Hydroxychloroquine.** *Front. Immunol.* 2020; 11:1409Gies V, Bekaddour N, Dieudonné Y *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32714335>
18. **Overview: Systemic Inflammatory Response Derived From Lung Injury Caused by SARS-CoV-2 Infection Explains Severe Outcomes in COVID-19.** *Front. Immunol.* 2020; 11:1626Polidoro RB, Hagan RS, de Santis Santiago R, Schmidt NW. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32714336>
19. **Severe Acute Respiratory Syndrome Coronavirus 2: From Gene Structure to Pathogenic Mechanisms and Potential Therapy.** *Front. Microbiol.* 2020; 11:1576Wu J, Yuan X, Wang B *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32719672>
20. **Progress in the Research and Development of Anti-COVID-19 Drugs.** *Front Public Health* 2020; 8:365Huang L, Chen Y, Xiao J *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32733842>

21. **A Perspective on Emerging Therapeutic Interventions for COVID-19.** *Front Public Health* 2020; 8:281Torequul Islam M, Nasiruddin M, Khan IN *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32733837>
22. **COVID-19 and liver disease: An update.** *Gastroenterol. Hepatol.* 2020; Téllez L, Martín Mateos RM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32727662>
23. **Current understanding, knowledge gaps and a perspective on the future of COVID-19 Infections: A systematic review.** *Indian J. Med. Microbiol.* 2020; 38:1-8Chakravarti A, Upadhyay S, Bharara T, Broor S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32719202>
24. **Guidelines for Surgical Tracheostomy and Tracheostomy Tube Change During the COVID-19 Pandemic: A Review Article.** *Indian J Otolaryngol Head Neck Surg.* 2020; 72:398-401Radhakrishnan S, Perumbally HA, Surya S, Ponneth MS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32719738>
25. **A Narrative Systematic Review of the Clinical Utility of Cycle Threshold Values in the Context of COVID-19.** *Infect Dis Ther* 2020; Rao SN, Manissero D, Steele VR, Pareja J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32725536>
26. **Co-infection of SARS-CoV-2 with Chlamydia or Mycoplasma pneumoniae: a case series and review of the literature.** *Infection* 2020; Oliva A, Siccardi G, Migliarini A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32725598>
27. **COVID-19 cardiovascular epidemiology, cellular pathogenesis, clinical manifestations and management.** *Int J Cardiol Heart Vasc* 2020; 29:100589Sattar Y, Ullah W, Rauf H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32724831>
28. **A comparative overview of COVID-19, MERS and SARS: Review article.** *Int J Surg* 2020; 81:1-8Liu J, Xie W, Wang Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32730205>
29. **Myocardial Injury in COVID-19 Patients: The Beginning or the End?** *J Am Coll Cardiol* 2020; 76:547-549Uriel N, Sayer G, Clerkin KJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32731932>
30. **Regional anesthesia in the time of COVID-19: a minireview.** *J. Anesth.* 2020; Hotta K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32712704>
31. **Role of extracorporeal membrane oxygenation in COVID-19: A systematic review.** *J. Card. Surg.* 2020; Haiduc AA, Alom S, Melamed N, Harky A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32717771>
32. **COVID-19 and cardiovascular diseases.** *J. Cardiol.* 2020; Mai F, Del Pinto R, Ferri C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32736906>
33. **Coronavirus disease- COVID-19: New perceptives towards epidemic to pandemic.** *J. Drug Target.* 2020;1-19S BS, A MST, M SM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32729367>
34. **Point-of-Care Ultrasound in COVID-19 Patients: The Beginning or the End?** *J. Emerg. Med.* 2020; Abrams ER, Rose G, Fields JM, Esener D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32712031>
35. **Best Practice Recommendations for Point-of-Care Lung Ultrasound in Patients with Suspected COVID-19.** *J. Emerg. Med.* 2020; Duggan NM, Shokoohi H, Liteplo AS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32713618>
36. **Immune response in COVID-19: A review.** *J Infect Public Health* 2020; Chowdhury MA, Hossain N, Kashem MA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32718895>
37. **Epidemiology of paediatric Middle East respiratory syndrome coronavirus and implications for the control of coronavirus virus disease 2019.** *J. Paediatr. Child Health* 2020; MacIntyre CR, Chen X, Adam DC, Chughtai AA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32729192>
38. **What we know about SARS-CoV-2 and the renin angiotensin system.** *Kardiovaskulare Medizin* 2020; 23Armelle T, Urs E, Nazmi K.
39. **Mesenchymal Stem Cells in COVID-19: A Journey from Bench to Bedside.** *Lab Med* 2020; Sahu KK, Siddiqui AD, Cerny J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32729620>
40. **Nanomedicine as a promising approach for diagnosis, treatment and prophylaxis against COVID-19.** *Nanomedicine (Lond)* 2020; Abd Allah NH, Gad SF, Muhammad K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32723142>
41. **The many pathways to a COVID-19 vaccine.** *Ned. Tijdschr. Geneesk.* 2020; 164Harmans L.
42. **Neuroinvasion, neurotropic, and neuroinflammatory events of SARS-CoV-2: understanding the neurological manifestations in COVID-19 patients.** *Neurol Sci* 2020; Yachou Y, El Idrissi A, Belapasov V, Ait Benali S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32725449>
43. **Impact of obesity on hospitalizations and mortality, due to COVID-19: A systematic review.** *Obes. Res. Clin. Pract.* 2020; de Siqueira JVV, Almeida LG, Zica BO *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32736969>
44. **Immune Pathogenesis of COVID-19 Intoxication: Storm or Silence?** *Pharmaceuticals (Basel)* 2020; 13Kiselevskiy M, Shubina I, Chikileva I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32722596>
45. **Non-Steroidal Anti-Inflammatory Drugs and the Risk of Pneumonia Complications: A Systematic Review.** *Pharmacotherapy* 2020; Sodhi M, Khosrow-Khavar F, FitzGerald JM, Etmnan M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32715498>
46. **Systematic Review of Changes and Recovery in Physical Function and Fitness After Severe Acute Respiratory Syndrome-Related Coronavirus Infection: Implications for COVID-19 Rehabilitation.** *Phys Ther* 2020; Rooney S, Webster A, Paul L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32737507>
47. **Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review.** *Pulmonology* 2020; Cortegiani A, Ippolito M, Greco M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32713784>
48. **Secondary Attack Rate of COVID-19 in household contacts: Systematic review.** *QJM* 2020; Shah K, Saxena D, Mavalankar D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32726452>
49. **General surgery and COVID-19: review of practical recommendations in the first pandemic phase.** *Surg. Today* 2020; Bresadola V, Biddau C, Puggioni A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32720009>
50. **SARS-CoV-2: characteristics and current advances in research.** *Virology* 2020; 17:117Yang Y, Xiao Z, Ye K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32727485>

Risk factors (59 articles)

1. **High neutrophil-to-lymphocyte ratio associated with progression to critical illness in older patients with COVID-19: a multicenter retrospective study.** *Aging (Albany NY)* 2020; 12Lian J, Jin C, Hao S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32730223>

2. **Development and validation of a risk stratification model for screening suspected cases of COVID-19 in China.** *Aging (Albany NY)* 2020; 12:Ma J, Shi X, Xu W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32727933>
3. **SARS-CoV-2 receptor ACE2 protein expression in serum is significantly associated with age.** *Allergy* 2020; Pavel AB, Wu J, Renert-Yuval Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32726474>
4. **Lactate dehydrogenase levels predict coronavirus disease 2019 (COVID-19) severity and mortality: A pooled analysis.** *Am J Emerg Med* 2020; 38:1722-1726 Henry BM, Aggarwal G, Wong J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32738466>
5. **ACE gene polymorphism and severe lung injury in patients with COVID-19.** *Am. J. Pathol.* 2020; Zheng H, Cao JJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32735889>
6. **The rise of electronic nicotine delivery systems and the emergence of electronic-cigarette-driven disease.** *Am J Physiol Lung Cell Mol Physiol* 2020; McAlinden KD, Eapen MSP, Lu W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32726146>
7. **Smell loss is a prognostic factor for lower severity of COVID-19.** *Ann. Allergy. Asthma. Immunol.* 2020; Foster KJ, Jauregui E, Tajudeen B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32717301>
8. **A nomogram to predict the risk of unfavourable outcome in COVID-19: a retrospective cohort of 279 hospitalized patients in Paris area.** *Ann. Med.* 2020; 1-23 Nguyen Y, Corre F, Honsel V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32723107>
9. **Prevalence of Comorbidities in COVID-19 Patients: A Systematic Review and Meta-Analysis.** *Arch Bone Jt Surg* 2020; 8:247-255 Baradaran A, Ebrahimzadeh MH, Baradaran A, Kachooei AR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32733980>
10. **High Viral Load and Poor Ventilation: Cause of High Mortality From COVID-19.** *Asia Pac. J. Public Health* 2020; 1010539520944725 Aggarwal S, Aggarwal S, Aggarwal A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32715729>
11. **Is there an association between oral health and severity of COVID-19 complications?** *Biomed J* 2020; Botros N, Iyer P, Ojcius DM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32713780>
12. **Predictive model of increased mortality and bed occupancy if thrombolysis becomes the initial treatment strategy for STEMI during the SARS-CoV-2 pandemic.** *Clin Med (Lond)* 2020; Dancy L, O'Gallagher K, Ryan M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32719037>
13. **CT lung lesions as predictors of early death or ICU admission in COVID-19 patients.** *Clin Microbiol Infect* 2020; Ruch Y, Kaeuffer C, Ohana M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32717417>
14. **Hemorrhagic presentations of COVID-19: Risk factors for mortality.** *Clin. Neurol. Neurosurg.* 2020; 198:106112 Altschul DJ, Unda SR, de La Garza Ramos R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32738585>
15. **Determinants of COVID-19 disease severity in patients with underlying rheumatic disease.** *Clin Rheumatol* 2020; Santos CS, Morales CM, Álvarez ED *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32720259>
16. **The Deadly Quartet (Covid-19, old age, lung disease, and heart failure) explain why coronavirus-related mortality in northern Italy was so high.** *Curr. Cardiol. Rev.* 2020; Calcaterra G, Bassareo PP, Barilla F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32735524>
17. **Blood type O as protective factor?: Gene variants have influence on the progression of COVID-19.** *Deutsche Apotheker Zeitung* 2020; 160.
18. **Fat mass as risk factor: Why overweight and obesity are adverse to the COVID-19 progression.** *Deutsche Apotheker Zeitung* 2020; 160 Stefan N.
19. **Hyperglycemia is a strong predictor of poor prognosis in COVID-19.** *Diabetes Res Clin Pract* 2020; 108338 Liu SP, Zhang Q, Wang W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32712122>
20. **Seroprevalence of SARS-CoV-2 and Infection Fatality Ratio, Orleans and Jefferson Parishes, Louisiana, USA, May 2020.** *Emerg Infect Dis* 2020; 26 Feehan AK, Fort D, Garcia-Diaz J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32731911>
21. **Predictors of Adverse Prognosis in Covid-19: A Systematic Review and Meta-analysis.** *Eur. J. Clin. Invest.* 2020; e13362 Figliozzi S, Masci PG, Ahmadi N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32726868>
22. **Clinical Characteristics of Adult Febrile COVID-19 Patients and Predictors for Developing Severe Events.** *Front Med (Lausanne)* 2020; 7:324 Wang G, Zhang Q, Wu C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32719804>
23. **Immune Phenotyping Based on the Neutrophil-to-Lymphocyte Ratio and IgG Level Predicts Disease Severity and Outcome for Patients With COVID-19.** *Front Mol Biosci* 2020; 7:157 Zhang B, Zhou X, Zhu C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32719810>
24. **Commentary: Coronavirus and Obesity: Could Insulin Resistance Mediate the Severity of Covid-19 Infection?** *Front Public Health* 2020; 8:351 Frisardi V. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32733840>
25. **COVID-19 Patient Health Prediction Using Boosted Random Forest Algorithm.** *Front Public Health* 2020; 8:357 Iwendi C, Bashir AK, Peshkar A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32719767>
26. **Younger ages at risk of Covid-19 mortality in communities of color.** *Gates Open Res* 2020; 4:69 Klugman KP, Zewdu S, Mahon BE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32715283>
27. **Lower Incidence of COVID-19 at High Altitude: Facts and Confounders.** *High. Alt. Med. Biol.* 2020; Pun M, Turner R, Strapazzon G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32716669>
28. **The African-American population with a low allele frequency of SNP rs1990760 (T allele) in IFIH1 predicts less IFN-beta expression and potential vulnerability to COVID-19 infection.** *Immunogenetics* 2020; Maiti AK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32737579>
29. **Prognostic value of serum amyloid A in patients with COVID-19.** *Infection* 2020; Cheng L, Yang JZ, Bai WH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32734556>
30. **Diagnostic performance of initial blood urea nitrogen combined with D-Dimer levels for predicting in-hospital mortality in COVID-19 patients.** *Int J Antimicrob Agents* 2020; 106110 Cheng A, Hu L, Wang Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32712332>
31. **Association between COVID-19 and cardiovascular disease.** *Int J Cardiol Heart Vasc* 2020; 29:100583 Srivastava K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32715080>
32. **A model of disparities: risk factors associated with COVID-19 infection.** *Int J Equity Health* 2020; 19:126 Rozenfeld Y, Beam J, Maier H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32727486>

33. **Comorbidities and the risk of severe or fatal outcomes associated with coronavirus disease 2019: A systematic review and meta-analysis.** *Int J Infect Dis* 2020; Zhou Y, Yang Q, Chi J *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32721533>
34. **A Quantitative and Radiomics approach to monitoring ARDS in COVID-19 patients based on chest CT: a retrospective cohort study.** *Int. J. Med. Sci.* 2020; 17:1773-1782Chen Y, Wang Y, Zhang Y *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32714080>
35. **HLA-B*44 and C*01 Prevalence Correlates with Covid19 Spreading across Italy.** *Int J Mol Sci* 2020; 21Correale P, Mutti L, Pentimalli F *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32717807>
36. **The Role of Health Preconditions on COVID-19 Deaths in Portugal: Evidence from Surveillance Data of the First 20293 Infection Cases.** *J Clin Med* 2020; 9Nogueira PJ, de Araújo Nobre M, Costa A *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32722159>
37. **Rise in nocturnal respiratory rate during CPAP may be an early sign of COVID-19 in patients with obstructive sleep apnea.** *J. Clin. Sleep Med.* 2020; Nakano H, Kadowaki M, Furukawa T, Yoshida M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32720641>
38. **The characteristics and outcomes of 681 severe cases with COVID-19 in China.** *J Crit Care* 2020; 60:32-37Chen FF, Zhong M, Liu Y *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32736197>
39. **Liver damage at admission is an independent prognostic factor for COVID-19.** *J Dig Dis* 2020; Chen LY, Chu HK, Bai T *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32713118>
40. **Clinical characteristics and outcomes of COVID-19 patients presenting with initial gastrointestinal symptoms in Wuhan, China: a retrospective cohort study.** *J Gastroenterol Hepatol* 2020; Luo S, Deng Z, Zhang X *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32721038>
41. **Comorbidities for fatal outcome among the COVID-19 patients: a hospital-based case-control study.** *J Infect* 2020; Lu QB, Jiang WL, Zhang X *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32731000>
42. **The impact of socioeconomic status on 30-day mortality in hospitalised patients with COVID-19 infection.** *J Med Virol* 2020; Khan KS, Torpiano G, McLellan M, Mahmud S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32729937>
43. **The Association of Interleukin-6 value, Interleukin inhibitors and Outcomes of Patients with COVID-19 in New York City.** *J Med Virol* 2020; Maeda T, Obata R, Rizk DD, Kuno T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32720702>
44. **Risk factors for the COVID-19 severity and its correlation with viral shedding: a retrospective cohort study.** *J Med Virol* 2020; Zheng X, Chen J, Deng L *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32725915>
45. **The actual and potential impact of the novel 2019 coronavirus on pediatric rehabilitation: A commentary and review of its effects and potential disparate influence on Black, Latinx and Native American marginalized populations in the United States.** *J. Pediatr. Rehabil. Med.* 2020; Sholas MG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32716335>
46. **A logistic model for age-specific COVID-19 case-fatality rates.** *JAMIA Open* 2020; 3:151-153Gao X, Dong Q. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32734152>
47. **Inflammation: A bridge between diabetes and COVID-19, and possible management with sitagliptin.** *Med. Hypotheses* 2020; 143:110111Mozafari N, Azadi S, Mehdi-Alamdarlou S *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32721805>
48. **Visceral fat shows the strongest association with the need of intensive Care in Patients with COVID-19.** *Metabolism* 2020:154319Watanabe M, Caruso D, Tuccinardi D *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32712222>
49. **Low Albumin Levels Are Associated with Poorer Outcomes in a Case Series of COVID-19 Patients in Spain: A Retrospective Cohort Study.** *Microorganisms* 2020; 8de la Rica R, Borges M, Aranda M *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32722020>
50. **Impact of obesity on hospitalizations and mortality, due to COVID-19: A systematic review.** *Obes. Res. Clin. Pract.* 2020; de Siqueira JVV, Almeida LG, Zica BO *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32736969>
51. **Oral cancer and ACE2 receptor of SARS-CoV-2.** *Oral Oncol* 2020:104920Martelli-Júnior H, Machado RA, Martelli DRB *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32713810>
52. **Nox2 activation in Covid-19.** *Redox Biol* 2020; 36:101655Violi F, Oliva A, Cangemi R *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32738789>
53. **[Variables associated with mortality in a selected sample of patients older than 80 years and with some degree of functional dependence hospitalized for COVID-19 in a Geriatrics Service].** *Rev Esp Geriatr Gerontol* 2020; Gutiérrez Rodríguez J, Montero Muñoz J, Jiménez Muela F *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32736821>
54. **COVID-19 Severity in Europe and the USA: Could the Seasonal Influenza Vaccination Play a Role?** *Ssrn* 2020:3621446Consortium E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32714123>
55. **Clinical Features of COVID-19 and Factors Associated with Severe Clinical Course: A Systematic Review and Meta-Analysis.** *Ssrn* 2020:3566166Kumar A, Arora A, Sharma P *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32714109>
56. **Countries with High Registered Nurse (RN) Concentrations Observe Reduced Mortality Rates of Coronavirus Disease 2019 (COVID-19).** *Ssrn* 2020:3566190Padula WV, Davidson P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32714110>
57. **The Role of Environmental Factors on Transmission Rates of the COVID-19 Outbreak: An Initial Assessment in Two Spatial Scales.** *Ssrn* 2020:3552677Poirier C, Luo W, Majumder MS *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32714106>
58. **Temperature, Humidity and Latitude Analysis to Predict Potential Spread and Seasonality for COVID-19.** *Ssrn* 2020:3550308Sajadi MM, Habibzadeh P, Vintzileos A *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32714105>
59. **The double-edged relationship between COVID-19 stress and smoking: Implications for smoking cessation.** *Tob Induc Dis* 2020; 18:63Bommele J, Hopman P, Walters BH *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32733178>

Safety (17 articles)

1. **Chloroquine in fighting COVID-19: good, bad, or both?** *Autophagy* 2020;1-3Tang D, Li J, Zhang R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32713288>
2. **Safety and potential efficacy of cyclooxygenase-2 inhibitors in coronavirus disease 2019.** *Clin Transl Immunology* 2020; 9:e1159Ong SWX, Tan WYT, Chan YH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32728438>
3. **ACEI/ARB therapy in COVID-19: the double-edged sword of ACE2 and SARS-CoV-2 viral docking.** *Crit Care* 2020; 24:475Onweni CL, Zhang YS, Caulfield T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32736573>
4. **Consequences of chemical impact of disinfectants: safe preventive measures against COVID-19.** *Crit. Rev. Toxicol.* 2020;1-8Rai NK, Ashok A, Akondi BR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32729370>
5. **Easy game for SARS-CoV-2?: Influence of ACE inhibitors and sartans on the risk of COVID-19 is examined carefully.** *Deutsche Apotheker Zeitung* 2020; 160Hein L, Lother A, Wirth L.
6. **The demystification of antimalarial drugs: Registry study on chloroquine/hydroxychloroquine in COVID-19 shows increased mortality.** *Deutsche Apotheker Zeitung* 2020; 160Jungmayr P.
7. **Legionella pneumonia: increased risk after COVID-19 lockdown? Italy, May to June 2020.** *Euro Surveill* 2020; 25Palazzolo C, Maffongelli G, D'Abramo A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32734857>
8. **Beyond Anti-viral Effects of Chloroquine/Hydroxychloroquine.** *Front. Immunol.* 2020; 11:1409Gies V, Bekaddour N, Dieudonné Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32714335>
9. **Periconceptional exposure to lopinavir, but not darunavir, impairs decidualization: a potential mechanism leading to poor birth outcomes in HIV-positive pregnancies.** *Hum. Reprod.* 2020; Kala S, Dunk C, Acosta S, Serghides L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32712670>
10. **Safety and efficacy of tocilizumab in the treatment of severe acute respiratory syndrome coronavirus-2 pneumonia: A retrospective cohort study.** *Indian J. Med. Microbiol.* 2020; 38:117-123Patel A, Shah K, Dharsandiya M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32719218>
11. **Assessing The Risk of Adalimumab Use For Hidradenitis Suppurativa During The COVID-19 Pandemic.** *J Am Acad Dermatol* 2020; Kearns DG, Chat VS, Uppal S, Wu JJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32735966>
12. **Antecedent Immunosuppressive Therapy for Immune-Mediated Inflammatory Diseases in the Setting of a COVID-19 Outbreak.** *J Am Acad Dermatol* 2020; Veenstra J, Buechler CR, Robinson G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32735965>
13. **Drug reaction with eosinophilia and systemic symptoms syndrome in a patient with COVID-19.** *J Eur Acad Dermatol Venereol* 2020; Herman A, Matthews M, Mairlot M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32735713>
14. **Heparin-Induced Thrombocytopenia in COVID-19.** *J Investig Med High Impact Case Rep* 2020; 8:2324709620944091Lingamaneni P, Gonakoti S, Moturi K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32720827>
15. **The interaction of RAAS inhibitors with COVID-19: Current progress, perspective and future.** *Life Sci* 2020;118142Zhang J, Wang M, Ding W, Wan J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32712300>
16. **Potential drug-drug interactions in COVID 19 patients in treatment with lopinavir/ritonavir.** *Med Clin (Barc)* 2020; Brandariz-Nuñez D, Correas-Sanahuja M, Guarc E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32718719>
17. **Adverse reactions of drugs specifically used for treatment of SARS-CoV-2 infection.** *Med Clin (Barc)* 2020; Herrera-Lasso Regás V, Dordal Culla MT, Lleonat Bellfill R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32718715>

Treatment options (58 articles)

1. **JAK/STAT Pathway Inhibition May Be a Promising Therapy for COVID-19-Related Hyperinflammation in Hematologic Patients.** *Acta Haematol.* 2020;1-5Rojas P, Sarmiento M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32726783>
2. **Can a Combination of AT1R Antagonist and Vitamin D Treat the Lung Complication of COVID-19?** *Am. J. Med. Sci.* 2020; Rafiullah M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32736832>
3. **Molecular Insights into Small Molecule Drug Discovery for SARS-CoV-2.** *Angew. Chem. Int. Ed. Engl.* 2020; Su H, Su H, Zhou F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32729180>
4. **Chloroquine in fighting COVID-19: good, bad, or both?** *Autophagy* 2020;1-3Tang D, Li J, Zhang R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32713288>
5. **A nicotinic hypothesis for Covid-19 with preventive and therapeutic implications.** *C R Biol* 2020; 343:33-39Changeux JP, Amoura Z, Rey FA, Miyara M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32720486>
6. **Vitamin D high doses supplementation could represent a promising alternative to prevent or treat COVID-19 infection.** *Clin Investig Arterioscler* 2020; Mansur JL, Tajer C, Mariani J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32718670>
7. **ACEI/ARB therapy in COVID-19: the double-edged sword of ACE2 and SARS-CoV-2 viral docking.** *Crit Care* 2020; 24:475Onweni CL, Zhang YS, Caulfield T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32736573>
8. **The Promise of Mesenchymal stem cells therapy for acute Respiratory Distress Syndrome Caused by COVID-19.** *Curr. Stem Cell Res. Ther.* 2020; Gu J, Zhao Q, Han Z, Han Z. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32729428>
9. **Classification of the present pharmaceutical agents based on the possible effective mechanism on the COVID-19 infection.** *Daru* 2020; Amini Pouya M, Afshani SM, Maghsoudi AS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32734518>
10. **The Committee for Medicinal Products for Human Use clears the way for remdesivir: Conditional approval for treatment of COVID-19 is expected soon.** *Deutsche Apotheker Zeitung* 2020; 160.
11. **Waiting for evidence: An update on the research on COVID-19 therapeutic agents.** *Deutsche Apotheker Zeitung* 2020; 160Blasius H.
12. **The demystification of antimalarial drugs: Registry study on chloroquine/hydroxychloroquine in COVID-19 shows increased mortality.** *Deutsche Apotheker Zeitung* 2020; 160Jungmayr P.

13. **From Farm to Finger Prick-A Perspective on How Plants Can Help in the Fight Against COVID-19.** *Front Bioeng Biotechnol* 2020; 8:782McDonald KA, Holtz RB. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32714921>
14. **Targeting GM-CSF in COVID-19 Pneumonia: Rationale and Strategies.** *Front. Immunol.* 2020; 11:1625Bonaventura A, Vecchié A, Wang TS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32719685>
15. **Beyond Anti-viral Effects of Chloroquine/Hydroxychloroquine.** *Front. Immunol.* 2020; 11:1409Gies V, Bekaddour N, Dieudonné Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32714335>
16. **Potential Fast COVID-19 Containment With Trehalose.** *Front. Immunol.* 2020; 11:1623Martinon D, Borges VF, Gomez AC, Shimada K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32733488>
17. **Mesenchymal Stem Cells: A New Piece in the Puzzle of COVID-19 Treatment.** *Front. Immunol.* 2020; 11:1563Saldanha-Araujo F, Melgaço Garcez E, Silva-Carvalho AE, Carvalho JL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32719683>
18. **Complement Inhibition in Coronavirus Disease (COVID)-19: A Neglected Therapeutic Option.** *Front. Immunol.* 2020; 11:1661Stahel PF, Barnum SR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32733489>
19. **Turning the Tide: Natural Products and Natural-Product-Inspired Chemicals as Potential Counters to SARS-CoV-2 Infection.** *Front. Pharmacol.* 2020; 11:1013Wang Z, Yang L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32714193>
20. **Progress in the Research and Development of Anti-COVID-19 Drugs.** *Front Public Health* 2020; 8:365Huang L, Chen Y, Xiao J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32733842>
21. **A Perspective on Emerging Therapeutic Interventions for COVID-19.** *Front Public Health* 2020; 8:281Torequ Islam M, Nasiruddin M, Khan IN *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32733837>
22. **Ascorbate as Prophylaxis and Therapy for COVID-19-Update From Shanghai and U.S. Medical Institutions.** *Glob Adv Health Med* 2020; 9:2164956120934768Cheng RZ, Kogan M, Davis D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32733775>
23. **Safety and efficacy of tocilizumab in the treatment of severe acute respiratory syndrome coronavirus-2 pneumonia: A retrospective cohort study.** *Indian J. Med. Microbiol.* 2020; 38:117-123Patel A, Shah K, Dharsandiya M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32719218>
24. **In Silico Identification of a Potent Arsenic Based Approved Drug Darinaparsin against SARS-CoV-2: Inhibitor of RNA Dependent RNA polymerase (RdRp) and Essential Proteases.** *Infect Disord Drug Targets* 2020; Chowdhury T, Roymahapatra G, Mandal SM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32718300>
25. **In silico Study of Azithromycin, Chloroquine and Hydroxychloroquine and their Potential Mechanisms of Action against SARS-CoV-2 Infection.** *Int J Antimicrob Agents* 2020:106119Braz HLB, de Moraes Silveira JA, Marinho AD *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32738306>
26. **Lactoferrin as potential preventative and treatment for COVID-19.** *Int J Antimicrob Agents* 2020:106118Chang R, Ng TB, Sun WZ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32738305>
27. **Tocilizumab for severe COVID-19: a systematic review and meta-analysis.** *Int J Antimicrob Agents* 2020:106103Lan SH, Lai CC, Huang HT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32712333>
28. **Systematic review of the role of renin-angiotensin system inhibitors in late studies on Covid-19: A new challenge overcome?** *Int J Cardiol* 2020; Volpe M, Battistoni A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32738257>
29. **Adsorptive granulocyte and monocyte apheresis: a potentially relevant therapeutic option for COVID-19.** *Int J Infect Dis* 2020; Kanekura T, Kawahara K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32721534>
30. **Appropriate use of Tocilizumab in COVID-19 Infection.** *Int J Infect Dis* 2020; Keske Ş, Tekin S, Sait B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32726724>
31. **Early administration of Interleukin-6 inhibitors for patients with severe Covid-19 disease is associated with decreased intubation, reduced mortality, and increased discharge.** *Int J Infect Dis* 2020; Sinha P, Mostaghim A, Bielick CG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32721528>
32. **Potential Anti-COVID-19 Therapeutics that Block the Early Stage of the Viral Life Cycle: Structures, Mechanisms, and Clinical Trials.** *Int J Mol Sci* 2020; 21Al-Horani RA, Kar S, Aliter KF. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32718020>
33. **Treatment of severe COVID-19 courses in intensive care medicine.** *Internist* 2020; Wiesner O, Busch M, David S.
34. **Tackling COVID-19: identification of potential main protease inhibitors via structural analysis, virtual screening, molecular docking and MM-PBSA calculations.** *J Biomol Struct Dyn* 2020:1-16Al-Shar'i NA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32734828>
35. **Identification of some novel oxazine substituted 9-anilinoacridines as SARS-CoV-2 inhibitors for COVID-19 by molecular docking, free energy calculation and molecular dynamics studies.** *J Biomol Struct Dyn* 2020:1-12Rajagopal K, Varakumar P, Aparna B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32720578>
36. **Virtual screening, ADMET prediction and dynamics simulation of potential compounds targeting the main protease of SARS-CoV-2.** *J Biomol Struct Dyn* 2020:1-16Yadav R, Imran M, Dhamija P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32715956>
37. **Efficacy of Corticosteroids in Patients with SARS, MERS and COVID-19: A Systematic Review and Meta-Analysis.** *J Clin Med* 2020; 9Lee KH, Yoon S, Jeong GH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32726951>
38. **Drug repurposing of nitazoxanide: can it be an effective therapy for COVID-19?** *J. Genet. Eng. Biotechnol.* 2020; 18:35Mahmoud DB, Shitu Z, Mostafa A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32725286>
39. **Mesenchymal Stem Cells in COVID-19: A Journey from Bench to Bedside.** *Lab Med* 2020; Sahu KK, Siddiqui AD, Cerny J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32729620>
40. **BCG vaccination early in life does not improve COVID-19 outcome of elderly populations, based on nationally reported data.** *Lett. Appl. Microbiol.* 2020; Wassenaar TM, Buzard GS, Newman DJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32734625>
41. **Potential drug-drug interactions in COVID 19 patients in treatment with lopinavir/ritonavir.** *Med Clin (Barc)* 2020; Brandariz-Nuñez D, Correas-Sanahuja M, Guarc E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32718719>
42. **Adverse reactions of drugs specifically used for treatment of SARS-CoV-2 infection.** *Med Clin (Barc)* 2020; Herrera-Lasso Regás V, Dordal Culla MT, Leonart Bellfill R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32718719>

- term=32718715
43. **Spironolactone may provide protection from SARS-CoV-2: Targeting androgens, angiotensin converting enzyme 2 (ACE2), and renin-angiotensin-aldosterone system (RAAS).** *Med. Hypotheses* 2020; 143:110112Cadegiani FA, Goren A, Wambier CG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32721806>
 44. **Rapid and Impressive Response to a Combined Treatment with Single-Dose Tocilizumab and NIV in a Patient with COVID-19 Pneumonia/ARDS.** *Medicina (Kaunas)* 2020; 56Cascella M, Mauro I, De Blasio E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32727107>
 45. **Identification of potential Mpro inhibitors for the treatment of COVID-19 by using systematic virtual screening approach.** *Mol. Divers.* 2020; Kanhed AM, Patel DV, Teli DM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32737681>
 46. **A Computational Approach to Identify Potential Novel Inhibitors against the Coronavirus SARS-CoV-2.** *Mol Inform* 2020; Battisti V, Wieder O, Garon A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32721082>
 47. **Nanomedicine as a promising approach for diagnosis, treatment and prophylaxis against COVID-19.** *Nanomedicine (Lond)* 2020; Abd Allah NH, Gad SF, Muhammad K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32723142>
 48. **Hypothesis: Pentoxifylline is a potential cytokine modulator therapeutic in COVID-19 patients.** *Pharmacol Res Perspect* 2020; 8:e00631Hendry BM, Stafford N, Arnold AD *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32715661>
 49. **Non-Steroidal Anti-Inflammatory Drugs and the Risk of Pneumonia Complications: A Systematic Review.** *Pharmacotherapy* 2020; Sodhi M, Khosrow-Khavar F, FitzGerald JM, Etmiman M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32715498>
 50. **Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review.** *Pulmonology* 2020; Cortegiani A, Ippolito M, Greco M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32713784>
 51. **Desperate Times, Desperate Measures: The Case for RRx-001 in the Treatment of COVID-19.** *Semin. Oncol.* 2020; Oronsky B, Knox S, Cabrales P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32718560>
 52. **Candidate Targets for Immune Responses to 2019-Novel Coronavirus (nCoV): Sequence Homology- and Bioinformatic-Based Predictions.** *Ssrn* 2020:3541361Grifoni A, Sidney J, Zhang Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32714104>
 53. **Pre-exposure prophylaxis with hydroxychloroquine for high-risk healthcare workers during the COVID-19 pandemic: A structured summary of a study protocol for a multicentre, double-blind randomized controlled trial.** *Trials* 2020; 21:688Grau-Pujol B, Camprubí D, Marti-Soler H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32727613>
 54. **[Analysis on formula of Mongolian medicine for prevention of COVID-19].** *Zhongguo Zhong Yao Za Zhi* 2020; 45:3013-3019Ji MY, Qi QG, Xi LT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32726006>
 55. **[Analysis of potential role of Chinese classic prescriptions in treatment of COVID-19 based on TCMATCOV platform].** *Zhongguo Zhong Yao Za Zhi* 2020; 45:3028-3034Tang X, Tong L, Guo FF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32726008>
 56. **[Analysis of medication regularity and pharmacodynamic characteristics of traditional Chinese medicine treatment in 444 severe cases of COVID-19].** *Zhongguo Zhong Yao Za Zhi* 2020; 45:3007-3012Wang C, Ming H, Jia W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32726005>
 57. **[Large- scale prospective clinical study on prophylactic intervention of COVID-19 in community population using Huoxiang Zhengqi Oral Liquid and Jinhao Jiere Granules].** *Zhongguo Zhong Yao Za Zhi* 2020; 45:2993-3000Yan BH, Jiang ZW, Zeng JP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32726003>
 58. **[Analysis of traditional Chinese medicine from patent information sharing platform of coronavirus disease 2019 (COVID-19)].** *Zhongguo Zhong Yao Za Zhi* 2020; 45:3001-3006Yang KL, Gao Y, Yang FW *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32726004>

Trials (16 articles)

1. **Point-of-care and utility in clinical trials: making quicker decisions to transform patient care and drug development.** *Bioanalysis* 2020; Fischer SK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32735127>
2. **Relationship Between serum SARS-CoV-2 nucleic acid(RNAemia) and Organ Damage in COVID-19 Patients: A Cohort Study.** *Clin Infect Dis* 2020; Xu D, Zhou F, Sun W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32720678>
3. **Authors' response: COVID-19: how accurate are seroprevalence studies?** *Euro Surveill* 2020; 25Cassaniti I, Percivalle E, Sarasini A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32734854>
4. **Letter to the editor: COVID-19: how accurate are seroprevalence studies?** *Euro Surveill* 2020; 25Kadkhoda K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32734860>
5. **Collateral Effect of COVID-19 Pandemic on Hospitalizations and Clinical Outcomes in Gastrointestinal and Liver Diseases - A Territory-wide Observational Study in Hong Kong.** *Gastroenterology* 2020; Lau LH, Wong SH, Yip TC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32721440>
6. **A Quantitative and Radiomics approach to monitoring ARDS in COVID-19 patients based on chest CT: a retrospective cohort study.** *Int. J. Med. Sci.* 2020; 17:1773-1782Chen Y, Wang Y, Zhang Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32714080>
7. **Potential Anti-COVID-19 Therapeutics that Block the Early Stage of the Viral Life Cycle: Structures, Mechanisms, and Clinical Trials.** *Int J Mol Sci* 2020; 21Al-Horani RA, Kar S, Aliter KF. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32718020>
8. **Characteristics of Clinical Trials relating to COVID-19 registered at ClinicalTrials.gov.** *J. Clin. Pharm. Ther.* 2020; Wang Y, Zhou Q, Xu M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32734670>
9. **Risk factors for the COVID-19 severity and its correlation with viral shedding: a retrospective cohort study.** *J Med Virol* 2020; Zheng X, Chen J, Deng L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32725915>
10. **Identification of the awareness level by the public of Arab countries toward COVID-19: cross-sectional study following an outbreak.** *J Pharm Policy Pract* 2020; 13:43Bonyan R, Al-Karasneh AF, El-Dahiyat F, Jairoun AA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32724659>

11. **Low Albumin Levels Are Associated with Poorer Outcomes in a Case Series of COVID-19 Patients in Spain: A Retrospective Cohort Study.** *Microorganisms* 2020; 8:de la Rica R, Borges M, Aranda M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32722020>
12. **Pre-exposure prophylaxis with hydroxychloroquine for high-risk healthcare workers during the COVID-19 pandemic: A structured summary of a study protocol for a multicentre, double-blind randomized controlled trial.** *Trials* 2020; 21:688Grau-Pujol B, Camprubí D, Marti-Soler H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32727613>
13. **muLTi-Arm Therapeutic study in pre-ICu patients admitted with Covid-19-Experimental drugs and mechanisms (TACTIC-E): A structured summary of a study protocol for a randomized controlled trial.** *Trials* 2020; 21:690Lu IN, Kulkarni S, Fisk M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32736592>
14. **PROTECT Trial: A cluster-randomized study with hydroxychloroquine versus observational support for prevention or early-phase treatment of Coronavirus disease (COVID-19): A structured summary of a study protocol for a randomized controlled trial.** *Trials* 2020; 21:689Nanni O, Viale P, Vertogen B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32736597>
15. **ACCORD: A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalised Patients: A structured summary of a study protocol for a randomised controlled trial.** *Trials* 2020; 21:691Wilkinson T, Dixon R, Page C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32736596>
16. **[Large- scale prospective clinical study on prophylactic intervention of COVID-19 in community population using Huoxiang Zhengqi Oral Liquid and Jinhao Jiere Granules].** *Zhongguo Zhong Yao Za Zhi* 2020; 45:2993-3000Yan BH, Jiang ZW, Zeng JP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32726003>

Vaccines (14 articles)

1. **The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity.** *Cell* 2020; Li Q, Wu J, Nie J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32730807>
2. **Computationally Optimized SARS-CoV-2 MHC Class I and II Vaccine Formulations Predicted to Target Human Haplotype Distributions.** *Cell Syst* 2020; Liu G, Carter B, Bricken T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32721383>
3. **Determination of an optimal control strategy for vaccine administration in COVID-19 pandemic treatment.** *Comput. Methods Programs Biomed.* 2020; 196:105664Libotte GB, Lobato FS, Platt GM, Silva Neto AJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32736332>
4. **Protection against COVID-19 by means of BCG vaccination?: Data from Israel show no advantage of an immunization.** *Deutsche Apotheker Zeitung* 2020; 160Buchheit M.
5. **mRNA vaccines as ray of hope?: With genetic information against corona.** *Deutsche Apotheker Zeitung* 2020; 160Oetzel S.
6. **COVID-19 Coronavirus Vaccine Design Using Reverse Vaccinology and Machine Learning.** *Front. Immunol.* 2020; 11:1581Ong E, Wong MU, Huffman A, He Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32719684>
7. **The use of the health belief model to assess predictors of intent to receive the COVID-19 vaccine and willingness to pay.** *Hum Vaccin Immunother* 2020:1-11Wong LP, Alias H, Wong PF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32730103>
8. **Strengthening vaccine confidence during the COVID-19 pandemic: A new opportunity for global hepatitis B virus elimination.** *J Hepatol* 2020; Lazarus JV, Picchio CA, Nayagam S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32732061>
9. **BCG vaccination early in life does not improve COVID-19 outcome of elderly populations, based on nationally reported data.** *Lett. Appl. Microbiol.* 2020; Wassenaar TM, Buzard GS, Newman DJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32734625>
10. **The many pathways to a COVID-19 vaccine.** *Ned. Tijdschr. Geneeskd.* 2020; 164Harmans L.
11. **DZK Recommendations for Tuberculosis, BCG and COVID-19 in Germany - (Official Abbreviation of Coronavirus Disease 2019 Caused by the New Coronavirus SARS-CoV-2).** *Pneumologie (Stuttgart, Germany)* 2020; 74:412-416Otto-Knapp R, Häcker B, Breuer C *et al.*
12. **A SARS-CoV-2 Vaccination Strategy Focused on Population-Scale Immunity.** *Ssrn* 2020:3575161Yarmarkovich M, Warrington JM, Farrel A, Maris JM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32714112>
13. **New Points of Departure for More Global Influenza Vaccine Use.** *Vaccines (Basel)* 2020; 8Kiseleva I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32718042>
14. **Immunogenic SARS-CoV-2 Epitopes: In Silico Study Towards Better Understanding of COVID-19 Disease-Paving the Way for Vaccine Development.** *Vaccines (Basel)* 2020; 8Ranga V, Niemelä E, Tamirat MZ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32717854>

Women – pregnancy (24 articles)

1. **Review of guidelines and recommendations from 17 countries highlights the challenges that clinicians face caring for neonates born to mothers with COVID-19.** *Acta Paediatr* 2020; Yeo KT, Oei JL, De Luca D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32716579>
2. **Are clinical outcomes worse for pregnant women \geq 20 weeks' gestation infected with COVID-19? A multicenter case-control study with propensity score matching.** *Am J Obstet Gynecol* 2020; Badr DA, Mattern J, Carlin A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32730899>
3. **COVID-19 outcomes of patients with gynecologic cancer in New York City.** *Cancer* 2020; Lara OD, O'Ceirbhail RE, Smith MJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32729142>
4. **Obstetric and intensive-care strategies in a high-risk pregnancy with critical respiratory failure due to COVID-19: A case report.** *Case Rep Womens Health* 2020; 27:e00240Kolkova Z, Bjurström MF, Länsberg JK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32714844>

5. **A Message from the Human Placenta: Structural and Immunomodulatory Defense against SARS-CoV-2.** *Cells* 2020; 9Kreis NN, Ritter A, Louwen F, Yuan J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32722449>
6. **Polymorphic eruption of pregnancy as a possible COVID-19 manifestation.** *Dermatol Ther* 2020; Proietti I, Bernardini N, Tolino E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32737915>
7. **Pregnant in times of corona: How to remain confident in spite of legitimate concerns.** *Deutsche Apotheker Zeitung* 2020; 160Borsch J.
8. **Facing the SARS-Cov-2 outbreak: What should Obstetricians and Gynecologists need to do?** *Disaster Med Public Health Prep* 2020;1-12Zhang H, Hu Y, Zhu Y, Chen X. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32713389>
9. **COVID-19 and its impact on gynaecologic oncology practice in India-results of a nationwide survey.** *Ecancermedalscience* 2020; 14:1067Subbian A, Kaur S, Patel V, Rajanbabu A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32728383>
10. **COVID-19 and Hypercoagulability: Potential Impact on Management with Oral Contraceptives, Estrogen Therapy and Pregnancy.** *Endocrinology* 2020; Spratt DI, Buchsbaum RJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32725207>
11. **ESMO management and treatment adapted recommendations in the COVID-19 era: gynaecological malignancies.** *ESMO Open* 2020; 5Colombo I, Zaccarelli E, Del Grande M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32718919>
12. **Maternal COVID-19 infection, clinical characteristics, pregnancy, and neonatal outcome: A prospective cohort study.** *Eur. J. Obstet. Gynecol. Reprod. Biol.* 2020; Antoun L, Taweel NE, Ahmed I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32732059>
13. **COVID-19 in pregnant women: A systematic review and meta-analysis.** *Eur. J. Obstet. Gynecol. Reprod. Biol.* 2020; Capobianco G, Sadleri L, Aliberti S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32713730>
14. **Pregnancy, Viral Infection, and COVID-19.** *Front. Immunol.* 2020; 11:1672Alberca RW, Pereira NZ, Oliveira L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32733490>
15. **Periconceptional exposure to lopinavir, but not darunavir, impairs decidualization: a potential mechanism leading to poor birth outcomes in HIV-positive pregnancies.** *Hum. Reprod.* 2020; Kala S, Dunk C, Acosta S, Serghides L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32712670>
16. **No evidence for vertical transmission of SARS-CoV-2 in two neonates with mothers infected in the second trimester.** *Infect Dis (Lond)* 2020:1-4Tang JY, Song WQ, Xu H, Wang N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32721199>
17. **Mistakes from the HIV pandemic should inform the COVID-19 response for maternal and newborn care.** *Int Breastfeed J* 2020; 15:67Gribble K, Mathisen R, Ververs MT, Coutsoudis A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32711567>
18. **Adapting antenatal care in a rural LMIC during COVID-19: A low literacy checklist to mitigate risk for community health workers.** *Int J Gynaecol Obstet* 2020; Hernandez S, Oliveria JB, Mendoza Sosof C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32736412>
19. **Racial and ethnic disparities in severity of COVID-19 disease in pregnancy in the United States.** *Int J Gynaecol Obstet* 2020; Onwuzurike C, Diouf K, Meadows AR, Nour NM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32735741>
20. **Psychological impact of the COVID-19 pandemic among pregnant women in Sri Lanka.** *Int J Gynaecol Obstet* 2020; Patabendige M, Gamage MM, Weerasinghe M, Jayawardane A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32731307>
21. **Maternal psychological distress & mental health service use during the COVID-19 pandemic.** *J. Affect. Disord.* 2020; 276:765-774Cameron EE, Joyce KM, Delaquis CP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32736186>
22. **Extremely Preterm Infant Born to a Mother With Severe COVID-19 Pneumonia.** *J Investig Med High Impact Case Rep* 2020; 8:2324709620946621Easterlin MC, De Beritto T, Yeh AM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32723092>
23. **Health Care Team Training and Simulation-Based Education in Obstetrics During the COVID-19 Pandemic.** *J. Obstet. Gynaecol. Can.* 2020; 42:1017-1020Kiely DJ, Posner GD, Sansregret A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32736852>
24. **Emotional Eating in Pregnant Women during the COVID-19 Pandemic and Its Association with Dietary Intake and Gestational Weight Gain.** *Nutrients* 2020; 12Zhang J, Zhang Y, Huo S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32731389>

to subscribe click [here](#)
